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Age-related complications such as neurodegenerative disorders comprise multifactorial 
disorders which are increasing and remain cureless. The possibility of altering the 
progression or the development of these multifactorial diseases through diet is an 
emerging and attractive approach with increasing supporting data. Epidemiological and 
clinical studies have highlighted the health potential of diets rich in fruits and vegetables. 
Such food sources are rich in (poly)phenols, natural compounds with increasing 
associated health benefits, having potential to  prevent and/or retard the development 
of such disorders. In fact, studies with (poly)phenols arising from our diet (dietary 
(poly)phenols) have been shown their multipotent and pleiotropic ability to modulate 
several cellular and molecular pathways. The prevention and treatment of 
neurodegeneration, characterized by a mechanistic complexity, will require novel multi-
targeted therapeutic strategies, targeting different disease hallmarks. In that sense, 
dietary (poly)phenols can emerge as an reliable pleiotropic alternative, with potential to 
be further explored. 
Berries are amongst the most promising rich sources of (poly)phenols with associated 
brain health benefits, presenting significant implications for neurodegenerative 
disorders, such as Parkinson’s disease (PD). In fact, PD is one of most common age-
related neurodegenerative disorders, still without cure, being characterized by several 
aspects such as dopaminergic cell loss, severe mitochondrial dysfunction, increased 
oxidative stress and neuroinflammation. The multiplicity of causes/effects that 
characterize PD raises the need for further investigation for multitarget agents, where 
berries-derived (poly)phenols can play an important role. 
Berries (poly)phenols’ potential against chronic oxidative stress was already described 
to be potentiated upon simulated gastrointestinal digestion, being the protective 
potential of the bioaccessible components derived from in vitro digestion (BDP) higher 
than the original extract and going beyond the direct radical scavenging properties of 
parent (poly)phenols. Modifications along digestive process, comprising absorption, 
distribution, metabolism and excretion, as well as the potential to overcome organs and 
tissues barriers should be better understood to more accurately design nutritional 
therapies to tackle disease progression. In here, these berries components derived from 
in vitro digestion, have proven to be transported across the endothelial cells of the blood-
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brain barrier (BBB), presenting strong neuroprotective effects against major 
neurodegeneration hallmarks. Associations between their cytoprotective capacity and 
the underlying molecular mechanisms highlighted mTOR signaling and unfolded protein 
response mechanisms as top canonical pathways regulated by BDP. However, to be 
effectively neuroprotective, these berries components must be not only bioaccessibe 
but also bioavailable. 
In fact, berries-derived bioavailable (poly)phenol metabolites were detected in urine and 
plasma samples from human individuals and, from a set of metabolites identified and 
correspondent circulating concentrations, simple phenolic sulfates emerged as the most 
abundant metabolites. The potential of these known bioavailable phenolic sulfates, 
arising from colonic metabolism of berries, however, was never assessed before. In this 
thesis, in silico predictions and in vitro transport studies across BBB endothelial cells, at 
circulating concentrations, provided evidence for their differential transport, likely related 
to their chemical structure. Moreover, endothelial metabolism of these phenolic sulfates 
produced a plethora of novel chemical entities with further potential bioactivities. Pre-
conditioning with phenolic sulfates improved cellular responses to oxidative, 
excitotoxicity and inflammatory injuries in different cellular models with increased 
complexity. Additionally, the role of these metabolites in the attenuation of neuro-
inflammatory processes was highlighted: phenolic sulfate anti-neuroinflammatory 
potential led to a dramatic decrease in TNF- release which could be related with a 
regulation of NF-κB nuclear translocation and IκBα levels modulation. 
In the end, the potential protective effects of these selected phenolic sulfates in a 
superior human cell model of PD is investigated. Lund human mesencephalic neural 
progenitor cells (LUHMES) differentiated in a 3D were used for the superior model of 
PD, based in 1-methyl-4-phenylpyridinium (MPP+) lesion of the differentiated 
neurospheroids. In this PD-like model, bioavailable (poly)phenol metabolites have 
shown a pre-conditioning protective effect at circulating concentrations. Moreover, such 
pre-conditioning effect could be related with their proven effects to modulate central 
pathways such as Nrf2 and p53 signaling in LUHMES neurospheroids. These 




key regulators involved in neuroprotection, emerging as a potential new candidates for 
PD.  
In conclusion, a better understanding of cellular and molecular mechanisms by which 
these small molecules, derived from dietary (poly)phenols, can reach the brain and 
influence pathological events related with major neurodegenerative diseases was 
explored. This work is just a small tip of the iceberg though it opens doors for further 
studies with these phenolic sulfates, perhaps the true preventive effectors emerging 

























Complicações associadas ao envelhecimento, tais como as doenças 
neurodegenerativas, fazem parte de um grupo de patologias multifatoriais, cada vez 
mais incidentes na população e presentemente sem cura. A possibilidade de alterar a 
progressão ou o desenvolvimento deste tipo de doenças através da dieta é uma 
abordagem emergente e atrativa, com cada vez mais suporte experimental. Estudos 
epidemiológicos e clínicos têm reforçado o potencial para a saúde de dietas ricas em 
(poli)fenóis, uma classe de compostos naturais abundantes em frutas e vegetais. Os 
(poli)fenóis são compostos naturais associados a um crescente número de benefícios 
para a saúde, apresentando potencial de prevenir e/ou atrasar o desenvolvimento deste 
tipo de doenças. Na verdade, estudos com (poli)fenóis provenientes da dieta têm 
demonstrado a sua capacidade multipotente e pleiotrópica de modular diferentes vias 
metabólicas, quer a nível celular quer a nível molecular. A prevenção e tratamento do 
processo de neurodegeneração, caracterizado por uma complexidade mecanística, irá 
requerer o uso de novas estratégias terapêuticas, capazes de atuar em diferentes 
aspetos centrais da patologia. Nesse sentido, os (poli)fenóis provenientes da dieta 
podem surgir como válidas alternativas pleiotrópicas e multialvo, com potencial para 
serem explorados neste sentido.  
Os pequenos frutos encontram-se entre as fontes de (poli)fenóis mais ricas e 
promissoras, fortemente associados com benefícios para o cérebro, tendo implicações 
significativas nas doenças neurodegenerativas, tais como a doença de Parkinson (PD). 
De facto, a doença de Parkinson é uma das doenças associadas ao envelhecimento 
mais comum, ainda sem cura. É caracterizada por vários aspetos tais como a perda de 
células dopaminérgicas, disfunção mitocondrial severa, stress oxidativo aumentado e 
neuro-inflamação. A multiplicidade de causas/efeitos que caracteriza a doença de 
Parkinson tem impulsionado o desenvolvimento da investigação no sentido de 
encontrar novos agentes multialvo, onde os (poli)fenóis derivados dos pequenos frutos 
podem desempenhar um papel importante. 
Já foi descrito anteriormente que o potencial benéfico dos (poli)fenóis provenientes dos 
pequenos frutos contra um stress oxidativo crónico é aumentado quando estes são 
submetidos a uma digestão gastrointestinal simulada. Este potencial protetor dos 
compostos bioacessíveis derivados da digestão in vitro é, na verdade, maior do que o 
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do extrato original, indo para além das propriedades de captação direta de radicais 
livres por parte dos (poli)fenóis presentes no extrato original. Modificações que ocorrem 
nos (poli)fenóis ao longo do processo digestivo, tais como absorção, distribuição, 
metabolismo, e excreção, bem como a sua capacidade de ultrapassar barreiras de 
tecidos e órgãos do corpo humano, devem ser exploradas e melhor compreendidas de 
modo a conseguir, de uma forma mais precisa, desenhar terapias nutricionais capazes 
de intervir na progressão da doença. Neste trabalho, estes componentes dos pequenos 
frutos derivados de uma digestão in vitro (BDP), provaram ser capazes de serem 
transportados através das células endoteliais da barreira hematoencefálica (BBB), 
apresentando efeitos neuro-protetores consideráveis contra mecanismos centrais 
associados à neurodegeneração. Associações entre a sua capacidade cito-protetora e 
os mecanismos moleculares subjacentes destacou a via do mTOR e mecanismos de 
resposta a proteínas com incorreta conformação como as principais vias de sinalização 
canónicas reguladas pelo BDP. Contudo, para que estes componentes derivados dos 
pequenos frutos sejam efetivamente neuroprotetores, devem ser não só bioacessíveis 
como também biodisponíveis. 
Metabolitos biodisponíveis de (poli)fenóis de pequenos frutos foram detetados em 
amostras de urina e plasma de voluntários e, de um conjunto de metabolitos 
identificados e correspondentes concentrações encontradas em circulação, simples 
sulfatos fenólicos surgiram como os mais abundantes. O potencial destes sulfatos 
fenólicos biodisponíveis, os quais são derivados do metabolismo dos pequenos frutos 
pela microbiota intestinal, nunca foi estudado. Nesta tese, previsões in silico e estudos 
de transporte ao nível da barreira hematoencefálica in vitro, utilizando concentrações 
equivalentes às detetadas em circulação, demonstraram o transporte diferencial destes 
metabolitos, muito provavelmente estando relacionado com diferenças em termos de 
estrutura química entre eles. Para além disso, o metabolismo endotelial destes sulfatos 
fenólicos deu origem a uma variedade de novos metabolitos, com potenciais 
bioatividades a serem exploradas. O pré-tratamento com os sulfatos fenólicos melhorou 
as respostas celulares a diferentes danos, tais como stress oxidativo, excitotoxicidade 
e inflamação em diferentes modelos celulares de complexidade crescente. 




inflamatórios foi evidenciado: o potencial anti-neuro-inflamatório dos sulfatos fenólicos 
levou a um decréscimo pronunciado na libertação de TNF-, potencialmente 
relacionado com uma regulação da translocação nuclear do NF-κB e modulação dos 
níveis de IκBα. 
Para terminar, os efeitos protetores destes sulfatos fenólicos selecionados foram 
investigados num modelo celular humano de doença de Parkinson. Células humanas, 
progenitores celulares neuronais mesencefálicos (LUHMES), foram diferenciadas em 
3D e usadas para obtenção de um modelo superior de PD, baseado numa lesão 
aplicadas nos neuro-esferoides diferenciados com 1-methyl-4-phenylpyridinium 
(MPP+). Neste modelo de PD, os metabolitos biodisponíveis de (poli)fenóis 
demonstraram um efeito protetor através de mecanismos de pré-condicionamento 
quando usados em concentrações equivalentes às circulantes. Para além disso, este 
efeito de pré-condicionamento poderá estar relacionado com a modulação de vias de 
sinalização centrais tais como a via do Nrf2 ou do p53. Estes sulfatos fenólicos 
demonstraram ainda efeitos pleiotrópicos com capacidade de modular vias centrais e 
reguladores chave envolvidos na neuroprotecção, emergindo como potenciais novos 
candidatos na prevenção doença de Parkinson.  
Em conclusão, uma melhor compreensão dos mecanismos celulares e moleculares 
pelos quais estes compostos, derivados do metabolismo de (poli)fenóis provenientes 
da dieta, podem chegar ao cérebro e influenciar eventos patológicos relacionados com 
as principais doenças neurodegenerativas, foi aqui explorado. Apesar deste trabalho 
constituir apenas uma pequena ponta do iceberg, abre portas para futuros estudos com 
estes sulfatos fenólicos, quem sabe, os verdadeiros agentes ativos na prevenção das 






















This thesis is organized in five parts: introduction, three chapters of experimental work 
and a general discussion. 
In the introduction section, major topics necessary for a broad comprehension of this 
thesis is described. Major aspects about neurodegenerative diseases and (poly)phenols 
importance in the disease prevention are present. State of art of major cellular models 
used for studying (poly)phenols role in Parkinson’s disease (PD) is also described. 
Emphasis to the knowledge gaps of (poly)phenols potential to act inside the brain was 
considered such as their ability to cross and/or interact with the blood-brain barrier 
(BBB). Finally, a thesis rational and major work objectives are concluding the 
introductory section. Part of this section was included in a review published in Current 
Neuropharmacology. 
The experimental work is divided in 3 chapters. The first chapter exploits the potential 
of components derived from the in vitro digestion of blackberry to be transported across 
the BBB and also validates their previous reported neuroprotective potential taking 
advantage of superior models of neurodegeneration. Moreover, a microarray data 
analysis highlighted major canonical pathways modulated by these blackberry 
components that could be responsible for the neuroprotection observed. The work 
presented in this chapter was published in European Journal of Nutrition. 
In the second chapter, human bioavailable polyphenol metabolites found in circulation 
after the ingestion of berries mixture puree were tested for their potential as 
neuroprotective compounds against common hallmarks of neurodegenerative diseases. 
These metabolites proven to be differentially transported across the BBB and brain 
microvascular endothelial cells metabolize them into new cellular metabolites. The 
human bioavailable polyphenol metabolites were protective against oxidative stress, 
glutamate excitotoxicity and neuroinflammation. This chapter was published in Scientific 
Reports. 
The third chapter comprises a manuscript in preparation validating the neuroprotective 
potential observed of the human bioavailable polyphenol metabolites in an advanced 
and superior model of PD. By using a 3D cell model of the disease, recapitulating better 
the three-dimensional architecture of a brain environment, we observed a hormetic 
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potential of the metabolites by the modulation of Nrf2 target genes, with neuroprotective 
potential against important PD hallmarks.  
Finally, an integrated discussion of the findings obtained is presented, as well as the 
main considerations and potential directions of future work. 
 
 


















1-MePyr-sulf – 1-O-methyl pyrogallol-O-sulfate (1-O-methyl pyrogallol-2-O-sulfate and 1-O-
methyl pyrogallol-3-O-sulfate) 
2-MePyr-sulf – 2-O-methyl pyrogallol-O-sulfate 
4-MeCat-sulf – 4-methyl catechol-O-sulfate (4-methyl catechol-1-O-sulfate and 4-methyl 
catechol-2-O-sulfate) 
4-MeGA – 4-O-methyl gallic acid 
4-MeGA-sulf – 4-methyl gallic acid-3-O-sulfate 
6-OHDA – 6-hydroxydopamine 
AADC – aromatic L-amino acid decarboxylase 
ABC – ATP-binding cassette 
accptHB – number of acceptor hydrogen bonds (QikProp) 
ACh – acetylcholine  
AChE – acetylcholinesterase  
ACN – acetonitrile  
ACOX1 – peroxisomal acyl-coenzyme A oxidase 1 
ACTB – beta-actin  
AD – Alzheimer’s disease 
ADME – absorption, distribution, metabolism, and excretion 
AKAP12 – A-kinase anchor protein 12 
Akt (AKT1) – serine/threonine kinase (also called protein kinase B) 
ALB – albumin  
ALS – amyotrophic lateral sclerosis 
AMP – adenosine monophosphate 
AMPK – 5’ AMP-activated protein kinase 
ANGPT2 – angiopoietin 2 
ANXA4 - annexin A4  
AP – aminopeptidase  
AP-1 – activator protein 1 
APP – amyloid precursor protein 
Arc/Arg3.1 – activity-regulated cytoskeleton-associated protein 
ARE – antioxidant response elements 
ARS – arylsulfatase  




ASNS – asparagine synthetase 
ATCC – American type culture collection 
ATF4 – activating transcription factor 4 
ATF5 – activating transcription factor 5 
AAmyloid beta 
B2M – β2 microglobulin 
BACE1 – beta-secretase 1 
Bax (BAX) – Bcl-2-associated X protein,  
BBB – blood-brain barrier 
Bcl-2 (BCL2) – B-cell lymphoma 2 
BCL2L1 – BCL2-like 1 
BCRP (ABCG2) – breast cancer resistant protein 
BDNF – brain-derived neurotrophic factor 
BDP – blackberry-driven (poly)phenols 
BMEC – brain microvascular endothelial cells 
C/EBP – CCAAT/enhancer-binding proteins 
CALR – calreticulin  
cAMP – cyclic adenosine monophosphate 
Cat-sulf – catechol-O-sulfate  
CBG – cytosolic -glucosidase 
CCND1 – cyclin D1 
CCND2 –cyclin D2 
CD40 – cluster of differentiation 40 
CDC45 – cell division cycle 45 
CDC6 – cell division cycle 6 
CDF – chip definition file  
CDKN1A – cyclin dependent kinase inhibitor 1A 
CDKN1B – cyclin dependent kinase inhibitor 1B 
CEBPB – CCAAT/enhancer-binding protein beta 
CEBPG – CCAAT/enhancer-binding protein gamma 
Cmax – maximum (or peak) serum concentration 
CNS – central nervous system 
COMT – catechol O-methyl transferase 
COX-2 – cyclooxygenase-2 
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c-Raf (RAF1) – RAF proto-oncogene serine/threonine-protein kinase 
CREB – cAMP response element-binding protein 
Cys-NAT – cysteine N-acetyl transferase 
DAPI – 4',6-diamidino-2-phenylindole 
DAT – dopamine transporter 
DDIT3 or CHOP – DNA damage-inducible transcript 3 
DGAV – Direção-Geral de Alimentação e Veterinária 
DiOC6(3) – 3,3′-dihexyloxacarbocyanine iodide 
DMEM – Dulbecco’s modified Eagle's medium 
DMSO – dimethyl sulfoxide 
DnaJ (Hsp40, HSP40) – chaperone DnaJ, heat-schock protein 40kDa 
DnaK (Hsp70, HSP70) – chaperone DnaK, heat-schock protein 70kDa 
donorHB – number of donor hydrogen bonds (QikProp) 
E2F1 – transcription factor E2F1 
ECACC – European collection of cell cultures 
ECL – enhanced chemiluminescence 
EGCG – epigallocatechin gallate 
eIF2a – eukaryotic translation initiation factor 2A 
eIF4G – eukaryotic translation initiation factor 4 gamma 
EMEM – Eagle's minimal essential medium 
ER – endoplasmic reticulum 
ERK – extracellular signal–regulated kinase 
ESI – electrospray ionization 
FBS – fetal bovine serum 
FCT – Fundação para a Ciência e Tecnologia 
FDA – fluoresceine diacetate 
FEDER – European Regional Development Fund 
FELASA – Federation of European Laboratory Animal Science Associations 
FGF – fibroblast growth factor 
FTH1 – ferritin heavy chain 
FUS/TLS – RNA binding protein fused in sarcoma/translocated in sarcoma 
GA – gallic acid 
GADD45A – growth arrest and DNA-damage-inducible protein GADD45 alpha 




GAPDH – glyceraldehyde 3-phosphate dehydrogenase 
GARS – glycine-tRNA ligase 
GCLC – glutamate-cysteine ligase  
GCLM – glutamate-cysteine ligase 
GDNF – glial cell-derived neurotrophic factor 
GFAP – glial fibrillary acidic protein 
GGT – gamma glutamyl transferase 
GLT1 – glutamate transporter 1 
GLUT1 – glucose transporter 1 
GPX1 – glutathione peroxidase 1 
GSH – glutathione  
GSK3 – glycogen synthase kinase 3 beta 
GSR – glutathione reductase 
GSSG – oxidized glutathione 
GST – glutathione S-transferase 
GSTM1 – glutathione S-transferase Mu 1 
GSTP1 – glutathione S-transferase Pi 1 
GSTT1 – glutathione S-transferase theta-1 
hBDP – hydrolyzed blackberry- driven (poly)phenols 
HBMEC – human brain microvascular endotelial cells 
HBSS – Hank’s balanced salt solution 
HD – Huntington disease 
HERPUD1 – homocysteine inducible ER protein with ubiquitin like domain 1 
HMOX1 – heme oxygenase 1 
HPLC – high performance liquid chromatography  
HPRT1 – hypoxanthine phosphoribosyltransferase 1 
Hsp – heat shock proteins  
HSP90AA1 – heat shock protein 90 alpha family class A member 1 
HSP90B1 – heat shock protein 90 beta family member 1 
HSPA5 – heat shock Ppotein family A (Hsp70) member 5 
Htt – huntingtin  
IARS – isoleucyl tRNA synthetase 
IKK – IκB kinase 
IL-1 – interleukin-1 
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IL-1 – interleukin-1 beta 
IL-6 – interleukin-6 
IL-8 – interleukin-8 
iNOS – inducible nitric oxide synthase 
IPA – Ingenuity Pathway Analysis 
iPSC – induced pluripotent stem cells 
IRS1 – insulin receptor substrate 1 
IB – nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
JAK – Janus kinase 
JAK2 – Janus kinase 2 
JNK – c-Jun N-terminal kinases 
JUN – c-Jun 
Keap1 – Kelch-like ECH-associated protein 1 
KEGG – Kyoto Encyclopedia of Genes and Genomes 
LBs – Lewy bodies 
LC-MS – liquid chromatography–mass spectrometry 
LPH – lactase phloridzin hydrolase 
LPS – lipopolysaccharide  
LUHMES – Lund human mesencephalic 
m/z – mass-to-charge ratio 
MAP3K5 – mitogen-activated protein kinase kinase kinase 5 
MAPK – mitogen-activated protein kinase 
MCM – minichromosome maintenance complex 
MeDi – Mediterranean diet 
MEK – mitogen-activated protein kinase kinase (also known as MAP2K, MAPKK) 
MEKK (MAP3K1) – MAP kinase kinase kinase 
MEM – minimum essential medium 
mhGAP – mental health gap action program 
MPP+ – 1-methyl-4-phenylpyridinium 
MPTP – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRP – multidrug resistance-associated protein 
MRP1 (ABCC1) – multidrug resistance-associated protein type 1 
MRP2 (ABCC2) – multidrug resistance-associated protein type 2 




MS/MS or MS2 – tandem mass spectrometry 
mTOR – mammalian target of rapamycin 
NAT2 – N-acetyltransferase 2 
NDs – neurodegenerative diseases 
NEAA – non-essential amino acids 
NFAT – nuclear factor of activated T-cells 
NF-B – nuclear factor kappa-light-chain-enhancer of activated B cells 
NQO1 – NAD(P)H dehydrogenase [quinone] 1 
Nrf2 – nuclear factor (erythroid-derived 2)-like 2 
NUPR1 – nuclear protein 1 
OATP1A2 – organic anion-transporting polypeptide 
OATs – organic anion transporters 
ORC1 – origin recognition complex subunit 1 
ORC6 – origin recognition complex subunit 6 
P/S – penicillin / streptomycin   
p53 / TP53 – tumor protein p53 
PBS – phosphate buffer saline 
PD – Parkinson’s disease 
PDA – photo diode array 
PEDF – pigment epithelium-derived factor 
PERK – protein kinase R-like endoplasmic reticulum kinase; eukaryotic translation initiation 
factor 2-alpha kinase 3  
P-gp (ABCB1) – P-glycoprotein 
PHGDH – phosphoglycerate dehydrogenase 
PI – propidium iodide 
PI3K – phosphoinositide 3-kinase 
Pitx3 – pituitary homeobox 3 
PKD – pyruvate dehydrogenase kinase 
PLO – poly-L-ornithine 
PPAR – peroxisome proliferator-activated receptors 
PRKD1 – protein kinase D1 
PSA – Van der Waals surface area (QikProp) 
PSPH – phosphoserine phosphatase 
PSTA1 – phosphate transport system permease protein PstA 1 
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PTP4A3 – protein tyrosine phosphatase type IVA, Member 3 
PVDF – polyvinylidene fluoride 
Pyr-sulf – pyrogallol-O-sulfate (pyrogallol-1-O-sulfate and pyrogallol-2-O-sulfate) 
QPlogBB – predicted brain/blood partition coefficient (QikProp) 
QPlogKhsa – prediction of binding to human serum albumin (QikProp) 
QPlogPo/w – predicted octanol/water partition coefficient (QikProp) 
QPPCaco – predicted apparent Caco-2 cell permeability (QikProp) 
QPPMDCK – predicted apparent MDCK cell permeability (QikProp) 
QREN – Quadro de Referência Estratégica Nacional 
RMA – robust multi-array average 
RNS – reactive nitrogen species 
ROS – reactive oxygen species 
RPA – replication proteins A 
RPL22 – ribosomal protein L22 
RPS6KA2 – ribosomal protein S6 kinase A2 
RT-qPCR – reverse transcription quantitative polymerase chain reaction 
SARS – seryl-tRNA synthetase 
SD – standard deviation 
SEM – standard error of the mean 
SERPINF1 – serpin F1 or PEDF 
SGLT1 – sodium/glucose cotransporter 1 
SHMT2 – serine hydroxymethyltransferase 
SIRT1 – sirtuin 1 
SLC – solute carrier family 
SOCS3 – suppressor of cytokine signaling 3 
SOD1 – superoxide dismutase 1 
SQSTM1 – sequestosome 1 
SREBF1 – sterol regulatory element-binding transcription factor 1 
SREBP – sterol regulatory element-binding protein 
STAT – signal transducer and activator of transcription 
Syn (SYP) – synaptophysin  
t-BHP – tert-butyl hydroperoxide 
TDP-43 – TAR DNA-binding protein 43 




TGF-transforming growth factor beta 
TH – tyrosine hydroxilase 
TNF- – tumor necrosis factor alpha 
TOR – target of rapamycin 
TrkB – tropomyosin receptor kinase B 
TXNRD1 – thioredoxin reductase 1 
UDP – uridine diphosphate 
UDPG – UDP-glucuronosyl transferase 
UPR – unfolded protein response 
VA-sulf – vanillic acid-O-sulfate 
VEGF – vascular endothelial growth factor 
VMAT2 – vesicular monoamine transporter 2 
WARS – tryptophanyl-tRNA synthetase 
WHO – World Health Organization 
XPOT – exportin-T 
m – mitochondrial transmembrane potential 
Syn – alpha-synuclein 
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1. NEURODEGENERATIVE DISORDERS 
Neurodegenerative disorders (NDs) collectively refer to debilitating, life-threatening 
conditions that affect brain cells. As chronic and progressive neurological syndromes, 
they are caused by nervous system dysfunction resulting from neuronal cell failure1, 
leading to impaired mental functioning (dementia) or movement complications (ataxia). 
These diseases can arise from hereditary or sporadic conditions, having a complex 
pathogenesis that triggers atrophy of central or peripheral structures of the nervous 
system2. Disease-modifying therapies to delay or reverse disease progression are not 
yet available, there is only a paucity of pharmacotherapy strategies focused on 
symptomatic relief.  
More than 600 disorders have been described to afflict the nervous system such as 
Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), 
amyotrophic lateral sclerosis (ALS), multiple sclerosis, brain cancer, degenerative nerve 
diseases, encephalitis, epilepsy, among others. They are heterogeneous and 
multifactorial pathologies, which affect different brain structures and have different 
aetiologies. AD, PD and HD, as well as ALS and others, share the aggregation of 
misfolded proteins as common pathological processes, being collectively designated as 
protein conformational disorders2, 3.  
AD is a clinical syndrome characterized by the progressive degeneration of 
hippocampus and neocortical brain neurons4, which is responsible for the major disease 
symptoms – memory loss and cognitive decline. AD pathological hallmarks include the 
accumulation of extracellular amyloid plaques, majorly composed by amyloid-β peptides 
(Aβ40 and Aβ42)5, and intracellular aggregates of hyperphosphorylated forms of tau, a 
microtubule-binding protein, designated neurofibrillary tangles6. AD represents the 
primary cause of dementia accounting for nearly 70% of known dementia cases and 
being one of the leading causes of mortality worldwide7, 8. The incidence rates vary 
between 5 and 8 per thousand persons–years, which corresponds to half of new 
dementia cases each year9, 10. 
PD is the second most common ND. Its clinical symptoms include muscle rigidity, 
bradykinesia, resting tremor and postural instability, caused by the loss of dopaminergic 
neurons in the substantia nigra pars compacta11. The cytoplasmic inclusions designated 
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Lewy bodies (LBs), predominantly enclosing aggregated -synuclein (Syn)12, are the 
major pathological hallmark of the disease. Syn is highly expressed in the brain and 
its function is thought to be involved in the regulation of dopamine neurotransmission 
and synaptic function/plasticity13-18. Following AD, PD is the second most common ND. 
The Parkinson’s disease Foundation predicts that PD affects 7-10 million people 
worldwide. The prevalence rates vary from circa 50-300 per 100.000 individuals 
whereas the incidence rates are about 10-20 new cases per 100.000, annually19, 20. 
HD displays a wide variety of symptoms including chorea, dementia, and emotional 
disturbance21, 22. It is characterized by neuronal demise especially in the striatal region 
of the basal ganglia. Genetic mutations causing HD are linked to the expression of N-
terminal polyglutamine (polyQ)-expanded huntingtin (Htt) beyond a critical length of ~35 
glutamine residues. The cleavage of these polyQ tails generates cytotoxic fragments 
with high propensity to cross-link and form protein aggregates in both neuronal and glial 
cells23, 24. As a rare neurodegenerative condition, the global HD prevalence is 2.71 per 
100,000 individuals, being higher in Europe, North America and Australia than in Asia25. 
ALS is a fatal motor neuron disease leading to death usually within 3-5 years after the 
disease onset, mostly due to respiratory failure. It is characterized by progressive 
muscle weakness, which frequently starts in the limbs, axial, bulbar, or respiratory 
muscles and afterwards generalizes relentlessly causing a gradual disability. The 
disease is caused by progressive loss of cortical, bulbar, and ventral cord motor 
neurons, with the major genetic risk factors being mutations in the genes encoding the 
superoxide dismutase SOD126, the TAR-DNA-binding protein27 and the fused in 
sarcoma or translocated in liposarcoma protein (FUS/TLS)28, 29. Consistent with the very 
limited survival of patients suffering ALS, prevalence is quite low, ranging between 4-5 
people out of 100.000 and accounting for 1/300 to 1/400 of all deaths in the US. The 
median annual incidence of the disease in Europe and the US is estimated at 0.7-2.5 
per 100,000 individuals19, 30. 
Besides the determinant protein aggregation role in major NDs, several other factors 
are common and transversal to them. As such, in the past years, a new paradigm has 
been emerging to devise interventions which target common mechanisms of ageing to 






hallmarks like increased oxidative stress, protein carbonylation, lipid peroxidation, DNA 
damage, mitochondrial dysfunction, vascular dysfunction, endoplasmic reticulum (ER) 
stress, unfolded protein response (UPR) dysregulation and imbalanced proteostasis, 
and also neuroinflammation are common and will require mutitargeted interventions to 
tackle disease progression. Importantly, neuroinflammation appears as one of the key 
processes involved in major NDs: neuroinflammation has been regarded as a double-
edged sword, being not only essential for the recovery from a number of conditions, but 
it may also play detrimental roles in neurodegenerative processes, contributing to 
disease progression. Altogether, this information reinforces the concomitant burden that 
NDs present in the developed world and the trend to increase over time. The need for 
novel therapies assisting to retard and prevent the development of these diseases is 
imperative and must be the focus of research in this area, rather than finding new 
alternatives to treat symptoms in later stages of disease progression. 
Though ageing is considered a primary process in neurodegeneration, it differently 
influences the onset of the various NDs. Advancing age is the leading risk factor for AD, 
and disease onset usually occurs at the age of 657. Reports indicate that the risk of 
developing this disease almost doubles every five years after this age9, 10. Likewise, PD 
majorly afflicts individuals over 60 with higher median prevalence rates over 65s than in 
the overall population of US and European countries19. As a consequence, median PD 
incidence ratios are also much higher in individuals over the 65s (160 per 100,000 
person-years) than in the overall population (14 per 100,000 person-years)19. Indeed, it 
is estimated that the development of treatments reducing severe cognitive impairment 
in older people by just 1% per year would cancel out the projected increases in the long-
term care costs due to our ageing population (Alzheimer’s Research Trust). 
 
1.1. Healthy ageing and transition to disease 
Ageing is a complex, irreversible, progressive and natural process, which is 
characterized by morphological, psychological, functional and biochemical changes, 
affecting the welfare and health of the individual. The maximization of the functional 
capacity and health of the elderly is conditioned by factors such as nutrition, physical 
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and social activity, education, and genetic background, which ultimately define healthy 
ageing. Some of these factors are not modifiable, such as genetic ones, while others 
(nutrition, physical and social activity, etc.) are subject to change (i.e. environmental, 
psychological, social and lifestyle). In this sense, nutrition and other modifiable factors 
have a huge impact on health and wellbeing. The nutritional status of elderly people has 
been increasingly considered a key aspect for a healthy ageing and, therefore, nutrition 
emerges as a critical modifiable risk factor to be exploited in policy strategies to prevent 
or delay the onset of NDs and dementia32. There are several evidences that a 
continuous and prolonged intake of fruit and vegetables, rich sources of compounds 
named (poly)phenols, may help in the prevention of several degenerative pathologies 
such as diabetes, cardiovascular diseases, NDs and cancer, and to prevent symptoms 
associated to ageing and menopause33, 34. 
If we consider the normal process of evolution of a healthy state to a disease state, we 
may resume that the evidences indicate an active role of dietary (poly)phenols to 
homeostasis maintenance, delaying or even reversing the transition from a healthy to a 
pathological state (Fig. 1). Then, nutrition, and in particular bioactive (poly)phenols 
identified in the diet, are strong contributors to the maintenance of a healthy condition. 
Moreover, (poly)phenols can also constitute lead compounds as basis for developing 
new drugs and therefore contribute to a pharmacology intervention (Fig. 1). Thus, 
pharmacological and nutritional approaches can be considered for the study of 







Fig. 1 Disease progression and transition from healthy to disease state. (Poly)phenols can potentially act 
in the prevention of disease, through nutrition, or to restore the healthy state in the earlier stages of a 
disease even before the administration of a drug. Drugs are only prescribed after a diagnostic marker has 
been identified and generally treat only the symptoms of degenerative diseases and are not a cure in most 
cases. (Poly)phenols can also be the basis for developing new therapeutic compounds and therefore 
contribute for a pharmacology intervention.  
 
2. (POLY)PHENOLS AND HEALTH 
Phenolic compounds, commonly referred as polyphenols, constitute one of the most 
extensive and ubiquitous group of secondary metabolites in the plant kingdom. These 
compounds are characterized structurally by the presence of, at least, one hydroxyl 
functional group (-HO) linked to an aromatic ring35. Some compounds that do not 
present structural characteristics of polyphenols are commonly integrated in the group 
of polyphenols as “honorary”, such as phenolic acids or stilbenes. For this reason, 
recently the term “polyphenols” has been rewritten as “(poly)phenols”36-38.  
(Poly)phenols represent an extremely differentiated group not only in terms of chemical 
structure but also in terms of their biological activity. They occur conjugated with sugars, 
carboxylic and organic acids, amines, lipids and other phenols. Different groups are 
classified in terms of the number of phenol rings that they encompass and according to 
the structural elements binding these rings39, 40. The main classes are represented in 
Fig. 2 and include phenolic acids, stilbenes, flavonoids, coumarins and lignans.  
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Hydroxybenzoic and hydroxycinnamic acids represent the two different groups of 
phenolic acids. The first ones can be found in plants, both free and esterified. Examples 
are gallic acid, present in fruits, herbs, tea and wine, or more complex compounds, the 
hydrolysable tannins such as ellagic acid, gallotannins and ellagitannins41. 
Hydroxycinnamic acids are generally represented by p-coumaric, caffeic, ferulic and 
sinapic acids, usually found glycosylated or conjugated with quinic, shikimic and tartaric 
acids39, 41. Chlorogenic acid, an ester of caffeic and quinic acids, can be found in several 
fruits and vegetables and is highly abundant in coffee. Ferulic acid is present in large 
amounts in cereal grains41, 42. Stilbenes frequently present in roots, barks, rhizomes and 
leaves, are not routinely consumed. By opposition we have a highly valued stilbene, 
resveratrol, present in grapes and in red wine43.  
The largest group of phenolic compounds in plants are flavonoids, with more than 
10,000 different structures being identified44. The main classes of flavonoids are 
flavonols, flavones, isoflavones, flavanones, anthocyanins and flavanols. Monomers of 
flavanols (catechins), such as (+)-catechin and (-)-epicatechin, are relatively abundant 
in fruits, wine, chocolate and green tea41, 45. Proanthocyanidins, also known as 
condensed tannins, are constituted by dimers, oligomers and polymers of catechins. 
Proanthocyanidins can be found in fruits such as apples and grapes, in wine, cider, tea 
and beer, and also in cocoa46. Anthocyanins are glycosylated pigments, responsible for 










Fig. 2 Main (poly)phenol classes with structure, name of representative compounds (in italic) and examples 
of food sources are represented.  
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2.1. Cognitive health and dietary (poly)phenols: epidemiological and 
population based studies 
The beneficial effects resulting from (poly)phenol intake have been extensively studied, 
as in the studies concerning the Mediterranean Diet (MeDi). MeDi is characterized by a 
high consumption of fruits, vegetables, and grains, as well as sea-fish on regular bases. 
It also includes a modest consume of wine and olive oil as the principal source of fat, 
both highly enriched in (poly)phenols. Additionally, the intake of meat, dairy products, 
sweets and convenience food is rather low in the MeDi47, 48.  
A survey of studies reporting the effects of MeDi, carried out by WHO, revealed that it 
is a promising strategy to prevent diseases and to enhance quality of life (World Health 
Organization, 2009). Furthermore, epidemiologic studies over the last decades have 
supported the positive correlation between Mediterranean eating patterns and a large 
number of health benefits49, 50, including (i) decreased risk of developing NDs; delayed 
AD and PD onset; (iii) lowered mortality in AD patients; and (iv) improved cognitive 
function32, 51-53. 
(Poly)phenols are abundant in MeDi and are believed to contribute to the beneficial 
effects of this diet when adopted in a regular basis, as revealed by studies showing that 
(poly)phenol-rich diets improve cognition, memory, learning, and vascular function in 
elderly people54, 55. The regular consumption of flavonoid rich-foods, representing the 
most common group of (poly)phenolic compounds in the human diet, has been 
associated to enhanced cognitive abilities and reduced risk of cognitive decline in aged 
individuals56, 57. Indeed, a large-scale population study indicated that flavonoids intake 
decreased dementia as well as premature death due to dementia57. Remarkably, it was 
found a correlation between high (poly)phenol concentrations in urine samples of older 
adults and lower risk of cognitive decline in global cognitive function in a prospective 
population-based study over a 3-year period58.  
Among the different food sources, berries are considered to be a rich source of 
(poly)phenols with brain health benefits. In fact, wild blueberry diet supplementation was 
proved to improve cognitive function in older adults59. Increased consumption of berries 
was shown to be associated to a slower progression of cognitive decline in a large 






consumption is associated with reduced risk of developing PD61. A recent study have 
shown that a chronic blueberry supplementation improved brain perfusion, task-related 
activation, and cognitive function in healthy older adults, highlighting that a diet 
supplementation with an anthocyanin-rich concentrate can improve brain activation in 
brain areas associated with cognitive function62. Moreover, in a double-blind, placebo 
controlled trial, the addition of easily achievable quantities of blueberry to the diets of 
older adults improved some aspects of cognition63. 
These studies support the hypothesis that (poly)phenol-rich foods or supplements have 
a positive impact towards NDs. How it is processed and by which mechanisms diet 
alterations may exert protective effects is still a field of intensive research that, in the 
future, may change our perspective of an effective treatment for NDs. 
2.2. Nutritional relevance and bioavailability of (poly)phenols 
Although (poly)phenols are not essential for humans, they have a positive impact on 
human nutrition. (Poly)phenols are widely spread in food, and the total (poly)phenols 
dietary intake could be as high as 100-150 mg per day, which is much higher than that 
of all other classes of phytochemicals41. Just for perspective, this is one order of 
magnitude higher than the intake of vitamin C and two orders of magnitude higher that 
the intake of vitamin E and carotenoids64, 65. (Poly)phenols’ main dietary sources are 
fruits and plant-derived beverages such as fruit juices, tea, coffee, and red wine. 
Vegetables, cereals, chocolate, and dry legumes also contribute to the total (poly)phenol 
intake41. The amount of research that has emerged in the past years in order to better 
understand (poly)phenols health benefits discloses a glimpse of the huge potential they 
may present66-68. However, for a deeper understanding of the effect of (poly)phenols in 
human health, their absorption, distribution, metabolism and excretion in the human 
digestive tract needs to be studied.  
The most common (poly)phenols present in the human diet are not necessarily the most 
active inside the body, either due to a low inherent activity or due to their poor 
absorption, extensively metabolism and rapid excretion41. Throughout digestion, 
(poly)phenols suffer several chemical modifications and metabolism, and the 
bioavailable metabolites found in blood and tissues may diverge from the native 
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compounds in terms of biological role. Many different models are used to obtain a 
deeper knowledge about these mechanisms, ranging from in vitro enzymatic activities, 
cellular models, animal models or even the man himself. Although many differences can 
be seen between human and other animals’ digestive process, animal studies have 
been essential for the current understanding gathered so far on (poly)phenols 
bioavailability and effects. 
One of the major difficulties on studying the bioavailability of (poly)phenols relies on their 
structural differences, resulting in different metabolic fates among compounds. Although 
some reactions could be common, several differences in the (poly)phenols metabolism 
can occur among classes or even within the same class. 
After ingestion, the availability of (poly)phenols, often associated with fibre or complex 
carbohydrates in the food matrix, can be modified in the oral cavity by amylase digestion 
and, perhaps, by particle size reduction69. Afterwards, the effective release of the 
phenolic compounds in the stomach maximizes the potential for absorption in the small 
intestine69. Absorption occurs mainly at the duodenum and at the proximal half of 
jejunum, where enterocytes are the predominant cells, being responsible for the 
absorption (Fig. 3). Being lipophilic compounds, most flavonoid aglycones and phenolic 
acids permeate intestinal cells by passive diffusion33, 70, 71. (Poly)phenols in the form of 
esters, glycosides or polymers, usually present in plants, cannot be directly absorbed 
and they probably resist to acid hydrolysis in the stomach, being able to reach the 
duodenum41. 
The absorption of glycosylated compounds is usually preceded by the hydrolysis of the 
glycoside and release of the aglycone (Fig. 3), by the enzyme lactase phloridzin 
hydrolase (LPH) in the brush-border of the small intestine epithelial cells. After 
hydrolysis, the free aglycone can enter the epithelial cells by passive diffusion72. 
Otherwise, glycosylated compounds are supposed to enter epithelial cells via the 
sodium-dependent glucose transporter, SGLT1, and be hydrolyzed by the cytosolic -
glucosidase (CBG), depending on the glycoside73. The highly stable oligomeric and 
polymeric flavanols, during digestion, are thought to have a very low absorption74.  
Compounds that are not absorbed in the proximal gastrointestinal tract can reach the 






degrade complex (poly)phenols into low molecular weight phenolics, aromatic acids75, 
and also into oxaloacetate and CO276.  
As usually happens with xenobiotics, (poly)phenols can undergo enzymatic 
modifications at the liver known as ‘biotransformations’, phase I and phase II reactions 
(Fig. 3)77. During phase I metabolism, oxidation reactions (mainly via cytochrome P450), 
reduction, and hydrolysis reactions occur, converting (poly)phenols into more polar 
(water soluble) metabolites by unmasking or inserting a polar functional group (-OH, -
SH, -NH2). Further conjugation reactions that increase water solubility of drug with a 
polar moiety take place during phase II metabolism, mainly glucuronidation, acetylation, 
and sulfation reactions. The resulting compounds are frequently less lipophilic so the 
body can more easily excrete them.  
Phase III transporters are responsible for the final step in the elimination and/or 
detoxification of xenobiotics, resulting in the removal of the undesired compounds in 
faeces, urine and bile78 (Fig. 3). These transporters are mainly constituted by the ABC 
protein family, including P-glycoprotein (P-gp), the multidrug resistance-associated 
proteins (MRP2, BCRP), and also by the solute carrier family (SLC) transporters79, 80.  
Importantly, most of the conjugated-(poly)phenols are excreted in urine. However, the 
mechanisms by which these conjugated-(poly)phenols can return into the intestinal 
lumen or to bile, by the action of intestinal cells or liver parenchymal cells, respectively, 
should also be considered (Fig. 3). Several (poly)phenols were shown to be 
considerably better absorbed in the presence of additional (poly)phenols, interfering with 
efflux transporters (P-gp, MRPs, BCRP), which normally reduce the intracellular 
concentration of such “xenobiotics” and, in that case, lead to their excretion to the apical 
side81, 82. On the other hand, transporters to the basolateral side are poorly understood. 
Compounds excreted into bile are eventually emptied in the duodenum. Usually, they 
are not absorbed in the small intestine, and reach the colon, where they can either be 






Fig. 3 Schematic representation of absorption, biotransformation and excretion of (poly)phenols in the 
human body. Along the digestive process, (poly)phenol-rich food suffers transformations, starting in the 
mouth, stomach and throughout  the entire gastrointestinal tract. The gastrointestinal tract is covered by the 
mucosa, covering intestinal epithelium which functions as a physical barrier, determining bioavailability of 
xenobiotics like (poly)phenols. This function is mediated by physical walls, metabolism and passive (solid 
arrows)/active (dashed arrows) transport mechanisms. Absorption occurs mainly at the duodenum and the 
proximal half of jejunum, in enterocytes. Enterocytes apical cell membranes contain microvilli, which 
increase the surface area of absorption. Passive intestinal permeability occurs mainly for aglycones and 
simple phenolic acids. Absorption of glycosylated compounds is usually preceded by release of aglycone 
through hydrolysis by lactase phloridzin hydrolase (LPH). Free aglycone can then enter the epithelial cells 
by passive diffusion. Alternatively, glycosylated compounds enter epithelial cells by the active sodium-
dependent glucose transporter SGLT1 and are hydrolyzed by the cytosolic β-glucosidase (CBG). Once 
inside enterocytes, (poly)phenols can be extruded into the lumen by efflux transporters (P-gp, MRPs, 
BCRP). Compounds not absorbed reach the colon where they can be extensively metabolized by 
microbiota. Several transformations in (poly)phenols structure can occur. Most of the colonic metabolites 
are excreted in feces, although absorption can still take place. Then, (poly)phenols can undergo phase I 
and phase II reactions. Phase I reactions include oxidative and reductive reactions. Glucuronidation, 
sulfation and methylation are the most frequent phase II reactions. The conjugates, being more water 
soluble, are rapidly excreted through bile or urine 77. Metabolites can then be transported into the bile 
(enterohepatic recirculation) and secreted back to the duodenum. Degradation of metabolites in the 
intestine generates catabolites available for reabsorption. 
 
 
Bioavailability of (poly)phenols is thus a multi-stage process comprising de-conjugation 
and possible catabolism, absorption, conjugation and excretion (Fig. 3). Moreover, the 
possible sequestration of some (poly)phenol metabolites inside tissues has been 









































bioavailability. The accessibility of (poly)phenol metabolites to the central nervous 
system is an example where the presence of an additional barrier, the blood-brain 
barrier (BBB), reduces even more (poly)phenols bioavailability, in addition to the 
described metabolism. Therefore, controlled target delivery to central nervous system 





3. NEUROPROTECTIVE POTENTIAL OF (POLY)PHENOLS  
In addition to the epidemiological evidences already mentioned, neuroprotective 
evidences for (poly)phenols also result from in vitro (cell free assays), cellular, animal 
and clinical studies54, 86. Another aspect important to consider is that (poly)phenols can 
be studied either in a pharmacological or a nutritional perspective. Besides the form of 
delivery/route of administration, we can consider studies focusing on pure compounds, 
namely studies with (poly)phenol aglycones (Table 3), with relevance in a 
pharmacological context, or with (poly)phenol metabolites (Tables 2, 4, 5), or even with 
the use of mixtures or whole extracts (Table 1), highlighting (poly)phenols potential in a 
more nutritional perspective.  
 
Neurodegeneration is a multifactorial process and (poly)phenols present pleiotropic 
effects (antioxidant, anti-inflammatory, immunomodulatory properties)87 due to their 
ability to modulate the activity of multiple targets involved in pathogenesis, thereby 
potentially halting the progression of these diseases. For many years, (poly)phenols 
were thought to protect cell constituents against oxidative damage through direct 
scavenging of free radicals. Such idea has become very popular leading to the 
appearance of several studies exploring extensively this property of (poly)phenols for 
NDs, since oxidative stress constitutes an important hallmark of these diseases. 
However, this concept now appears to be an oversimplified view of their mode of action. 
There is an emerging acceptance that (poly)phenols, as well as their metabolites, exert 
modulatory actions in proteins/enzymes through direct interaction with receptors or 
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enzymes involved in signal transduction, such as protein kinase and lipid kinase 
signalling pathways88. Moreover, several neurochemical mechanisms underlying the 
protective action of (poly)phenols have been described: iron chelating properties89; 
modulation of signalling pathways related with neuronal survival and differentiation88, 90; 
inhibition of neuropathological processes91, 92; and regulation of mitochondrial function93-
95. Other mechanisms by which flavonoids can be neuroprotective include their positive 
role on peripheral and cerebrovascular blood flow, ultimately affecting synaptic plasticity 
processes and cognitive function96. Accumulating evidence highlights the molecular and 
cellular pathways mainly modulated by parent (poly)phenols, which, though not always 
nutritionally relevant, can give us clues about the putative mode of action of their 
(poly)phenol metabolites in a nutritional context. The study of the neuroprotective 
potential of (poly)phenol metabolites resulting from extensive human metabolism (Fig. 
3), however, is still in its infancy and should be further explored.  
Importantly to notice, the study of pure compounds is limited to their molecular 
mechanisms in neurodegeneration cell models and their specific biological effects in 
animal models and such studies miss the synergies of different (poly)phenols. The 
overall diet complexity, the potential synergy that may occur in compounds derived from 
the metabolism cannot be fully depicted in studies using pure compounds97. Studies 
with (poly)phenol-enriched fractions or with the bulk of digested/metabolized 
compounds may be useful to approach this interactions and depict the molecular effects 
of the overall metabolites in cells. Since (poly)phenols and (poly)phenol metabolites are 
emerging as key compounds for the development of novel therapeutic agents for NDs, 
the identification of the molecular targets taking advantage from in vitro (cell free) 
studies, cell models and in vivo studies has become an emerging area of research 
(Tables 1-5).  
 
3.1. In vitro (cell free) studies 
The consensus on the important role of free radical-mediated reactions in the 
pathophysiology of most NDs lead to the extensive study of (poly)phenols chemical 






Table 1. Neuroprotective evidences (in vitro, cellular models and animal studies) for the most representative 
dietary (poly)phenolic extracts. 
 
 
Substantial presynaptic cholinergic deficit is a feature registered in most NDs134. 
Malfunction of the cholinergic system may be tackled pharmacologically through 
 
In vitro 
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 Scavenging intracellular RNOS 
and induced endogenous 
antioxidant defences preventing 
DNA damage 100 
 Protects primary rat cortical 
neurons against Aβ-induced 
cytotoxicity 103 
Ageing and neurodegeneration models: 
 ↓ Protein/lipid oxidation 104 
 ↑ Spatial learning 104 
 Modulation of glutathione levels and 
antioxidant enzyme activities 105 
 ↑ CREB activation 105 
 ↑ BDNF and Bcl-2 levels 105 
 ↑ Cognitive and behavioural capacities 106 
 Protects against deltamethrin-induced 
neurotoxicity in rat 107 
AD rodent models: 
 ↓ Aluminium chloride toxicity 108 
PD non-human primates model: 
 Alleviate motor impairments, dopaminergic 

























 ↑ IL-6 and respective mRNAs in 
primary culture of astrocytes, 
which functions as a 
neuroprotective paracrine, 
protected neuronal cells from 
death by oxidative stress 111 
 Protects neuronal cells against 
low extracellular Mg2+ 
concentration and oxygen 
glucose deprivation-induced 
neurotoxicity, in cultured rat 
hippocampal neurons mediated 
by inhibition of glutamate-
induced calcium signaling and 
NO formation 112 
  
AD rodent model: 
 ↓ cognitive deterioration 92 
 ↑ cognitive function 113 
 ↓ oligomerization of Aβ peptides and 
amyloid plaques 92 
 ↓ microglial activation 114 
 ↓ extracellular-signal-regulated kinases 
(ERK) 1 and 2 in the brain, suppressing tau 
neuropathy 115 
 Interferes with the assembly of Aβ peptides 
into neurotoxic aggregates 116 
 ↑ Spatial memory performance, ↓ cognitive 
deterioration and Aβ neuropathy 117 
HD rodent model:  



























 ↓ Toxicity of Aβ aggregates 
toward Neuro2a cells 122 
 ↑ Aβ aggregates clearance, ↓ 
fibrillation and supressed 
microglia activation, in murine 
cell cultures 123, 124 
 Protection of neuronal cultures 
from oxidative stress 125 
 ↓ Neuroinflammation 126  
 ↓ Neuronal death in cells 
expressing Aβ by improving 
cellular metabolism 127 
Ageing and neurodegeneration rodent models: 
 Reverse age-related deficits in spatial 
working memory (↑CREB activity, ↑BDNF, 
hippocampal Akt  phosphorylation, 
activation of TOR and ↑ expression of 
Arc/Arg3.1 128 
 Delayed age-related motor and cognitive 
behavioural deficits 129-132 
AD rodent model:  
 ↓ cognitive degeneration 122 
 Reverses Aβ-induced effects on protein 
expression: mitochondrial apoptotic 
pathway (Bax, cytochrome C, caspase-9 
and 3) and AD markers (Aβ, APP, P-tau and 
BACE-1) 127 
 Pomegranate juice oral intake improved 




inhibition of acetylcholinesterase (AChE)135, which catalyses the hydrolysis of the 
neurotransmitter acetylcholine (ACh) to choline. Therefore, AChE inhibition has been 
reported to ameliorate the symptoms of some NDs and has been used as a rationale to 
develop drugs to treat AD136. Interestingly, green tea and white tea digested metabolites 
were described to inhibit AChE102.  
Another common pathological hallmark of many NDs is the generation of aberrant 
misfolded proteins with formation of intra- or extra-cellular high-ordered insoluble fibrils 
deposits137, 138. Potent activities towards the several steps of fibrils formation are 
modulated either by extracts or by isolated compounds. For instance, inhibition of Aβ-
peptide aggregation and fibril formation was described for blueberry anthocyanins 
enriched extract122; epigallocatechin gallate (EGCG)139, 140; myricetin141 and resveratrol 
derivatives119-121, 142, 143.Moreover, the ability to destabilize preformed fibrils in vitro was 
also described for curcumin144, catechins and procyanidins145. Similarly, the protein 
αSyn is an amyloidogenic polypeptide that forms cytotoxic oligomers and quercetin was 
described to reduce αSyn fibrillization146. It was also shown that EGCG redirect the 
aggregation of αSyn monomers and remodel αSyn amyloid fibrils into disordered 
oligomers139, 147. In addition to (poly)phenol parent compounds, a study have shown that 
brain-accumulating phenolic acids, derived from colonic metabolism (namely 3-
hydroxybenzoic acid and 3-(3´-hydroxyphenyl)propionic acid), also potently interfere 
with aggregation of Aβ peptides, in vitro148. Moreover, the brain-targeted bioactive 
dietary quercetin-3-O-glucuronide was shown to be capable of interfering with the initial 
protein-protein interaction of Aβ(1-40) and Aβ(1-42) that is necessary for the formation 
of neurotoxic oligomeric Aβ species149. Urolithins, the ellagitanins physiologically-
relevant gut microbiota-derived metabolites, have also shown to prevent Aβ fibrillation 
in vitro150.  
In vitro cell free studies are particularly relevant to determine the effect of (poly)phenols 
and (poly)phenol metabolites in specific pathological processes, without the interference 
of other cellular pathways. However, in vitro findings must be interpreted with caution, 
as some are not translatable into cell and animal models. For instance, (poly)phenols 
present a very promising in vitro antioxidant capacity, leading to the misconception that 






animal models were valuable to demystify this concept, and now we know that the mode 
of action of (poly)phenols go far beyond than their antioxidant potential151.  
 
Table 2. Neuroprotective evidences (in vitro – cell free studies) for some bioavailable (polyphenol 
metabolites. 
 










Albumin (BSA) + 
glucose 
Ellagitannin-derived catabolites 
(urolithins and pyrogallol) are 
the most effective antiglycative 
agents 





linking of unmodified 
protein assay w/ 
A(1-42) and  
A(1-40) 
The brain-targeted bioactive 
dietary quercetin-3-O-
glucuronide interfere with the 
initial protein-protein interaction 
of Aβ(1-40) and Aβ(1-42) that 
is necessary for the formation 
of neurotoxic oligomeric Aβ 
species  









Thioflavin-T assay  
w/ A(1-42) 
Inhibition on Aβ(1−42) 
fibrillation 




linking of unmodified 
protein assay 
Circular dichroism 
Thioflavin-T assay  
Electron microscopy 
w/ A(1-42) 
3-hydroxybenzoic acid and 3-
(3´-hydroxyphenyl)propionic 
acid potently interfere with the 
assembly of β-amyloid peptides 
into neurotoxic β-amyloid 
aggregates that play key roles 
in AD pathogenesis 




3.2. Cellular models 
Cellular models are very important to unravel the molecular mechanisms underlying the 
(poly)phenol protective effects observed in animals. They allow to study the cross-talk 
between pathways affected by (poly)phenols and (poly)phenol metabolites, giving an 
integrated view of the metabolic pathways affected by these compounds. In contrast to 
cell free studies, focused on a particular aspect or protein/enzyme function, in cellular 
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models the whole cellular metabolism is evaluated. Studies analysing the potential of a 
mixture of compounds, as food extracts, (Table 1) can present advantages, such as the 
existence of potential synergisms between (poly)phenols components (as it occurs in 
our diet, where (poly)phenols are embed in a food matrix), but over caution should be 
taken when interpreting the nutritional and biological relevance of such studies: 
conclusions taken from the usage of  conventional food extracts directly on cells may 
not be translatable to real potential beneficial effects. The usage of extracts resulting 
from in vitro digestion methods can present an elegant approach to obtain (poly)phenol 
compounds’ mixtures more close to the in vivo situation. Such mixtures of (poly)phenol 
components resulting from in vitro digestion are more appropriate for being used in cell 
studies than conventional extracts when the aim of the studies is to evaluate the 
potential of complex mixtures of compounds, as equivalent to our diet. 
A plethora of mammalian cell models have been used to study the protective action of 
(poly)phenols towards NDs. Some of these models cover common disease hallmarks 
such as oxidative stress, DNA damage, lipid peroxidation, and mitochondrial 
dysfunction. On the other hand, more complex models address particular pathological 
processes associated to each disease as well as toxicity of specific disease proteins.  
Given the close association between inflammation and NDs, a special attention has 
been given to the use of reliable cellular models to access the anti-inflammatory 
potential of (poly)phenols for neurodegeneration. In fact, inflammation is a defence 
mechanism against insults, designed to remove noxious agents and to inhibit their 
detrimental effects. In neurodegenerative diseases, neuroinflammation may be 
triggered by external signals arising from systemic inflammation, by the accumulation of 
proteins with abnormal conformations or by signals emanating from injured neurons. 
Altered expression of different inflammatory factors can either promote or counteract 
neurodegenerative processes. By opposition to normal conditions, where microglia 
activation promotes the resolution of inflammatory damages caused by external agents, 
in a neurodegeneration scenario, an over-activation of microglia is observed, leading to 
a chronic state of neuroinflammation, which is deleterious and toxic for the cells. The 
sustained release of pro-inflammatory mediators’ production became harmful to cells 






cytokines and neurotrophic factors, it is crucial to efficiently repair the damage and 
restore the mediator’s balance, downregulating the inflammation. In the past few years, 
(poly)phenols potential in modulating this chronic neuroinflammation has also been 
explored. 
Different cell lines have been used to explore therapeutic molecules attenuating 
inflammation induced by lipopolissacharide (LPS) or tumor necrosis factor α (TNF-α). 
Since microglia represents the CNS resident innate immune cells, microglial cell lines 
such as N9 and BV2 have been the preferred ones. Increasing evidences suggest that 
flavonoids inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-6 and 
IL-1 in BV2 microglial cells, suggesting its close involvement in pathways such as NF-
κB or MAPK126. In addition, there is strong evidence that blueberry (poly)phenols inhibit 
the production of NO, IL-1β and TNF-α in activated BV2 cells123. Studies evaluating 
(poly)phenols metabolites effects against neuroinflammation are starting to emerge as 
well. The potential to reduce LPS‐induced TNF‐α secretion in THP‐1 monocytes was 
evaluated, demonstrating that some metabolites of flavonoids, individually and in 
combination, appear to present more anti‐inflammatory effects then their precursors153. 
A more recent study from Esteban-Fernández et al. pointed out the effects of wine-
derived human metabolites, at physiological concentrations, in protecting 
neuroblastoma cells from nitrosative stress injury154. However, the modulatory effects of 
(poly)phenol metabolites in microglial cells, the brain resident macrophage cells, which 
act as the first and main form of active immune defence in the CNS and which are mainly 
responsible for neuroinflammation modulation is still very scarce. 
Despite of the growing evidence which suggests that metabolism of (poly)phenols  may 
actually increase their biological activity, the extensive research with single parent 
(poly)phenols also revealed targeted potential neuroprotective actions which can 
provide valuable clues for further studies with relevant circulating metabolites. As such, 






Table 3.  Neuroprotective evidences (in vitro, cellular models and animals) for the most representative 






In vitro  
(cell free) 
















)  Prevent Aβ 
fibril formation 
139 










 ↑ neuronal viability, 




functions 16, 155 
 ↓ neurotoxins and Aβ 
toxicity in cell lines 
and primary cultures 
106, 156-160 
 ↓ caspase activation 
mediated by Aβ in 
hippocampal neurons 
157 
Ageing and neurodegeneration rodent models:  
 Prevention of spatial learning and memory decline 29 
 ↑ life span 161;  
 Prevention brain inflammation 162 
AD rodent model:  
 ↓ amyloidosis 91; 
 Rescue memory impairment (↓NF-кB pathway and ↓oxidative 
stress 163 
 Restored mitochondria function in the brain hippocampus, 
cortex and striatum 164 
MS rodent model:  
 Neuroprotective effects by modulating neuroinflammation and 
attenuating neural damage 165 
Cerebral ischemia rodent model:  
 Ameliorated redox imbalance and limited inflammation 165 
 EGCG improved age–related cognitive decline and protected 











 ↓ Aβ toxicity 167 
 Modulation of NF-кB 
and SIRT1 pathways 
in cell models 167-169  
AD rodent model:  
 ↓ formation of amyloid plaques, without affecting APP levels 
170 
 Protection from Aβ neurotoxicity by inhibiting iNOS 171 
 ↓ hippocampal neurodegeneration 168 
PD rodent model: 
 ↓ neural inflammation  (↓ mRNA levels of COX-2 and TNF-α 
in the substantia nigra) 172 
 ↓oxidative stress, lipid peroxidation, and protein carbonyl 173  
HD rodent model: 
  SIRT1 activation 174 
MS rodent model:  
 ↓ neural damage (↑ SIRT1) 175 
 Prevention neural loss without immunosuppression 176  
Cerebral ischemia rodent model: 
 Improve brain energy metabolism 177 
 Modulation of the release of neurotransmitters and 
neuromodulators 178 
Non-human primate study: 

















(↓COX-2) in both rat 
primary microglial 
and murine BV2 
microglial cells 182 
 ↓ iNOS and inhibition 
of NF-B and AP-1 
activation 183 
AD rodent model:  
 ↓ Aβ plaques, oxidized proteins and Interleukin-1 beta (IL-1β) 
144, 184 
HD rodent model:  
 Counteract huntingtin aggregates formation and partial 
improvement of transcriptional deficits, as well as an 










By far, the most explored ND in the aim of (poly)phenols neuroprotection is AD. The 
majority of the mammalian cell models employed in (poly)phenol research in AD takes 
advantage of cell lines or primary cultures, being neuroblastoma cell lines the most 
frequently used. In such models, disease phenotype is induced by the addition of Aβ 
peptide or toxic Aβ oligomers to the medium203, by the overexpression of Tau protein, 
or even by transfection of cells with the amyloid precursor protein (APP)204. In these 
studies, (poly)phenols have been described to protect from Aβ toxicity205, favouring the 
formation of stable protofibrils, reversing the rise of ER markers as well as tau 
 
In vitro 
 (cell free) 







  ↓ aSyn 
fibrillization 
146 




apoptosis in cultured 
neurons 186 
 Protected cells from 
oxidative insults, IL-1β 
and PD related toxins 187 
 Control immune 
response via modulation 
of IL-1β and TNF-α and 
reduced the proliferation 
of peripheral blood 
mononuclear cells 
isolated from MS 
patients 188. 
Neurodegeneration rodent models: 
 ↑ memory and synaptic plasticity upon chronic lead 
exposure 189 
 Protection against colchicine-induced cognitive 
impairment 190 
 Improved motor function in a model of acute spinal 
cord injury 191 
AD rodent model: 
 ↑ Performance on learning and spatial memory tasks 
and greater risk assessment behaviour 192 
 ↓ Extracellular β-amyloidosis, tauopathy, astrogliosis 
and microgliosis in the hippocampus and the amygdala 
192 
 ↓ Plaque burden and mitochondrial dysfunction 
(↑AMPK activity) and ↑ cognitive impairment 193 
PD rodent model:  
 Neuroprotective by inducing antioxidant defences and 
ATPases 194 
Cerebral ischemia rodent model:  
 ↓ Lesion 195 
 ↓ Hippocampal neuronal death 196 
 ↓Apoptosis (activation of BDNF-TrkB-PI3K/Akt 










  Scavenging 
peroxynitrite 
101 
 Protects neurons from 
oxidative stress 198, 199 
AD and ALS rodent model: 
 Alleviated memory impairment, delayed disease 







   Cytoprotective effects in 
mouse primary neurons 
135  
 Cytoprotective in a cell 
model of PD induced by 
rotenone 201 
AD rodent model:  
 Restore deficit in non-cognitive nesting ability and 
social interaction; attenuation on β-amyloid deposition, 
plaque associated APP expression, microglial 
activation and TGF-β immunoreactivity 202 
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phosphorylation206, increasing the cytosolic levels of calcium that leads to AMPK 
activation207, and diminishing extracellular accumulation of Aβ207.  
Protection from neurotoxicity induced by Aβ was already observed for green tea 
extracts, in primary rat cortical neurons103; blueberry anthocyanin-rich extract, in 
Neuro2a cells122; and Korean black soybeans anthocyanin-rich extract, in the 
hippocampal HT22 cell line127. Other mechanisms impaired by Aβ were also described 
to be ameliorated by some extracts. For example, blueberry anthocyanin-rich extract 
increase microglial Aβ clearance, inhibit its fibrillation and suppress microglial activation 
in murine cell cultures124. Similarly, the rescue of Syn aggregation toxicity was 
described for C. album (poly)phenols extract in human neuroglioma cells208. 
Similarly to AD, mammalian cell models available for studying PD are quite diverse, 
ranging from cell lines to primary cells. PD is usually associated with an increase of 
oxidative stress and mitochondrial dysfunction209. Due to their pleotropic activities, the 
search for compounds targeting PD has identified many phenolics as potential effectors 
redox and mitochondria homeostasis. The models used are mostly models of 
mitochondrial dysfunction induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ 1-
methyl-4-phenylpyridinium (MPTP/MPP+)160, 6-hydroxidopamine (6-OHDA)210, 
paraquat211 or rotenone injury201 and several studies used cell lines, such PC12, N27 or 
SH-SY5Y as PD models to evaluate the potential of phenolics compounds. 
Notwithstanding, models based on αSyn aggregation are less explored in the field of 
(poly)phenols, comparatively with Aβ-based models, for instance. Nevertheless, since 
αSyn aggregation is an important pathological process in PD, αSyn-based cell models 
should be further improved to better understand the effect of (poly)phenols as potential 
molecules against PD. 
 
The potential of resveratrol in NDs prevention has been extensively exploited. It was 
shown to reduce Aβ mediated accumulation of ROS and apoptosis in cell models167, 
being its protection related with the modulation of NF-кB and SIRT1 pathways167-169. In 
yeast, resveratrol mimics caloric restriction, described to slow the pace of ageing, by 
stimulating Sir2 (the homologue of SIRT1), increasing DNA stability and extending life 






including neurodegeneration212.  Microbial-derived phenolic metabolites found in blood 
after wine consumption, 3,4-dihydroxyphenylacetic acid, 3-hydroxyphenylacetic acid, 
and salicylic -D-O-glucuronide have shown to be neuroprotective by significantly 
decreasing mitogen-activated protein kinase (MAPK) p38 and ERK 1/2 activation, as 
well as in caspase 3 activity in SH-SY5Y cells154. The neuroprotective effect of selected 
bioavailable (poly)phenol derived metabolites (namely 3,4-dihydroxyphenylacetic acid, 
3,4-hydroxyphenylpropionic acid, gallic acid, ellagic acid and urolithins) against 
oxidative stress in SH-SY5Y cells was also already reported, being involved with the 
prevention of neuronal apoptosis213. In another study, the secretion of Aβ from neurons 
and associated damage seems to be attenuated by gallic acid treatment214.  
Ellagitannin-derived metabolites (urolithins and pyrogallol) have shown to be effective 
antiglycative agents, whereas chlorogenic acid-derived metabolites (dihydrocaffeic acid, 
dihydroferulic acid and feruloylglycine), generated in vivo in the colon, proven to be 
effective in combination in protecting neuronal cells, being able to counteract key 
features of diabetic complications, i.e. protein glycation and neurodegeneration152. 
Curcumin has also been pointed as a (poly)phenol with a plethora of protective 
activities180, 215 including MPTP protective activity181. Using rat primary hippocampal 
cultures, it was show that tetrahydrocurcumin, a metabolite of curcumin, presented 
protective effects against oligomeric A induced toxicity216.  
The flavonoid quercetin is also among the well-characterized (poly)phenols in terms of 
biological activity [reviewed in 160, 187]. Pre-treatment of primary hippocampal cultures 
with quercetin significantly attenuated Aβ-induced cytotoxicity, protein oxidation, lipid 
peroxidation and apoptosis186. Moreover, the brain-available metabolite of quercetin, 
quercetin-3-O-glucuronide, also significantly inhibited the generation of Aβ(1–40) 
peptides from Tg2576 primary neuron cultures149, 
5-(3’, 5’-dihydroxyphenyl)-γ-valerolactone, the main ring-fission metabolite of EGCG, 
showed slightly higher BBB permeability than EGCG and presented neuritogenic activity 
in SH-SY5Y cells, suggesting a possible role of this metabolite in brain neurogenesis217. 
Chlorogenic acid, a (poly)phenol present in coffee, was shown to protect cortical primary 
neurons against glutamate neurotoxicity, with potential for ischemic stroke treatment218. 
The 3-O-caffeoylquinic acid reduced neuroinflammation by reducing microglia mediated 
26 
 
ROS production and neuronal excitotoxicity219, whereas hesperetin, a flavanone 
glycoside abundant in citrus fruits, have also revealed neurprotective effects in mouse 
primary neurons135 and in a rotenone-induced apoptosis human neuroblastoma SK-N-
SH cells, considered a cellular model of PD201. Other study reported that less 
representative flavonoids (chrysin, puerarin, naringenin, genestein) presented 
neuroprotective activity in mesencephalic cultures challenged with MPP+, another model 
of PD160. 
 
The studies presented in Table 1 have in common the use of complex mixtures of 
compounds of dietary origin and the studies presented in Table 3 have in common the 
use of aglycones of parent (poly)phenols. However, they do not consider (poly)phenols’ 
metabolism and therefore they could only be considered in a pharmacological 
perspective with controlled target delivery to the CNS. In fact, the described effects seen 
in these cellular assays could be completely altered by human metabolism and therefore 
metabolites mechanism of action should be considered. Blackberry extracts submitted 
to a simulated gastro-intestinal digestion revealed that neuronal protection to oxidative 
insult can be unrelated to the modulation of reactive oxygen species (ROS) and 
glutathione (GSH) levels, suggesting a pre-conditioning effect by the induction of 
caspase activity220, 221. Moreover, bioaccessible raspberry metabolites resulting from the 
in vitro digestion of raspberry extract significantly inhibited microglial pro-inflammatory 
activation by LPS through the inhibition of Iba1 expression, TNF-α release and NO 
production222. Such studies, taking advantage of (poly)phenol components resulting 
from in vitro digestion, present a step forward in terms of considering human metabolism 
of (poly)phenols and comprise a more physiologically-relevant approach. 
 
Cellular studies taking into consideration (poly)phenols metabolism and biological 
activity against neurodegeneration (Table 4), using physiologically-relevant 
concentrations and relevant resident time, mark a mentality shift and the beginning of a 
new era in phytochemical research. Such research work, however, is in its infancy and 







Table 4. Neuroprotective evidences (using cellular models) for some bioavailable (polyphenol metabolites. 
 





of mouse cortical 
neurons + H2O2 
Pre-treatment with epicathechin 
glucuronide exibited no significant 
protection, but both epicathechin and 3'-O-
methyl epicatechin were neuroprotective  





of mouse striatal 
neurons + oxLDL 
A major in vivo metabolite of epicatechin, 
3'-O-methyl-epicatechin was as effective 
as epicatechin in protecting neurons from 
oxidized low-density lipoprotein (oxLDL) 
as the oxidative insult 







of mouse cortical 
neurons + H2O2 
Whilst hesperetin glucuronide failed to 
exert protection, both hesperetin and 5-
nitro-hesperetin were effective at 
preventing neuronal apoptosis via a 
mechanism involving the 
activation/phosphorylation of both 
Akt/protein kinase B and extracellular 
signal-regulated kinase 1 and 2 (ERK1/2) 


















The antioxidant activity of urolithins was 
correlated with the number of hydroxy 
groups as well as the lipophilicity of the 
molecule. The most potent antioxidants 
are urolithins C and D, being higher than 
the parent ellagic acid and punicalagins. 
The dihydroxylated urolithin A showed 
weaker antioxidant activity; however, the 
potency was within the range of urolithin A 
plasma concentrations. 
















Chlorogenic acid-derived catabolites 
(dihydrocaffeic acid, dihydroferulic acid 
and feruloylglycine) were most effective in 
combination in protecting neuronal cells 
from oxidative stress. 





neuron cultures + 
oligomeric A 
Tetrahydrocurcumin protects hippocampal 
cells against A-induced toxicity. 
Tetrahydrocurcumin may have beneficial 
effects in Alzheimer’s disease and other 
neurodegenerative diseases that involve 
oxidative stress and neuronal loss. 





neuron cultures + 
A(1-40) 
Brain-targeted quercetin-3-O-glucuronide 
significantly inhibits generation of A(1–
40) peptides from Tg2576 primary neuron 
cultures. 







Table 4. Cont. 
(Poly)phenol metabolite(s) Cell model Neuroprotective evidence Reference 









protocatechuic acid‐3‐sulfate  
protocatechuic acid‐4‐sulfate  
vanillic acid‐glucuronide  
vanillic acid‐sulfate  
isovanillic acid 
isovanillic acid‐glucuronide  
isovanillic acid‐sulfate 
THP‐1 monocytic 
cells + LPS 
Five metabolites (isovanillic acid, 
isovanillic acid ‐glucuronide, benzoic acid‐
sulfate, protocatechuic acid‐3‐sulfate, and 
vanillic acid‐glucuronide) reduced LPS-
induced TNF‐α secretion. Some 
bioavailable metabolites of flavonoids, 
individually and in combination, appear 
more bioactive then their precursor 
flavonoids, at equivalent concentration 






SH-SY5Y cells + 
anisomycin 
Gallic acid was able to reduce 
anisomycin-induced Aβ deposition, 
suggesting that gallic acid exerted 
protective effects on SH-SY5Y cells, 
which may be considered a novel 
therapeutic strategy in the treatment of 
patients with AD 














urolithins (A, B, C, D) 
urolithin A 3-O-glucuronide 
urolithin A 8-O-glucuronide 
iso-urolithin A 
iso-urolithin A 3-O-glucuronide 
iso-urolithin A 9-O-glucuronide 
SH-SY5Y cells + 
H2O2 
Among the 19 metabolites tested, 3,4-
dihydroxyphenylpropionic acid, 3,4-
dihydroxyphenylacetic acid, gallic acid, 
ellagic acid, and urolithins prevented 
neuronal apoptosis via attenuation of ROS 
levels, increased REDOX activity, and 
decreased oxidative stress-induced 
apoptosis by preventing the caspase-3 
activation via the mitochondrial apoptotic 
pathway in SH-SY5Y cells. 
González-










In human neuroblastoma SH-SY5Y cells, 
neurite length was significantly prolonged 
by 5-(3',5'-dihydroxyphenyl)-γ-
valerolactone, and the number of neurites 
was increased significantly by all 
metabolites examined. 










SH-SY5Y cells + 
SIN-1 
Cell pretreatment with microbial 
metabolites found in blood after wine 
consumption, 3,4-dihydroxyphenylacetic, 
3-hydroxyphenylacetic acids and salicylic 
β-d-O-glucuronide, at physiologically 
concentrations (0.1-10 μM) resulted in 
increased cell viability versus SIN-1 
control group 
Esteban-







Table 4. Cont. 






cell + LPS 
BV2 microglial 
cell + H2O2 
SH-SY5Y cells + 
H2O2 
BV2 microglial 
cell + LPS 
(conditioned 
medium) applied 
to SH-SY5Y cells 
Urolithins decreased media levels of nitric 
oxide, interleukin 6 (IL-6), prostaglandin 
E2, and tumor necrosis factor alpha from 
LPS-BV2 microglia. In the co-culture cell 
model, media from LPS-BV2 cells treated 
with urolithins preserved SH-SY5Y cell 
viability greater than media from cells 
treated without urolithins. Urolithins 
mitigated apoptosis and caspase 3/7 and 
9 release from H2O2-induced oxidative 
stress of BV2 and SH-SY5Y cells. 




Considerations regarding cellular models in (poly)phenols research 
Cellular models are indispensable to understand the molecular mechanisms of 
(poly)phenols and (poly)phenol metabolites and how they can affect cellular 
homeostasis. However, current studies take conclusions from 2D systems and using 
cell lines as disease models, which still present some limitations for a real physiological 
answers. Therefore the current trend of cellular models to study NDs for drug 
development is already moving away from mammalian cell lines, converging into more 
complex cell systems. Advances in reprogramming technology have allowed the 
generation of human neurons derived from fibroblasts of disease patients. These cells 
harbour a disease genetic background allowing the recapitulation of AD or PD 
pathogenesis in vitro when differentiated into mature neurons228-230. Such models, 
however, still present limitations mainly associate with the limitation of reconstituting ND 
conditions in vitro over a short time course while the pathogenic changes of NDs 
progress slowly. In addition, differentiation and maturation of human neural stem cells 
occurs over a span of months, and it may not be enough to establish the aged brain 
conditions under which patients develop robust neurodegenerative pathologies231. 
Studies have shown that 3D conditions recapitulate more closely the in vivo scenario 
and can accelerate neuronal differentiation and neural network formation232-234. Neurons 
grown in a 2D environment do not have the support for vertical growth, which can lead 
to inadvertent polarity instead of a more precise neuronal phenotype235. Additionally, in 
2D, the space between cells does not recapitulate the in vivo situation: 2D models tend 
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to have reduced connections between neurons, and synaptic distances are bigger than 
physiological. Neurons grown in a 3D environment are able to express neuronal markers 
more accurately, as compared to neurons grown in a monolayer, with elevated mature 
neuronal marker expression236, 237. Moreover, in 2D cell cultures, the secreted Aβ 
species from fibroblasts of AD patients diffuse into the cell culture media, which will be 
removed during regular media changes. Such phenomenon may explain why it is 
difficult to detect Aβ aggregation in a 2D cell culture, for instance. In this sense, 3D 
cultures provide a local environment that promotes aggregation of β-amyloid, which can 
trigger pathogenic cascades237, being a more suitable model for studying disease 
pathology. 3D culture conditions, as compared with 2D, present additional advantages 
in recapitulating ND conditions, being able to be applied in large scale for high-
throughput screening for novel therapeutic targets, or even for validation during the 
initial stages of drug discovery that are not feasible in the current animal models237-239. 
The development of increasingly robust advanced models systems is a fast-growing 
field owing the great demand by the pharmaceutical industry. In the future, (poly)phenol 
research can benefit from their utilization to accelerate the discovery of bioactive 
molecules with potential application in the therapeutics of neurodegenerative conditions. 
 
Nevertheless, cellular models are indispensable to understand the molecular 
mechanisms of (poly)phenols and how they affect cellular homeostasis. Currently, there 
are already a lot of evidences for pure parent (poly)phenols mode of action regarding 
their potential against neurodegeneration. However, the presence of these compounds 
in neuronal tissues can only be considered by pharmacological approaches. There is 
still a considerable gap in knowledge regarding (poly)phenol metabolites potential taking 
advantage of cell models. These nutritionally-relevant metabolites are the ones that 
circulate in higher percentage and that can comprise the true effectors against 
neurodegeneration. Yet, in order to design nutritional or pharmaceutical approaches 
using (poly)phenols, it is mandatory to translate their benefits into animal models, and 







3.3. In vivo animal assays 
Most of the evidences for neuroprotection in animal models come from studies where 
foods or plant extracts are given orally to animals. Those are defined as nutritional 
(nutraceutical) interventions since (poly)phenols can cross/interact with the gastro-
intestinal barrier and be metabolized as dietary compounds. Only encapsulated 
compounds, intravenous or other forms of delivery can be considered in a 
pharmacological perspective. 
Accumulating evidence of (poly)phenol potential in vivo reinforces the in vitro (cell free) 
and cellular models conclusions. Intake of berries such as pomegranate, strawberry, 
blueberry and blackberry ameliorated several aspects of memory and learning240, 
delayed age-related motor and cognitive behavioural deficits in rodent models130, 132, 241. 
Oral administration of quercetin protected against colchicine-induced memory 
impairment and oxidative damage in rats190. In PD in vivo models, quercetin showed to 
be neuroprotective by inducing antioxidant defences and ATPases194.  
Several attempts were done with a pharmacological approach, by direct injection of 
bioactive (poly)phenols to the organism with the aim to circumvent its metabolism and 
improving their efficacy. Resveratrol was tested by intraperitoneal injection on a 6-
hydroxydopamine (6-OHDA)-induced PD in rats and revealed attenuation of oxidative 
stress, lipid peroxidation, and protein carbonyl content173. Notably, curcumin when 
injected in the tail vein of an AD rodent model, was able to cross the BBB, target and 
disrupt existing plaques184; moreover, it also reduced Aβ plaques, oxidized proteins and 
IL-1β in AD transgenic mice144. Intraperitoneal administration of quercetin improved 
motor function in a model of acute spinal cord injury191, reduced ischemic lesion195, as 
well as hippocampal neuronal death196, and also cell apoptosis in a rat model of cerebral 
ischemia197. By the same route, quercetin improved memory and synaptic plasticity 
upon chronic lead exposure in rats189.  
Despite of the importance of this studies in a pharmacological perspective, the 
understanding of the true bioavailable (poly)phenol metabolites effects should be better 
clarified. Only having such information we may be able to translate the nutritional value 
of (poly)phenol-rich foods towards human health. Some authors have already started to 
take such considerations into account. A study have shown that both curcumin and its 
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metabolite tetrahydrocurcumin exerted neuroprotection against MPTP induced 
neurotoxicity in mice242. Two brain-available polyphenol metabolites, quercetin-3-O-
glucuronide and malvidin-3-O-glucoside, significantly attenuated sleep deprivation-
induced cognitive impairment in a mouse model of acute sleep deprivation243.  
 
Table 5.  Neuroprotective evidences (in vivo) for some bioavailable (polyphenol metabolites. 
(Poly)phenol 
metabolite(s) 
Animal model Neuroprotective evidences Reference 
curcumin 
tetrahydrocurcumin 
Mice + MPTP 
Curcumin and tetrahydrocurcumin reversed 
the MPTP induced depletion of dopamine and 
DOPAC which may in part be due to inhibition 
of MAO-B activity, exerting neuroprotection 
against MPTP induced neurotoxicity 







Dawley rats  
Genistein and equol significantly reduced 
infarct size in both sexes.  Neuroprotection in 
ovariectomized female rats was accompanied 
by a decrease in NAD(P)H oxidase activity 
and superoxide levels in the brain. In addition, 
equol reduced plasma thiobarbituric acid 
reactive substances, and neurological deficits 
Ma et al. 
2010244 
equol 
Rats + cerebral 
ischemia/reperfusion 
injury 
Equol decreased the mortality, neurological 
deficit, brain histological damage, infarct 
volume, serum lactate dehydrogenase activity 
and malondialdehyde content in a dose-
dependent manner in rats  





Mice model of acute 
sleep deprivation 
Quercetin-3-O-glucuronide and malvidin-3-O-
glucoside, significantly attenuated sleep 
deprivation-induced cognitive impairment in a 
mouse model of acute sleep deprivation 











elegans + A(1-42) 
Methyl-urolithin B but not pomegranate 
predominant ellagitannins had a protective 
effect in Caenorhabditis elegans post 
induction of Aβ(1−42)-induced neurotoxicity 
and paralysis 









Urolithins extend lifespan and improve fitness 
in C. elegans. Treatment with ellagic acid had 
no effect on lifespan. Urolithin A exerts its 
beneficial effects through the induction of 
mitophagy 
 Ryu et al. 
2016246 
 
An integrated view of in vitro, cellular and animal model studies either with food or plant 
extracts or pure compounds, parent (polyphenols and (poly)phenol metabolites (Tables 
1-5) reveals a complete panorama of knowledge gathered for (poly)phenols, and clearly 






the closest to the real scenario, they are time and cost consuming. The animal and 
cellular models have constituted unparalleled tools to dissect mechanisms of action, and 
for genetic and compound screening assays. On the other hand, the in vitro assays are 
crucial to understand the interaction of (poly)phenols with proteins, metals or other small 
molecules, by excluding cell components interference and serving as a fundamental tool 
to tune the overall picture revealed by cell studies. Nevertheless, the importance of 
(poly)phenols and (poly)phenol-rich foods against relevant aspects of 
neurodegeneration should be properly addressed to provide relevant tools to validate 
the aspects observed using the aforementioned models. 
 
3.4. Human trials 
Human clinical trials to ascertain the impact of (poly)phenols in NDs and ageing are still 
very scarce. Although allusive of a protective role in neurodegeneration, there are still 
too many fragmented evidences to build an integrated picture based on the mechanistic 
studies. 
Concerning green tea extracts, human studies revealed the increase of brain activity in 
the dorsolateral prefrontal cortex, an area involved in memory processing247. Recently, 
consumption of green and black tea by healthy volunteers increased the brain theta 
waves, suggesting a role in cognitive function, specifically alertness and attention248. 
Moreover, EGCG reduced cognitive deficits in a pilot study with Down syndrome 
individuals, with effects on memory recognition, working memory and quality of life249.  
In an intervention study, blueberry juice supplementation improved memory in older 
adults59. Also, supplementation with Concord grape juice enhanced neurocognitive 
function in older adults with pre-described mild cognitive impairments, which was 
supported by studies on brain activity using functional magnetic resonance imaging250. 
There are several studies examining flavanols and anthocyanins neuroprotective 
properties in humans but little investigation into the flavonoid subclass known as 
flavanones. This is an incredible gap in knowledge once orange juice, a rich source of 
flavanones, is one of the most-commonly consumed juices throughout the world. A 
recent study evaluated the consumption of flavanone-rich orange juice over 8 weeks 
and concluded that there was an association with benefits for global cognitive function 
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in healthy older adults, in comparison to the consumption of a low-flavanone control 
juice251. Moreover, the same authors observed that ingestion of a flavonoid-rich orange 
juice promoted acute cognitive benefits over 6 h in healthy middle-aged adults252. 
A recent study examined the effects of curcumin on cognition and mood in a healthy 
older population. Working memory and mood were significantly improved following 4 
weeks treatment, confirming the potential psychological and cognitive benefits of 
curcumin in an older population253. 
On the other hand, a contradictory study in a large community sample, with a 12-week 
supplementation of quercetin, provided evidence that quercetin may not have an 
ergogenic effect on neurocognitive functioning254, consistent with a growing body of 
literature raising concerns about the generalization of findings from in vitro and animal 
quercetin research to human populations. 
Two recent studies have reinforced the impact of diets rich in berries for cognition 
improvement in older adults: a chronic blueberry supplementation improved brain 
perfusion, task-related activation, and cognitive function in healthy older adults62, and in 
a double-blind, placebo controlled trial, the addition of blueberry to the diets improved 
some specific aspects related with cognition63.  
Some human studies have been performed for dietary formulations that include mixtures 
of (poly)phenols or (poly)phenols with other compounds, highlighting possible synergies 
between constituents. For instance, in a double-blind clinical trial with older adults255, 
the intake of a pill-based nutraceutical that contained a proprietary formulation of 
blueberry, green tea, carnosine, vitamin D3 and biotin, resulted in significantly increased 
processing speed. Also, in healthy overweight older individuals, a daily intake of a 
formulation containing resveratrol and quercetin significantly improved memory 
performance256.  
The evaluation of (poly)phenol metabolites effects in humans could be more difficult. 
Although these metabolites are produced in the human gut, the administration of 
synthetic (poly)phenol metabolites to humans can raise safety concerns since these are 
not found as such (at least in relevant concentrations) in foodstuffs, and therefore they 
cannot be considered as dietary compounds. In this regard, the toxicological evaluation 






Nevertheless, for (poly)phenols and their circulating metabolites reach the brain and be 
able to exert neuroprotective actions, they have to be able to cross to and/or interact 
with the BBB.  An increasing body of evidence regarding this subject has been growing 
and the next section will discuss the latest advances regarding it.  
 
4. (POLY)PHENOLS AND RESTRAINS: INTERACTION WITH BARRIERS 
AND BEYOND  
The extensive metabolism to which dietary (poly)phenols are submitted once ingested, 
either in the intestine, liver and or in cells, leads to the arise of a broad range of 
(poly)phenol derivatives. Despite accumulating evidence concerning dietary 
(poly)phenols aglycones and their metabolites neuroprotection (Tables 1-5), and 
assuming the effective transport/distribution/delivery of dietary (poly)phenol metabolites 
to target tissues, we also need to consider the existence of other barriers that must be 
crossed by these (poly)phenols metabolites or, at least, be able to alter the surrounding 
environment in order to induce responses in the target organs. 
4.1. Blood-brain barrier  
The existence of three layers of barrier at the CNS limits and regulates molecular 
exchanges between the blood and the neuronal tissue, or its fluidic spaces: i) the BBB, 
majorly constituted by cerebromicrovascular endothelial cells, located between the 
blood and the brain interstitial fluid; ii) the choroid plexus epithelium, located between 
the blood and ventricular cerebrospinal fluid; iii) and the arachnoid epithelium, located 
between the blood and subarachnoid cerebrospinal fluid257. In particular, the choroid 
plexus is responsible for the transport of vitamins, small peptides, amino acids, inorganic 
ions and hormones to the cerebrospinal fluid258. Among the different barriers of the CNS, 
the BBB exerts the highest control over the close microenvironment of brain cells, since 
its surface area is 5000 times larger than the blood-cerebrospinal fluid barrier, having a 
dominant role in providing nutrients for the brain, as well as controlling metabolites, like 
(poly)phenols, accessibility to neuronal cells 259. 
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The BBB is a dynamically selective and complex interface, protecting the CNS from 
toxic compounds and pathogens, acting as a border between the periphery and the 
brain260. Besides the microvascular endothelial cells that comprise the anatomical basis 
of the BBB, it is surrounded and interacts with perycites, astrocytic endfeet, microglia 
and neurons, which constitute the neurovascular unit (Fig. 4) 257, 259, 261. The 
neurovascular unit complexity, together with the tight control exerted by the brain 
endothelium due to the presence of intracellular tight junctions, lack of fenestrations, 
low pinocytic activity and efflux pumps, controls the passage of the smallest polar 
molecules and macromolecules259, 262, 263 (Fig. 4). (Poly)phenols are no exception and 
in order for them or their metabolites to access the brain, they must cross a tightly 
regulated, selectively permeable endothelial layer. As a growing number of biological 
effects have been attributed to these molecules in the past few years, attention to their 
role as modulators of the transport capacity of epithelial barriers has also received great 
attention. 
Youdim and co-workers have attempted to demonstrate (poly)phenols permeation 
through the BBB264, 265. They suggested that (poly)phenols transmembrane diffusion in 
vitro is related with its lipophilicity, where less polar derivatives (e.g. methylated 
derivatives) are capable of higher brain uptake than more polar metabolites (e.g. 
sulphated and glucuronides). Accumulating evidence of (poly)phenols uptake by the 
BBB reinforces their putative potential in a neurological context. Nevertheless, it is not 
yet totally clear whether the primary route by which (poly)phenols cross the BBB is 
simple diffusion or carrier-mediated transport266. To date, only a few compounds from 
each flavonoid subclasses have been studied, and there is limited knowledge on the 
effects of flavonoid structure on their bioavailability at the brain level. Therefore, the true 
mechanisms by which flavonoids and their circulating metabolites interact with the BBB 








Fig 4. The neurovascular unit. The BBB is composed by endothelial cells, astrocytes and perycites, where 
endothelial cells form a boundary between the blood and the CNS. The flux of nutrients and metabolites 
from the blood to the CNS is regulated by the BBB, which controls their availability by transport systems. 
Transport across the BBB occurs via several pathways: lipid-mediated diffusion (transcellular transport), 
paracellular diffusion, carrier-mediated transport through proteins, receptor-mediated transcytosis and 
absorptive-mediated transcytosis. Besides these pathways, active efflux transport through ABC 
transporters such as P-gp, BCRP and MRPs family also takes place, in order to prevent the entry and 
accumulation of harmful substances to the brain. 
 
Considering (poly)phenol and their metabolites permeability across the BBB, the 
existence of different specialized transporters in the plasma membranes of luminal 
(blood) and abluminal (brain) sides of the endothelial cells should be taken into account. 
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The endothelial cells permeability to (poly)phenols is particularly influenced by the 
expression profile, functionality and precise location/orientation of efflux transporters, 
solute carriers and organic-anionic transporters267. Nevertheless, there are strong 
evidences of the effective capacity of (poly)phenols to reach the brain and exert 
neuroprotection, and it is an ever-growing field of investigation (Table 6). 
In terms of uptake, there is evidence suggesting that transport mediated by glucose 
transporter 1 (GLUT1), organic anion transporters (OATs) and organic anion-
transporting polypeptide (OATP1A2) may affect the distribution of flavonoid 
glucuronides into the brain, in a similar fashion to other glucuronidated metabolites268, 
269. In fact, the presence of these glucuronidated metabolites can be partially derived, 
due to the high expression of both GLUT1 and OATP1A2 on both luminal and abluminal 
membrane of endothelial cells. In a recent study, the authors successfully localized 
quercetin-3-O-glucuronide, a major phase-II metabolite of quercetin, in human brain 
tissue, namely at epithelial cells of the choroid plexus and also in macrophages270.  
Microdialysis sampling in rats also showed that (+)-catechin and (-)-epicatechin could 
pass through the BBB271. In fact, several (poly)phenols have been identified in different 
brain regions of the rat272, 273 and pig274, 275, usually accumulating in a nonregion-specific 
manner276. Several animal studies also indicate that (poly)phenols are able to cross the 
BBB and co-localize within the brain tissues independently of their route of 
administration: epigallocatechin gallate277, epicatechin278, and anthocyanins273, 279 were 
detected in the brain after oral administration; naringenin and its glucuronide were 
identified in the cerebral cortex, after intravenous administration280, and intravenously 
administered hesperetin was also detected in the brain, especially in the striatum281. 
Another study has examined the permeability of flavonoids and their known circulating 
metabolites across an in vitro model of the BBB264. Hesperetin, naringenin, and their 
respective in vivo glucuronides, as well as the anthocyanins cyanidin-3-rutinoside and 
pelargonidin-3-glucoside, all showed measurable permeability. In another study, both 
catechin and epicatechin could cross a cellular model of BBB in a time-dependent and 
stereo-selective manner, with epicatechin presenting a substantially higher transport 
than catechin282. In vitro transmembrane transport of different flavonoids (flavonols, 






metabolites was also observed, where in most cases the metabolites exhibited higher 
transport efficiency than their parent compounds283. All these collected data strongly 
suggest the effective uptake of dietary (poly)phenols and their metabolites through the 
BBB endothelium, reinforcing their ultimate neuroprotective potential. 
(Poly)phenols as modulators of membrane transport 
Importantly, (poly)phenols have also shown to be able to modulate the activity of some 
ATP-binding cassette transporters (ABC transporters).  The ABC transporters are efflux 
pumps responsible for controlling the bioavailability of many xenobiotics, being vastly 
present in the epithelia of the gut, placenta and BBB, as well as in cancer cells. Cancer 
cells tend to overexpress these ABC transporters, which confers them bigger resistance 
to chemotherapy284. 
Several studies have demonstrated inhibition of ABC transporters by flavonoids (Table 
6). The interaction between flavonoids and ABC-transporters could be advantageous 
for poorly absorbed drugs; otherwise, this interaction could also lead to drug intoxication, 
particularly in the context of drugs with a narrow therapeutic window. Additionally, some 
flavonoids are themselves substrates of the most pharmacologically relevant ABC 
transporters: P-gp, multidrug resistant protein type 2 (MRP2) and breast cancer 
resistant protein (BCRP)285. 
For example, it was shown that extracts from St John’s Wort upregulate the expression 
of P-gp at intestinal level, which could ultimately reduce the bioavailability of substrate 
pharmaceuticals286. On the other hand, diterpenes, triterpenes and carotenoids, 
naturally occurring lipophilic phytochemicals, were able to inhibit human P-gp in vitro at 
a low range, while other combinations had a synergistic activity151, 287. Quercetin, 
hypericin and kaempferol were shown to promote the cellular uptake of ritonavir on P-
gp overexpressing cells288. Besides, both in vitro and in vivo assays (only with short-
term exposure) with these (poly)phenols inhibited the action of efflux pumps and 
increased substrate bioavailability;  in vivo assays of chronic exposure boosted the 
expression of P-gp and lead to a reducing bioavailability of substrate drugs289, 290. 
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Besides their modulation of ABC transporter function, (poly)phenols can also be 
substrates of these transporters, a property that can dramatically limit their 
bioavailability. Youdim and co-workers have showed the limitations that quercetin has  
to BBB transposition: when co-administrated with a P-gp or BCRP inhibitor, this 
(poly)phenol was able to enter epithelial cells of the BBB, possibly by passive diffusion 
due to its hydrophobicity, but was then specifically exported by the BCRP 264. Such 
phenomenon explains, at least in some extent, why quercetin and resveratrol presented 
very limited bioavailability, despite the amount ingested291, 292. 
Taking all this information into account, it could be interesting to explore the combination 
of an inhibitor of the ABC transporters and a beneficial (poly)phenol, in order to increase 
the accumulation of such (poly)phenol in the target region and potentiate its efficiency.  
The co-administration of a quercetin-rich product and an inhibitor of BCRP may increase 
quercetin’s access into the brain and then unleash novel bioactivities from this 
(poly)phenol293. In addition, if the inhibitors of ABC transporters themselves are orally 
bioavailable, they may assist (poly)phenols transport through the BBB265.  
Importantly to notice, most of what is known nowadays regarding (poly)phenols 
interaction/modulation of ABC transporters is essentially about dietary (poly)phenol 
aglycones effects and not to their circulating metabolites. As such, it is imperative to 
evaluate in the future the interactions that could be established between transporters 
and bioavailable (poly)phenols metabolites which chemically diverge from their parent 
compounds. As such, we may anticipate differences regarding interactions and/or 
modulation of ABC transporters activity, not directly translatable from what is currently 














Table 6. Evidences of (poly)phenol transport at the BBB, concerning interaction studies with ABC efflux 
transporters expressed in endothelial cells at the BBB. P-gp - P-glycoprotein, MRP - multidrug resistant 
protein, BCRP - breast cancer resistant protein, BMEC - brain microvascular endothelial cells, TR-rats - 
transport deficient rats, N. D. – not described. 
 
4.2. Beyond barriers 
In the light of today’s knowledge, novel mechanisms of action for (poly)phenols are 
proposed far beyond the classical direct antioxidant radical scavenging power. In fact, 
(Poly)phenol 







Apigenin  Yes 294 
P-gp inhibitor Rat BMEC 294 
P-gp inhibitor CCRF-CEM, CEM/ADR5000 leukemia cells 295 




P-gp activator NIH-3T3-G185 cells 113 
MRP2 substrate Caco-2 cells 296 
MRP1/MRP2 substrate MDCKII/MRP1 cells & MDCKII/MRP2 cells 297 
Chrysin N. D.  
P-gp inhibitor Mouse BMEC 298 
MRP2 substrate Caco-2 cells 299 
BCRP inhibitor MCF-7 MX100 cells 300 
Curcumin Yes 184 
P-gp inhibitor MCF-7 cells 301 
BCRP inhibitor Rat brain capillaries 302 
Fisetin Yes 303 MRPs inhibitor Caco-2 cells 304 
Genistein Yes 305 
P-gp inhibitor MCF7/BC19-3, rats 306, 307 
MRP2 inhibitor TR-rats 308 
BCRP inhibitor K562/BCRP cells 309 
Hesperitin Yes 264 
P-gp inhibitor Mouse BMEC 298 
BCRP inhibitor ABCG2 over-expressing cells 310 
Kaempferol Yes 294 
P-gp inhibitor Mouse BMEC 298 
MRPs inhibitor Human glioblastoma cell line T98G 311 
BCRP inhibitor MDCK/Bcrp1 cells 312 
Myricetin Yes 313 
P-gp inhibitor MCF-7/ADR cells 314 
BCRP inhibitor HEK293/ABCG2 cells 284 
Naringenin Yes 291, 315 
P-gp inhibitor Mouse BMEC 298 
MRPs inhibitor HEK293/ABCG2 cells 284 
Quercetin Yes 265 
P-gp inhibitor Mouse BMEC 298 
MRPs inhibitor HEK293/MRP1, HEK/MRP4, HEK/MRP5 cells 316 
BCRP inhibitor ABCG2 over-expressing cells 310 
Resveratrol Yes 207 
P-gp inhibitor MCF-7/ADR cells 317 
BCRP inhibitor ABCG2 over-expressing cells 310 
Rutin Yes 294 P-gp inhibitor Rat BMEC 294 
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(poly)phenol concentration at cerebrospinal fluid rarely exceeds 1-5 mol. Therefore, it 
is highly improbable that (poly)phenol intracellular concentrations in neurons and glial 
cells would exceed the micromolar-nanomolar range, which is not enough to exert 
significant direct antioxidant effects. Nevertheless, such concentrations are in fact 
beneficial, pointing out that (poly)phenols and their metabolites modulate other cellular 
parameters and pathways at the CNS level, even at low concentrations266.  
The noteworthy effect of (poly)phenols and their metabolites in cellular signalling 
pathways at concentrations as low as 1 mol has been reported already318, reinforcing 
the idea of indirect mechanisms that could be involved in (poly)phenols neuroprotection. 
The activation of hormetic responses and effects on peripheral systems of the body, 
that culminate in changes in the CNS function are the proposed indirect mechanisms of 
action of (poly)phenols and degradation metabolites. Hormesis describes a process in 
which exposure to a low dose of an agent, that is toxic at higher doses, induces a 
beneficial effect on the cell or organism 318. Direct evidence for hormesis induction in 
vivo has already been reported in mammals: pre-treatment of mice with epicatechin 
significantly reduced the negative impact of stroke induction in wild-type but not nuclear 
factor erythroid 2 (Nrf2) knock-out animals, as the transcription factor Nrf2 is one of the 
key regulators responsible for the induction of antioxidant and cell protective genes319. 
Additionally, the regulation of brain integrity and function must not be seen as an isolated 
process, but instead as strongly dependent on feedback information (in the form of 
hormones, nutrients, metabolites and, of course, sensory neuron signalling of the body 
periphery). 
Furthermore, evidences of the metabolism of (poly)phenols at the BBB level has already 
been reported with the detection of the compounds conjugated with glucuronic acid282. 
The hypothesis that (poly)phenol metabolites resulting from biotransformation in 
endothelial cells, are the key actors in neuroprotection, arises as a novel creed in a 
nutritional/nutraceutical perspective. The physiological role of conjugated-flavonoids is 
discussible, but there is the possibility of their presence in the extracellular fluid in the 
CNS, and exerting biological effects. In fact, some reports have suggested that flavonoid 
metabolites possess more biological activity than the intact form153, 320. Noteworthy, 






into more water-soluble metabolites, and subsequently facilitate its elimination from the 
body or, oppositely, allow an easier xenobiotic transport and delivery around the body.  
In a pioneer pharmacokinetics study, 23 (poly)phenols microbial metabolites were 
administered intravenously to rats, to reliably reproduce a physiological post absorption 
situation321. Remarkably, the brain was found to be a specific target organ for 10 of the 
23 (poly)phenol metabolites injected, which significantly increased in the treated animals 
and most compounds were excreted into the urine321. 
In that sense, it is imperative to adjust the study of (poly)phenols beyond the reductionist 
dogma of (poly)phenol-effect: research should focus not only in the study of 
(poly)phenols but also the metabolites arising from digestion and metabolism. Dietary 
and colonic metabolites derived from (poly)phenols present in foods and drinks can 
reach considerable concentrations in circulation, usually higher than their parent 
compounds, and such physiologically-relevant concentrations must be studied, taking 
into account the multiplicity of interactions inside the human body as an overall 
beneficial outcome to the CNS. 
 
5. THESIS RATIONALE 
Taking into account all the evidences and all the gaps in knowledge highlighted in this 
introduction, the disclosure of important mechanisms behind (poly)phenols metabolites  
BBB putative transport and ultimate neuroprotection is imperative.  
Since several epidemiological studies indicate that regular intake of fruits and 
vegetables can beneficially prevent brain aging-associated cognitive dysfunction, 
berries emerged as a rich source of phytochemicals that offer antioxidant, anti-
inflammatory and direct effects in the brain, with evidences of mild cognitive impairment 
improvement59. Previous studies from our lab confirmed the brain health potential of 
blackberry-driven (poly)phenols (BDP) in a simple neurodegeneration cell model220, 221. 
BDP can be obtained by an in vitro digestion procedure, a reproducible method that has 
been validated against in vivo studies and comprises major chemical and biochemical 
alterations that occur in the upper gastrointestinal tract322. Therefore, BDP will mimic the 
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metabolites available in the bloodstream, which can reach the luminal surface of the 
BBB and therefore could cross it or interact with cell surface receptors. 
Moreover, and in line with this, in a human intervention study conducted in our lab, the 
main bioavailable metabolites arising from the ingestion of (poly)phenols present in 
berries fruits were identified323, 324. These circulating metabolites, mainly simple phenolic 
sulfates, emerged as obvious targets for the assessment of BBB permeability and 
neuroprotection, in parallel with BDP. 
Once the BBB is a dynamic and complex interface between blood and the CNS, strictly 
controlling exchanges, playing a key role in homeostasis and providing protection 
against toxic compounds260, BDP and berry-derived bioavailable (poly)phenol 
metabolites transport across the BBB may be limited.  The proper understanding of their 
BBB putative transport would clarify in deeper extent their ultimate neuroprotective 
potential and help to identify the key (poly)phenol metabolites responsible for such 
benefits. Endothelial cells of BBB, human brain microvascular endothelial cells 
(HBMEC), have a unique pattern of receptors and transport systems that facilitate the 
uptake of nutrients and hormones, in addition to active pumps that help to regulate the 
ions, metabolites and xenobiotics levels in the brain257. Due to their properties and 
location, endothelial cells are key players in BBB, considered as the anatomic basis of 
it and are widely used as simplified in vitro model for BBB transport assessment. 
Besides the understanding of BBB transport of BDP and of berry-derived bioavailable 
(poly)phenol metabolites, their potential against several hallmarks of NDs must be 
clarified. The prevention and treatment of NDs, characterized by a mechanistic 
complexity, will needs novel therapeutic strategies targeted for multiple genes and 
proteins, such as (poly)phenol metabolites can potentially do. As more physiologically-
relevant molecules, with potential to reach brain parenchyma, their role against oxidative 
stress, glutamate excitotoxicity and neuroinfammation, using superior and more 
complex cell models to modulate neurodegeneration, should be pursued. If such 
potential emerges, their potential in a specific NDs should be further analysed. 
Among the several life-threatening and debilitating NDs, PD arises as a chronic, 
progressive movement disorder that primarily affects dopaminergic neurons. The 






therapies, have traditionally relied on genetic modified mouse models and primary 
neuronal cell cultures derived from rodents, which often diverge considerably from that 
of human phenotype325 and poorly mimic human disease progression in vivo. Human 
pluripotent stem cells, with their ability to differentiate in all human cellular phenotypes, 
hold great potential for treating PD through cell replacement therapies. Moreover, these 
cells are highly relevant to be used as a model to study the disease pathology.. In this 
sense, (poly)phenol metabolites potential towards PD will be evaluated in a more 
physiologically-relevant human cell model of PD. This improved model is based on 3D 
dopaminergic differentiation of Lund human mesencephalic neural progenitor cells 
(LUHMES) and treatment with the dopaminergic neurotoxicant 1-methyl-4-
phenylpyridinium (MPP+)326, 327. LUHMES-derived dopaminergic neurons have been 
extensively characterized and are morphologically and functionally similar to mature 
human dopaminergic neurons328, 329. 
 
6. AIM OF THE THESIS 
This work focused on the study of blackberry and berry-derived bioavailable 
(poly)phenol metabolites with neuroprotective potential, especially towards PD, 
exploring their blood-brain barrier transport and mechanism of action. To achieve this 
major goal, intermediate aims were determined: 
 
 Assess BDP transport across the BBB; evaluate BDP cytoprotective and 
neuroprotective potential in relevant cell models comprising different hallmarks of 
NDs; as well as understand gene expression alterations caused by BDP pre-
incubation in concentrations close to the physiologically-described range. 
 
 Evaluate berry-derived bioavailable (poly)phenol metabolites BBB transport in 
circulating concentrations; disclose their putative further metabolism by BBB 
endothelial cells; unveil bioavailable (poly)phenol metabolites cytoprotective and 
neuroprotective potential in relevant cell models with increased complexity 




 Study the neuroprotective potential of berry-derived bioavailable (poly)phenol 
metabolites against PD using an improved three-dimensional cell model of the 
disease; disclose the molecular mechanism behind bioavailable (poly)phenols 
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Epidemiological and intervention studies have attempted to link the health effects of a 
diet rich in fruits and vegetables with the consumption of polyphenols and their impact 
in neurodegenerative diseases. Studies have shown that polyphenols can cross the 
intestinal barrier and reach concentrations in the bloodstream able to exert effects in 
vivo. However, the effective uptake of polyphenols in the brain is still regarded with some 
reservations. Here we describe a combination of approaches to examine the putative 
transport of blackberry-digested polyphenols (BDP) across the blood-brain barrier (BBB) 
and ultimate evaluation of their neuroprotective effects.  
BDP was obtained by in vitro digestion of blackberry extract and BDP major aglycones 
(hBDP) were obtained by enzymatic hydrolysis. Chemical characterization and BBB 
transport of extracts were evaluated by LC-MSn. BBB transport and cytoprotection of 
both extracts was assessed in HBMEC monolayers. Neuroprotective potential of BDP 
was assessed in NT2-derived 3D co-cultures of neurons and astrocytes and in primary 
mouse cerebellar granule cells. BDP-modulated genes were evaluated by microarray 
analysis. 
Components from BDP and hBDP were shown to be transported across the BBB. 
Physiologically-relevant concentrations of both extracts were cytoprotective at 
endothelial level and BDP was neuroprotective in advanced 3D cell models. The major 
canonical pathways involved in the neuroprotective effect of BDP were unveiled, 
including mTOR signaling and the unfolded protein response pathway. Genes like 
ASNS and ATF5 emerged as novel BDP modulated targets. 
BBB transport of BDP and hBDP components reinforces the health benefits of a diet 
rich in polyphenols in neurodegenerative disorders. Our results suggest some novel 
pathways and genes that may be involved in the neuroprotective mechanism of the BDP 




The increase in life expectancy in developed countries has increased the incidence of 
age-related diseases, especially neurodegenerative diseases. Those diseases are 
becoming a major problem in terms of health and wellbeing with a substantial impact on 
welfare care costs. In the past few years, studies have shown that dietary 
supplementation with fruits and vegetables, in particular berries, have effects on brain 
health1.  A growing body of preclinical and clinical research identifying neurological 
benefits associated with the consumption of berry fruits, rich sources of (poly)phenols, 
have shown their potential in preventing age-related neurodegeneration, by changing 
cognitive and motor functions2. Taking advantage of cell and animal models, berry fruits 
have been shown to mediate signaling pathways involved in inflammation and cell 
survival3, in addition to neuroplasticity and neurotransmission enhancement, leading to 
attenuation of age- and pathology-related deficits in behavior1, 4. 
 
A large number of signaling pathways and protein kinase cascades (including  protein 
kinase C, Nrf2/ARE antioxidant pathway, pro-survival MEK/ERK and PI3K/AKT 
pathways), have been reported to be  affected by phenolic compounds5. However, many 
reports are based on in vitro cell assays that study single compounds at relatively high 
doses, mainly as they occur in food6. Although these studies are important to unravel 
the potential mechanisms involved, such components are unlikely to reach these levels 
in vivo. (Poly)phenols are normally ingested as mixtures of different compounds 
immersed in a complex food matrix that undergoes a digestion process, and 
(poly)phenols undergo additional alterations and overcome various barriers before 
reaching the target organ. Following ingestion, absorption from the digestive tract often 
requires the hydrolysis of glycoside conjugates by small intestine enzymes (e.g. lactase 
phlorizin hydrolase or cytosolic β-glucosidase) giving rise to the corresponding 
aglycones7, 8. These aglycones can then be further metabolized by phase II enzymes, 
giving rise to methylated, sulfated and glucuronidated compounds 9. On the other hand, 
(poly)phenols that are not absorbed in the small intestine can reach the colon and then 
be biotransformed by the colonic microbiota into simpler metabolites that are absorbed 






Importantly, to exert their beneficial effects in target tissues and cells, (poly)phenols and 
their metabolites must be both bioaccessible and bioavailable. Bioaccessible can be 
defined as being released and surviving gastrointestinal digestion and therefore 
(bio)accessible in the gut lumen. Bioavailable can be defined as being taken up into the 
serum and into systemic circulation. It is imperative to understand the 
pharmacodynamics and pharmacokinetics of dietary (poly)phenols, like  any other brain-
targeted drug, and determine their ability to cross the blood-brain barrier (BBB) and their 
ultimate protective role inside the brain. Recent studies have started to address this 
issue, evaluating the effective targeting of isolated parent (poly)phenols and 
(poly)phenol metabolites to the brain11-15. In this study, the blackberry extracts were 
subjected to an in vitro digestion procedure that simulates the major physiochemical 
effects of gastrointestinal digestion16. The resulting in vitro digested molecules represent 
the bioaccessible components that could putatively reach the serum by passive 
diffusion.  
 
Previous work confirmed that similar bioaccessible components from blackberry 
promote protective actions in neuronal cells17. This protection was not related with 
enhanced intracellular antioxidant capacity nor glutathione redox status, but another 
mechanism was proposed17, i.e. that these components caused a pre-conditioning or 
hormetic situation, inducing mild stress, which ultimately triggered downstream 
mechanisms, priming the cells against future stresses17. The aim of this work is to 
assess if these components can be transported across the BBB endothelium and also 
to test if they exert further neuroprotective effects using more physiologically-relevant 
cell models with different degrees of complexity. A transcriptomic approach was also 
exploited to identify major genes and networks, which were modulated by blackberry-






Composition of BDP and hBDP metabolites 
Blackberry-digested (poly)phenols (BDP) were obtained by in vitro digestion of 
blackberry extract. BDP mimics the composition of components bioaccessible in the 
gastro-intestinal tract, available for uptake into the bloodstream through passive 
transport. Enzymatic hydrolysis of BDP was also performed to obtain a more 
physiologically-relevant bioaccessible fraction, hBDP, which mimics the deglycosylation 
reactions that occur in the intestine.  
Both BDP and hBDP were chemically characterized by LC-MSn (Fig. 1 and Table 1) 
and major peaks identified by comparing PDA profiles, m/z values and fragmentation 
pattern with literature data. LC-MSn analysis of BDP confirmed the presence of 
glycosylated derivatives of quercetin, cyanidin, kaempferol and myricetin, as already 
reported17 but hBDP lacked most of these derivatives, being enriched in the 
corresponding aglycones, and other breakdown products.  
 
 
Fig. 1 PDA profile of blackberry-digested (poly)phenols (BDP – top chromatogram) and hydrolyzed BDP 
(hBDP – bottom chromatogram).  Representative traces recorded at 280 nm are presented and the full 
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Table 1 Putative identification of major components of BDP and hBDP. Chemical profiling of BDP and hBDP 
was performed by LC-MSn and major peaks identified by their PDA, m/z and fragmentation pattern data. 
Peaks named as in Fig 1. Bold = main m/z or MS2 signal. 
 
 Compound nomenclature PDA MS2 m/z 
RT 
(min) 
K Kaempferol 278 285 165 18.66 
K1 Kaempferol-rutinoside 350 593 285 18.58 
K2 Kaempferol-glucuronide 350 461 285 19.92 
            
Q Quercetin 350 301 257, 185 18.09 
Q1 Quercetin-xyloside 355 433 301 17.03 
Q2 Quercetin-rutinoside 355 609 301 17.62 
Q3 Quercetin-glucoside 355 463 301 18.2 
Q4 Quercetin-galactoside 355 463 301 18.36 
Q5 Quercetin-glucuronide 355 477 301 18.31 
Q6 Quercetin-HMG-glucoside 355 607, 463  463, 301 19.17 
            
M Myricetin 265-360 317 317, 301 22.19 
      
I1 Isorhamnetin xyloside (+formate) 350 493 447, 315 22.57 
            
C1 Cyanidin-3-O-glucoside 515 449(+) 287 13.13 
C2 Cyanidin-3-O-rutinoside 520 595(+) 287 13.57 
C3 Cyanidin derivative 520 477(+) 287 16.05 
            
E Ellagic acid 365 301 189 15.22 
            
B1 Dihydroxybenzoic acid 265 153 109 8.8 
            
G1 Gallic acid derivative 275 305 169 19.16 
            
U1 Unknown 222-276 431 385 14.15 
U2 Triterpenoid derivative  ND 725 679, 517 24.37 
U3 Unknown 284 127 109 6.51 
U4 Unknown 265 127 99, 83 9.91 







Metabolites of both BDP and hBDP are transported across the BBB endothelium 
Transport of BDP and hBDP components across confluent monolayers of human brain 
microvascular endothelial plated on semi-permeable membranes, a well-established in 
vitro BBB model18-20 was assessed and results are indicated in Table 2. The kaempferol 
derivatives, kaempferol rutinoside and kaempferol glucuronide present in BDP were not 
detected in the basal compartment, suggesting that they were not transported across 
the monolayer. However, the aglycone kaempferol, which was not detected in the 
original BDP sample, was detected in basal compartment at both 2h and 24h. Moreover, 
in hBDP samples, which contained the aglycone kaempferol but no glycosides, the 
levels of kaempferol increased with time from 2h to 24h. On the other hand, all the 
quercetin glycosides derivatives present in BDP, except for quercetin xyloside and 
quercetin HMG-glucoside, were detected in the basal compartment after 2h and 24h. 
Moreover, the transport of quercetin-rutinoside seemed to increase with incubation time. 
However, the quercetin aglycone was not detected on the basal compartment when 
either BDP or hBDP samples were applied. Conversely, after application of hBDP, which 
lacked quercetin glycosides (due to enzymatic hydrolysis), both quercetin glucoside and 
galactoside were detected in the basal compartment. Myricetin and myricetin xyloside 
were present in both BDP and in hBDP. With hBDP, myricetin transport across BBB 
endothelium increased over the incubation time. Cyanidin derivatives were not detected 
in the basal compartment after 2h or after 24h of incubation. Ellagic acid transport across 
the BBB was also not detected.  For both the digested extracts, the main transported 
metabolites were quercetin glucosides, kaempferol, myricetin and myricetin glucosides, 
and these components are therefore potential candidates to exert beneficial effects 













Table 2 Blood-brain barrier endothelial transport of major (poly)phenol metabolites identified in BDP and 
hBDP based on basal compartment detection. Substituents positions were inferred based on the 
information reported in the Human Metabolome Database (http://www.hmdb.ca/). 
 
* - presence detected in basal compartment; n.d. – not detected; relative change ratioed for 1.0 at 2h of incubation. 
 
BDP and hBDP protect human brain microvascular endothelial cells against 
oxidative insult 
To evaluate the protective potential of BDP and hBDP at the luminal face of brain 
capillaries of the BBB, HBMEC were exposed to an oxidative insult after 
incubation with either BDP or hBDP. Pre-incubation of HBMEC with 
physiologically-relevant concentrations of BDP9, 13, 21, 22 for 24h protected the 
cells from the oxidative damage caused by hydrogen peroxide (Fig. 2a). 
Moreover, hBDP also revealed protective activity at concentrations greater than 
Compound Structure Compound nomenclature BDP hBDP  BDP hBDP
Kaempferol (R1,2=H) n.d. a 0.98 1.4
Kaempferol-rutinoside (R1=rutin, R2=H) a n.d. n.d n.d
Kaempferol-glucuronide (R1=glucuronic acid, R2=H) a n.d. n.d. n.d.
Quercetin (R1-4=H) a a n.d. n.d.
Quercetin-xyloside (R2,3,4=H, R1=xylose) a n.d. n.d. n.d.
Quercetin-rutinoside (R1=rutin, R2-4=H) a n.d. 1.4 n.d.
Quercetin-glucoside (R2-4=H, R1=glucose) a n.d. 0.7 0.46
Quercetin-galactoside (R1=galactose, R2-4=H) a n.d. 0.87 0.57
Quercetin-glucuronide (R1=glucuronic acid, R2-4=H) a a 0.64 0.53
Quercetin-HMG-glucoside (R1=HMG-glucose, R2-4=H) a n.d. n.d. n.d.
Myricetin (R=H) a a 0.48 1.9
Cyanidin-3-O-glucoside (R= glucose) a n.d. n.d. n.d.
Cyanidin-3-O-rutinoside (R=rutin) a a n.d. n.d.
Cyanidin derivative a n.d. n.d. n.d.
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1.25 µg GAE/mL (Fig. 2b). Indeed, BDP and hBDP treatments restored cell 
viability to levels comparable with control cells (Fig. 2a and 2b).  
 
 
Fig. 2 Cytoprotective potential of BDP (a) and hBDP (b) in the HBMEC line. Cells were pre-incubated with 
different concentrations of BDP or hBDP (0.625-5 µg GAE/mL) for 24h and then submitted to oxidative 
stress (300µM H2O2). Cell viability was assessed and is presented as percentage relative to control. 
Statistical differences are denoted as ***p<0.001, relative to control, and ###p<0.001 and ##p<0.01 relative 
to H2O2 treatment. Data are presented as means ± SD, n=3.  
 
BDP is neuroprotective against oxidative insult and excitotoxicity 
We further explored the neuroprotective potential of BDP using a more physiologically 
relevant cellular model comprising of a mixture of neurons and astrocytes in a three-
dimensional architecture (Fig. 3)23, 24. The cell viability of the 3D co-cultures was greatly 
reduced after oxidative stress induction with t-BHP (Fig. 3a). However, pre-incubation 
with BDP, prior to the oxidative insult, significantly protected the neuronal cells from the 
oxidative injury (Fig. 3a).  
The neuroprotective effect of BDP in an excitotoxic environment was also explored, a 
scenario never reported before for these components. Primary cultures of mouse 
cerebellar granule cells pre-incubated with BDP were injured with glutamate to cause 
excitotoxicity-related damage (Fig. 3b). Of the three physiologically-relevant 
concentrations of BDP used, only the highest (1µg GAE/mL) significantly protected cells 
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Fig. 3 Neuroprotective potential of BDP in NT2 aggregates (a) and in primary neuronal cultures (b). NT2 
aggregates were pre-incubated with different concentrations of BDP (0.5-2 µg GAE/mL) for 24h and then 
submitted to oxidative stress (300 µM tert-butylhydroperoxide, t-BHP). Primary mouse cerebellar granule 
cells were pre-incubated with different concentrations of BDP (0.25-1 µg GAE/mL) for 24h and then 
submitted to an excitotoxic stimulus (100 µM glutamate). Cell viability was assessed and is presented as 
percentage relative to control. Statistical differences are denoted as ***p<0.001, relative to control, and 
##p<0.01and #p<0.05 relative to glutamate insult. Data are presented as means ± SD, n=3.  
 
Differentially expressed genes induced by BDP in neuronal cells  
As we have already demonstrated the protective potential of BDP in SK-N-MC cells 25, 
we evaluated BDP-driven gene expression alterations in these cells by microarray 
analysis.  The number of genes whose transcription was altered (p <0.05) by BDP pre-
treatment was 1124 from a total of 19557 genes, 663 being significantly up-regulated 
and 461 down- regulated. BDP treatment induced changes in transcription with relatively 
low fold change (ranging from -2.554 to 2.549).  
A set of genes with the highest significance levels and expression ratios was selected 
for validation by RT-qPCR (Table 3). HPRT1, GAPDH and B2M were used as reference 
housekeeping genes for fold change normalization. Our validation results were in 
accordance with the microarray data and gave alterations in the same order of 
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Table 3 Comparison of gene expression ratios in response to BDP treatment as determined by microarrays 
analysis and RT-qPCR. 
 
 
Functional enrichment analysis  
Functional enrichment analysis was performed on microarray data using Ingenuity® 
Pathway Analysis (IPA) software. Enrichment analysis on Canonical Pathways of IPA 
identified the significant over-represented pathways across all differentially expressed 
genes (Fig. 4). In this analysis, Cell cycle control of chromosomal replication was 
identified as the top canonical pathway, with the highest –log (p-value). This contained 
mainly downregulated genes, such as CDC6 (cell division cycle 6), ORC1 (origin 
recognition complex subunit 1), ORC6 (origin recognition complex subunit 6), MCM 
(minichromosome maintenance complex), genes involved in pre-replication complex 
assembly, as well as CDC45 (cell division cycle 45), RPA (replication proteins A), 
required at G1-S phase transition.  
 
                
  Gene symbol              
    Microarray   RT-qPCR     
    FC p-value   FC p-value   
                
  ESRP1 2.36 0.000524   2.882 0.00398   
  PPIL6 2.35 2.38E-06   1.945 0.00098   
  ALDH1L2 2.3 3.12E-07   1.845 0.02143   
  ASNS 2.28 7.78E-08   3.614 0.07206   
  ASS1 2.23 3.06E-05   2.877 <0.0001   
  ATF5 2.21 6.82E-05   1.476 0.05147   
  PAG1 2.14 2.35E-06   1.842 0.00018   
  NQO1 2.12 5.84E-06   2.659 0.02104   
  SERPINF1 2.08 9.19E-05   2.495 0.00050   
                
  SNORD56B -2.07 0.014491   -1.669 0.00751   
                









Fig. 4 Canonical pathways significantly modulated by BDP. Cells were treated with BDP for 24 h. Fisher’s 
exact test was used to calculate a p-value determining the probability that the association between the 
genes in the data set and the canonical pathway is explained by chance. Stacked histograms display % of 
up- (red) and down (green) -regulated genes in a given pathway. Values at the right side indicate the number 
of genes involved in each particular pathway. 
 
 
mTOR signaling was also identified as one of the affected canonical pathways, with the 
highest number of genes involved, and the related unfolded protein response pathway 
was also selected. Examining in detail the mTOR pathway, there were major effects 
arising from BDP treatment related to the upregulation of eukaryotic translation initiation 
factor 4EBP, together with PDL, RAS, eIF3, AMPK and VEGF, and downregulation of 
the mammalian target of rapamycin (mTOR), phosphatidylinositol-3-kinases (PI3K), 
IRS1 and eIF4G (Fig. 5). Therefore, this analysis predicts final outcomes resulting from 
BDP treatment, such as induction of protein translation, autophagy regulation, and 




Fig. 5 Canonical pathways representing mTOR signaling obtained with Ingenuity® Pathway Analysis (IPA) 
from the analysis of dataset modulated by BDP. Genes whose expression was significantly modulated by 
BDP are depicted (purple) together with others involved in the cascade (but not significantly modulated, 
depicted in grey). Complexes or groups of genes are surrounded by a double line. Up-regulated genes are 
depicted in red and down-regulated genes are depicted in green. Note: some complexes/groups depicted 
have both up- and down-regulated genes. 
 
The Unfolded protein response pathway (Fig. 6), related to autophagy regulation 
mechanisms, was another major canonical pathway over-represented after BDP 
treatment. BDP modulation of genes in unfolded protein response signaling pathway 
indicates an attenuation of translation, modulation of lipid accumulation and reduction 







Fig. 6 Canonical pathway representing unfolded protein response obtained with Ingenuity® Pathway 
Analysis (IPA) from the analysis of dataset modulated by BDP. Genes whose expression was significantly 
modulated by BDP are depicted (purple) together with the others involved in the cascade (but not 
significantly modulated, depicted in grey Complexes/groups of genes are surrounded by double lines. Up-
regulated genes are depicted in red and down-regulated genes are depicted in green. Note: some 
complex/group depicted have both up- and down-regulated genes. 
 
The Upstream Regulator Analysis tool infers the modulation of enzymes, kinases and 
transcription regulators that could explain the observed gene expression changes 
(Table 4). The cascade of events that lead to these gene expression alterations 
presumes the early involvement of these regulators.  TP53 and ATF4 were two 
transcription regulators with the highest z-score and with significant p-value of overlap 
suggesting activation (Table 4). Moreover, this tool also predicted the inhibition of 
upstream regulators, among which E2F1 and CCND1 presented the lowest z-score and 
also significant p-value of overlap (Table 4). Among the downstream target genes 
regulated by TP53, the major significantly upregulated in our dataset were asparagine 
synthetase (glutamine-hydrolyzing, ASNS), annexin A4 (ANXA4), protein tyrosine 
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phosphatase type IVA - member 3 (PTP4A3), and ribosomal protein S6 kinase A2 
(RPS6KA2), and the major downregulated ones were protein kinase D1 (PRKD1) and 
A-kinase anchoring protein 12 (AKAP12).  
 
Table 4 Upstream regulator analysis obtained from the gene expression dataset from cells incubated with 
BDP, using IPA software. Predicted activation state correlates with calculated z-score, which if it is above 
or equal to 2 corresponds to an activation, and if it is below or equal to -2 corresponds to an inhibition. 
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Genes such as ASNS (also under control of TP53) and ATF5, which were strongly 
upregulated by BDP, are downstream of ATF4 (Fg. 7). Moreover, ATF4 also modulates 
genes involved in the “unfolded protein response pathway” (CEBPB, CEBPG, SREBF1), 
in the “asparagine and serine pathway” (ASNS, PHGDH, PSTA1, PSPH, SHMT2), and 
in “tRNA charging and processing pathway” (GARS, IARS, SARS, WARS, XPOT) (Fig. 
7). In addition, downstream of ATF4 is the central signaling hub JUN which was 







Fig. 7 Identification of ATF4 as an upstream regulator of transcriptional regulation by BDP. Bioinformatic 
analysis with IPA software predicted the activation of ATF4 (orange) as a regulator of genes that are 
upregulated (28, depicted in red) and downregulated (6, depicted in green). Arrows represent predicted 
relationships: orange – leads to activation; yellow – findings inconsistent with state of downstream molecule; 






Blackberry extract was subjected to an in vitro digestion procedure that mimics the 
physiochemical alterations that occur in the gastro-intestinal tract. Although it cannot 
mimic the dynamic changes occurring in the gastro-intestinal tract or active processes 
such as uptake26, including gastric absorption of anthocyanins, which can influence 
serum levels27, this procedure captures the major changes in (poly)phenol stability to 
digestion that occur in vivo. It is a reproducible method16, 17 and recent in vivo studies 
on ileal fluids after raspberry intake28 indicate that it replicates the major alterations 
including ellagitannin stability and anthocyanin degradation. We have already described 
that BDP improved neuroprotective capacity, which may arise due to the phenolic 
composition alteration as a consequence of digestion (i.e. lower levels of anthocyanins 
and ellagitannins but relatively enhanced levels of quercetin derivatives, with evidence 
of accumulation of breakdown products)17. However, as intestinal absorption is not 
taken into account in the in vitro digestion method used, we obtained hBDP which 
mimicked the enzymatic hydrolysis of glycoside conjugates that can occur in the 
intestine7, 8, 21. . 
It is not yet completely clear if (poly)phenol metabolites can cross the BBB by simple 
diffusion or by specific carrier-mediated transport, or how structure influences brain 
bioavailability29. Previous work from our lab demonstrated that differences in endothelial 
transport could be related with the degree of chemical modification, where methylation 
combined with sulfation enhanced the transport of bioavailable (poly)phenol 
metabolites30. Moreover, the presence of efflux transporters at BBB endothelial level 
can also limit (poly)phenol metabolites transport from the blood to the brain30. 
The results from BBB endothelial transport of BDP suggest that the glycosides, 
glucuronic acid and rutinoside, may be removed from the kaempferol glycosides during 
transport. Indeed, animal studies with Ginkgo biloba extract EGb 761®, rich in quercetin 
and kaempferol glycosides, revealed that kaempferol reached the brain of the rats after 
single oral administration and Cmax was reached 8h after ingestion11. 
The detection of quercetin glucosides (quercetin glucoside and galactoside) in the basal 
compartment after application of hBDP samples, which are devoid of these components, 






such as UDP-glucuronosyltransferase, capable of metabolizing (poly)phenols into 
glucuronide derivatives, have been described in the BBB endothelium30, 31. In fact, 
enzymes primarily associated with hepatic drug metabolism have been shown to exist 
in the brain, albeit at relatively low specific activities32 and may influence cerebral 
availability of various compounds at the blood-brain interface31, 33. 
There were clear differences in the BBB endothelial transport of kaempferol and 
myricetin compared to quercetin. Kaempferol, quercetin and myricetin are flavonols and 
differ only in the number of hydroxyl groups in the B-ring (1, 2 or 3 -OH, respectively). 
Intermolecular hydrogen bonds can form between the two hydroxyls at the B-ring of 
quercetin34 and the same could occur between two of the three hydroxyls in the B-ring 
of myricetin. We can speculate that the “free” hydroxyl group in kaempferol and myricetin 
could influence its BBB permeation; however, other factors may contribute to explain 
the pattern of transport specificity noted. As these flavonol components are present in 
mixtures and at differing concentrations, it is possible that they, or other components 
(such as the cyanidins), interfere with each other’s transport. It is also possible that 
certain components (e.g. the acylated HMG-glucoside of quercetin) are less stable in 
the cell media and are degraded before they can be transported. Moreover, in such 
mixtures, certain components (such as anthocyanins) may be more sensitive to 
oxidative degradation. The stability of components could be examined by monitoring 
recovery from media and transport of degradation products examined using radio- or 
isotopically labeled components. Despite the accumulating evidence for free quercetin 
detected in the brain after oral administration22, 35, we propose that it may result from 
degradation of conjugated forms, which are transported across the BBB, and quercetin 
alone may not be able to be transported. In fact, in a previous study36 we have detected 
the transport of quercetin glucosides but not of free quercetin. Accordingly, a very low 
efficiency of free quercetin transport (around 8% after 18 h incubation) was reported37 
which was attributed to: (i) a low uptake at the apical membrane, (ii) reduced transport 
through the basolateral membrane, (iii) a high metabolism/ degradation rate, or (iv) an 
increased efflux37. Actually, quercetin has been described both as a P-glycoprotein 
inhibitor and/or substrate38, which could contribute to its low BBB transport. 
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The fact that no cyanidin derivatives were detected in basal compartment is in line with 
our previous data: for example, even for higher concentrations, only 1% of cyanidin-3-
O-glucoside crossed a confluent monolayer of HBMEC36. Several studies have reported 
the capacity of anthocyanin derivatives to reach the brain, and their pharmacokinetics 
is very rapid, being detected in the brain after 10 minutes from their introduction into the 
stomach39. Moreover, the biotransformation of cyanidin-3-O-glucoside is very fast and 
substantial, with the appearance of methylated derivatives such as peonidin-3-O-
glucoside and malvidin-3-O-glucoside, both in plasma and in the brain 15. We can 
speculate that such metabolism may occur at the BBB level, but we cannot confirm this 
from our LC-MSn data.  
Enzymatic hydrolysis of BDP may lead to a more bioavailable fraction in terms of 
intestinal absorption but, once in circulation, the aglycones present will be further 
metabolized and the end-products that ultimately can reach the luminal surface of 
endothelial cells of brain capillaries of the BBB may be methylated, sulfated and/or 
glucuronidated9, 40. Our data demonstrates that (poly)phenol components arising from 
blackberry extract after in vitro digestion (BDP) and subsequently enzymatically 
hydrolyzed (hBDP) are able to be transported across the BBB endothelium and in some 
cases even further metabolized. 
Endothelial cells of the brain microvasculature are the “front line” in the protection the of 
brain cells from external agents which may lead to increased as oxidative stress, 
inflammation, vascular reactivity and excitotoxicity41, 42. Although hBDP had some 
protective potential at the BBB interface, BDP was more effective at lower levels, which 
were more comparable to those that may reach the brain 9, 13, 22, and therefore BDP was 
explored in greater depth. We have already evaluated the neuroprotective potential of 
BDP in a simplified neurodegeneration cell model17, 25 so we extended our studies to a 
more physiologically relevant cell model, i.e. a complex cell system comprising a mixture 
of neurons and astrocytes with a three-dimensional architecture23, 24. The 3D aggregates 
are mainly composed of astrocytes (~77% of the cells)23 and glial cells (astrocytes and 
microglia), which are responsible for the repair process of the brain in the case of 
injury43, being stronger and less susceptible to damage than neurons. In our previous 






astrocytes within the aggregates39. We argued that protection conferred by bioavailable 
concentrations of (poly)phenol metabolites in this system could be related to improving 
the functionality of the astrocytic population and not directly in the reduction of the 
deleterious effects caused by the oxidative injury30.  
BDP was also neuroprotective in an excitotoxicity scenario. Previous studies have 
reported neuroprotective effects of blueberry fruit extracts towards glutamate toxicity, 
but using whole fruit extracts and in concentrations higher than what might be achieved 
in vivo44. Another frequent approach is to test pure compounds, which is interesting for 
elucidating the chemical basis related with different neuroprotective effects of the 
compounds, but is not nutritionally translatable. To our knowledge, this is the first report 
of protection against excitotoxicity by bioaccessible (poly)phenol components. 
Most of the in vitro data on the effects of (poly)phenols on molecular pathways and 
protein kinase cascades involved in neuroprotection  have been gathered using pure 
(poly)phenols, in isolation and often at non-physiologically-relevant concentrations. 
Gene expression analysis was performed in SK-N-MC cells, where BDP has already 
proven to be protective25. BDP led to modest alterations (~ 2-fold) in gene expression, 
which is consistent with previously reported actions of dietary-derived compounds: 
which although usually complex, are characterized by the induction of a broad array of 
genes with modest changes in their intensity45. Furthermore, modest alterations may be 
expected as low, physiological but cytoprotective concentrations of BDP (0.5 µg 
GAE/mL) were used17. Among such genes was NQO1, a member of the NAD(P)H 
dehydrogenase (quinone) family, described to be involved in oxidative stress and 
antioxidant response pathways, preventing the one electron reduction of quinones that 
results in the production of radical species46. Moreover, the ubiquitin-independent p53 
degradation pathway is regulated by NQO1 by stabilizing p53, protecting it from 
degradation47. In fact, tumor suppressor p53 is responsible for conserving the stability 
of the genome, preventing the rise of mutations in the DNA48. We suspect that NQO1 
upregulation can modulate p53 signaling, with ultimate benefits to cell survival. Another 
upregulated gene was SERPINF1, coding for pigment epithelium-derived factor (PEDF, 
also known as serpin F1), described to be anti-angiogenic, anti-tumorigenic and 
neurotrophic. PEDF has been shown to be neuroprotective against acute glutamate 
88 
 
toxicity49, and high glucose or H2O250. PEDF can also induce p53 through PPARγ 
expression, stimulating several other signaling cascades like Ras and NF-κB 
pathways51. The significant upregulation of such genes may, at least in part, justify the 
protective effect conferred by BDP (poly)phenols.  
Functional enrichment analysis identified the major canonical pathways predicted to be 
modulated by BDP, such as mTOR signaling and Unfolded Protein Response. Several 
reports demonstrate positive effects of dietary (poly)phenols in mTOR signaling and 
induction of protein translation, autophagy regulation, and regulation of VEGF signaling 
and of PI3K/AKT signaling52, 53. For instance, fisetin significantly increased p-PI3K, p-
Akt and p-GSK3β expression in Aβ1-42-treated mice, accompanied by a marked 
reversion of synaptic dysfunction, with improvement of mouse memory54. A mixture of 
grape seed extract, Concord grape juice and resveratrol significantly improved sleep 
deprivation-induced cognitive impairment, in which brain-available quercetin-3-O-
glucuronide activated CREB signaling and malvidin-3-O-glucoside activated mTOR 
signaling55. Our results confirm that blackberry (poly)phenols resulting from in vitro 
digestion affect these same signaling pathways with putative neuroprotective outcomes.  
The upregulation of the regulatory subunit of eukaryotic initiation factor 2 (eIF2α) in 
unfolded protein response pathway is related with endoplasmic reticulum (ER) stress, 
normally through increases in its phosphorylation by PERK56. This regulation, mediated 
by BDP, suggests that translation might be slowed since initiation may be blocked. On 
the other hand, modulation of eIF2α has already been described to be linked to key 
regulators of lipid accumulation (PPARγ, C/EBP, SREBP)56. As lipid peroxidation is 
associated with brain injury, BDP may modulate lipid accumulation and then confer an 
adaptive advantage for further cellular stress. 
Apoptosis is also an important mechanism suggested to be affected by BDP. For 
instance, ASK1 codes for mitogen-activated protein kinase 5 (MAP3K5), a member of 
MAP kinase family, responsible for the activation of c-Jun N-terminal kinase (JNK) and 
p38 mitogen-activated protein kinases under stress (e.g. oxidative stress, ER stress or 
calcium influx)57. The downregulation of ASK1 may reduce its activity, which may lead 






cytoprotective/neuroprotective mechanisms that help the cell to cope with the effects of 
an oxidative agent.  
Another upregulated gene was chaperone Hsp40 (DnaJ), which acts through ATPase 
activity stimulation of Hsp70 activity, and also associates with unfolded polypeptide 
chains to prevent their aggregation 58. Indeed, we also observed downregulation of 
Hsp70 mRNA levels. Our results suggest an Hsp40-mediated activation of the 
regulatory mechanism of Hsp70 activity, which is independent of Hsp70 cellular levels. 
This regulation could comprise an important mechanism of protection by priming the 
cells to cope with a later stress. Acquisition of stress tolerance by Hsps regulatory 
mechanisms was already described in mammalian cells pre-exposed to thermal stress59 
and by resveratrol60. To our knowledge, this the first study where bioaccessible 
(poly)phenols from blackberry fruits are described to modulate key players in the 
unfolded protein response. 
The major upstream regulator predicted to be activated by BDP was TP53. The p53 and 
p53-signaling pathway has already been involved as a functional mechanism for 
protection using non-nutritional approaches with pure (poly)phenols61, 62. However it is 
not clear what (poly)phenols may  target in the p53 regulatory pathway and how this can 
affect downstream metabolism. Our analysis reveals potential novel targets that were 
modulated by bioaccessible (poly)phenols at physiologically-relevant concentrations, 
including ASNS and ANX4. The only previous reports describing enhanced expression 
of these genes referred to very different conditions: e.g. effects of lignin on ASNS in 
macrophages63 and low, non-toxic concentrations of ethanol for ANX4 in rat glioma C6 
cells and human adenocarcinoma A549 cells64. 
Activating transcription factor 4 (ATF4), involved in ER stress response, was also 
predicted to be activated by BDP. ATF4 plays a crucial role in stress adaptation and its 
major function is to mediate the induction of the integrated stress response65, 66. Several 
ATF4 target genes, such as CHOP, are themselves transcription factors that regulate 
and amplify the signal initiated by the original stress. Downstream of ATF4 is ATF5, a 
similar but less studied ATF4 homolog. ATF4 has established roles in cell susceptibility 
to ER stress through the regulation of CHOP, whereas ATF5 has been found to have 
anti-apoptotic roles in several tissues67, 68. Two direct transcriptional targets of ATF5 
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have been identified, the anti-apoptotic factor B-cell chronic lymphocytic 
leukemia/lymphoma 2 (BCL-2) and mTOR69, 70. The dual role of ATF5 in cell survival 
and stress response appears as new and promising target for the study of (poly)phenol-
derived metabolites. To date, there are no studies reporting the modulatory effects of 
(poly)phenols or (poly)phenol-derived metabolites on ATF5.  
The modulatory effect of BDP on tRNA charging and processing at the level of gene 
expression is a novel layer of regulation for (poly)phenol components. Direct physical 
interactions of pure (poly)phenols with tRNA have already been described, with 
evidence that low flavonoid concentration induced helical stabilization71, 72. Jointly, these 
effects, when mediated by (poly)phenol components, may impact central and fine-tuned 
mechanisms of the cell. It was demonstrated that EGCG significantly inhibited 
phosphorylation of the MAPK p38 and JNK, and NF-κB and AP-1 transcriptional 
activities, whilst causing anti-inflammatory and anti-oxidant effects in human corneal 
epithelial cells73. Moreover, a (poly)phenol-rich peanut extract reduced extracellular 
TNF-α release by inhibiting c-Jun transcription factor activity74. BDP-predicted 
upregulation of ATF4, at physiologically-relevant concentrations, may be one of the 
most important regulatory pathways responsible for BDP neuroprotective effects against 
stress. Under the umbrella of ATF4, our results pinpoint some pathways already 
associated with (poly)phenols but also indicate novel targets for  (poly)phenols, such as 
ATF5 or regulation of tRNA charging and processing. 
 
Conclusion  
Blackberry (poly)phenol components, resulting from a validated in vitro digestion 
protocol, are transported across the blood-brain barrier endothelium and therefore may 
exert neuroprotective action in situ. Neuroprotective activities were observed in more-
physiological and biological relevant complex cellular models such as mixed 3D cellular 
culture systems. Our results support the hypothesis that exposure to chronic low levels 
of bioaccessible and nutritionally relevant metabolites may significantly influence key 
cellular mechanisms in neuronal cells in a preventive context. From gene expression 
analysis, we conclude that the blackberry (poly)phenol components  modulated genes 






identified, involved in cell cycle control, mTOR signaling and unfolded protein response, 
have already been described to be modulated by dietary (poly)phenols. However, to our 
knowledge, this is the first time that such alterations in gene regulation by bioaccessible 
(poly)phenol components have been described. Additionally, genes modulated by these 
components may indicate novel mechanistic targets for neuroprotection. 
Overall, our results illustrate how bioaccessible (poly)phenol components, at 
physiological concentrations, may access brain cells and be protective. By revealing 
significant gene modulatory effects of diet-derived compounds, we enlarge our 
understanding of how the food we eat impacts gene expression and ultimately prevent 




Material and Methods 
Preparation of blackberry-digested (poly)phenols 
Blackberry fruits (Rubus L. subgenus Rubus Watson) were grown at Fataca 
experimental field station (Odemira, Portugal). The frozen ripe berries were freeze-
dried, ground without separation of seeds in an IKA M20 mill to pass a 0.5 mm sieve 
and stored at -80 ºC prior to extraction. Fruit extracts were prepared using a 
hydroethanolic solution (ethanol 50 %, v/v)75.  In vitro digested extract [named 
blackberry-digested (poly)phenols (BDP)] was obtained using the previously described 
method in which the final digestate is obtained following passive diffusion  through a 
dialysis membrane3.  
Preparation of hydrolyzed blackberry-digested (poly)phenols  
Enzymatic hydrolysis of BDP was performed as described previously21 with some 
modifications. BDP extract was acidified to pH 5.0 with acetic acid and cellulase was 
added to a final concentration of 20 U/mL (1 U corresponds to 0.885 mg of protein and 
is defined as the amount required to liberate 1.0 μmol of glucose from cellulose in 1h at 
pH 5.0 at 37 °C). Samples [named as the hydrolyzed blackberry-digested (poly)phenols 
(hBDP)] were incubated for 6 h at 37 °C and then purified by solid phase extraction.  
The total phenolic content of BDP and hBDP was determined by the Folin–Ciocalteu 
method adapted to microplate reader76 using gallic acid as standard and expressed as 
mg of gallic acid equivalents per gram of dry weight (mg GAE/g dw). Both BDP and 
hBDP were dried by rotary evaporation, re-suspended in 5% (v/v) acetonitrile in water 
and analyzed by LC-MSn as described below.   
BBB Endothelial Transport Assays 
A cell line derived from primary cultures of human brain microvascular endothelial cells 
(HBMEC) transfected with SV40 large T antigen77 was used as a simplified in vitro model 
of BBB. The HBMEC line was cultured as previously described78. For transport studies, 
endothelial cells were cultured on semipermeable filters (polyester transwell inserts, 0.4 
μm, Corning Costar Corp., USA) placed in 12-well culture plates, which separate two 
compartments: the upper compartment that can be considered as the “blood-side”, 






considered the “brain side”. Cells were seeded at a density of 8×104 cell/insert and 
treated after 8 days in culture. All experiments were performed in triplicate and after 
monolayer formation. 
Transport assays were conducted in a specific incubation medium: HBSS (Hank's 
Balanced Salt Solution) with calcium and magnesium (Gibco), supplemented with 0.1% 
FBS. Confluent monolayers of HBMEC were incubated with 5μg GAE/mL of BDP or 
hBDP. In order to evaluate a time-dependent transport, BDP or hBDP were added to 
the upper compartment and samples from upper and lower compartments were 
collected after 2 and 24 h. Monolayer integrity was ensured in all experiments by 
monitoring transendothelial electrical resistance (TEER) and paracellular permeability 
78. No alterations were observed reflecting barrier integrity throughout the experiments. 
In the end, cell medium from upper and lower compartments were collected and frozen 
at -80 °C until analysis.  
Liquid Chromatography Mass Spectrometry (LC-MSn) 
Deproteinization of samples of upper and lower compartments was performed before 
LC-MSn analysis. To 1 mL of cell medium it was added 139 µL of 50% formic acid, 
ascorbic acid (final concentration of 1 mM) and taxifolin as internal standard (final 
concentration of 9 µM). To precipitate proteins, 2.5 mL of acetonitrile was added 
dropwise and samples were vortexed before centrifugation at 3200 g for 15 min. The 
supernatant was removed and dried under centrifugal evaporation (CentriVap Vacuum 
Concentrator, Labconco). Samples were dissolved in 5% acetonitrile in 0.1% formic acid 
and immediately analyzed on a LC-Orbitrap MS. Samples were separated on an HPLC 
Accela 600 HPLC system (Thermo Scientific, Bremen, Germany) using a C18 Synergi 
Hydro RP18 column [Phenomenex, Macclesfield, UK) 4 μm particle size and dimensions 
2 mm ID × 150 mm] fitted with a Security GuardTM guard [Aqua 10 μm C18 Guard 
Cartridge (2mm ID×4 mm; Phenomenex)]. Samples were eluted over a gradient of 98% 
solvent A (0.1% formic acid in ultra-pure water) to reach 5% B (0.1% formic acid in 
acetonitrile) at 5 min, 35% B at 25 min, increase to 100% B at 26 min, 100% B at 29 
min, and back to 2% B at 30 min at a flow rate of 0.2 mL/min. LC-MSn analysis was 
carried out on an LTQ OrbitrapTM XL hybrid mass spectrometer (Thermo Scientific, 
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Bremen, Germany). MS analysis was performed using data-dependent Nth order double 
play analysis comprising full scan mass range 80–2000 amu, 30 000 resolution, data-
type centroid and data dependent MS/MS (60 s of exclusion duration) on the top three 
most intense ions detected above threshold automatically in the independent scan 
event. ESI settings were as follows: source voltage, 3.4 kV; capillary temperature was 
275°C with a sheath gas at 40 psi and auxiliary gas at 5 psi. MS data handling software 
(Xcalibur QualBrowser software, Thermo Electron Corp.) was used to search for 
predicted metabolites by their appropriate m/z value. All peaks were checked for m/z 
value and fragmentation products. 
Cytoprotection assays 
Cytoprotection in HBMEC 
For cytoprotection studies, cells were seeded at a density of 8×104 cell/mL in 96-well 
plates. Briefly, 24 h after seeding, HBMEC cells were pre-incubated for 24h with 0.625, 
1.25, 2.5 and 5 µg GAE/mL of BDP or hBDP in cell medium. After pre-incubation, 
medium was replaced by new medium containing 300 µM H2O2, for 24 h25, 79. In the end, 
cell viability was assessed using the CellTiter-Blue® Cell Viability Assay (Promega), 
according to the manufacturer’s instructions. Final cell viability was calculated as a 
percentage of control cells viability. 
 
Neuroprotection in 3D co-cultures of neurons and astrocytes  
NTera-2/cl.D1 (NT2) cells (ATCC), were differentiated in stirred suspension culture 
systems, as 3D aggregates, as previously described23. Stable 3D co-cultures of human 
neurons and astrocytes were maintained up to day 50 of culture.  For neuroprotection 
assays, 3D co-cultures were collected (between day 38 and 50) and distributed in 96-
well plates. BDP or hBDP (0.5 and 2 µg GAE/mL) were added to the cultures and after 
24 h, an oxidative insult was induced by addition of 300 µM tert-buthyl hydroperoxide 
(t-BHP; Sigma-Aldrich) for 48 h as previously described24. Cell viability was accessed 
with PrestoBlue® Cell Viability Reagent (Thermo Fisher Scientific), accordingly to 








Neuroprotection in cerebellar granule cells 
Primary cultures of mouse cerebellar granule cells were prepared from cerebella of 7d-
old BALB-C mice as previously described80. Three concentrations of BDP (0.25, 0.5 and 
1 µg GAE/mL) were added to the cells at 7d in culture. Cells were then incubated for 24 
h and morphology was evaluated. At day 8 in culture, 100 µM of glutamate (Sigma-
Aldrich) was added. Cells were incubated for another 24 h, morphology was evaluated 
and viability determined by fluorescence microscopy with propidium iodide (PI) and 
Hoechst 33342 labeling, as previously described80. Final cell viability was calculated as 
a percentage of control cells viability. 
Microarray analysis 
Human neuroblastoma SK-N-MC cells (ECACC) were cultured as previously 
described25. SK-N-MC cells were seeded at 5x104 cells/cm2 and grown for 24 h. BDP 
was supplied to cells (0.5 µg GAE/mL) dissolved in medium containing 0.5% (v/v) FBS 
for 24 h25. After incubation, cells were washed with PBS, trypsinized, collected into a 
tube and 0.05 volumes of FBS added to inactivate trypsin. Dihexyloxacarbocyanine 
iodide (DiOC6(3)) and PI were added to cells at a final concentration of 20 nM  and 1 
µg/mL, respectively, and incubated for 30 min at 37 ºC.  DiOC6(3) was used to evaluate 
the mitochondrial transmembrane potential (ΔΨm) and PI to determine cell viability, 
based on plasma membrane integrity25. Cells were then sorted in a FACSAria High 
Speed Cell Sorter (Becton Dickinson), using a 100 µm nozzle with 206.8 kPa (30 psi) 
sheath pressure. A 488 nm laser was used for DiOC6(3) and PI excitation and detection 
was performed using a 530/30 nm and a 695/40 nm HQ band pass filter, respectively. 
Only cells that exhibited cellular membrane integrity and high mitochondrial 
transmembrane potential were collected in tubes containing PBS for further analysis 
(Supplementary Fig. S1). 
 
Total RNA extraction of sorted cells was performed using AxyPrep Multisource Total 
RNA Miniprep (Axygen) as previously described81. Total RNA was treated with Turbo™ 
DNase I (Ambion), accordingly to the manufacturer’s instructions. RNA quantity was 
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assessed using a Nano-Drop® ND-1000 spectrophotometer (NanoDrop Technologies) 
and RNA quality using an Agilent 2100 Bioanalyser with an RNA 6000 Nano Assay 
(Agilent Technologies). Biological triplicates were processed for use on Affymetrix 
(Santa Clara, CA, USA) GeneChip HuGene 1.0 ST Arrays at the Gene Expression Unit 
of Instituto Gulbenkian de Ciência (Oeiras, Portugal), and, according to the 
manufacturer’s Whole Transcript Sense Target Labeling Assay. Briefly, 100 ng of total 
RNA containing “spiked in” Poly-A RNA controls (GeneChip Expression GeneChip 
Eukaryotic Poly-A RNA Control Kit; Affymetrix) was used in a reverse transcription 
reaction (GeneChip® WT cDNA Synthesis Kit; Affymetrix) to generate first-strand cDNA. 
After second-strand synthesis, double-stranded cDNA was used in an in vitro 
transcription reaction to generate cRNA (GeneChip® WT cDNA Amplification Kit; 
Affymetrix). Fifteen µg of this cRNA was used for a second cycle of first-strand cDNA 
synthesis (GeneChip® WT cDNA Synthesis Kit; Affymetrix). From the single stranded 
cDNA, 5.5 µg was fragmented and end-labeled (GeneChip® WT Terminal Labeling Kit; 
Affymetrix). Size distribution of the fragmented and end-labeled cDNA, respectively, was 
assessed using an Agilent 2100 Bioanalyzer with a RNA 6000 Nano Assay. Five µg of 
end-labeled, fragmented cDNA was used in a 100-µL hybridization cocktail containing 
added hybridization controls. Eighty µL of mixture was hybridized on arrays for 17 h at 
45°C. Standard post hybridization wash and double-stain protocols (FS450_0007; 
GeneChip HWS kit, Affymetrix) were used on an Affymetrix GeneChip Fluidics Station 
450. Arrays were scanned on an Affymetrix GeneChip scanner 3000 7G. Scanned 
arrays were analyzed first with Affymetrix Expression Console software for quality 
control. For subsequent analyses, Chipster 2.0 (http://chipster.csc.fi/) was used with 
custom cdf file HuGene10stv1_Hs_ENTREZG.cdf as available from Brainarray 
database version 14.1.0. GeneChip datasets for the arrays used in this study will be 
available in a MIAME-compliant format through Gene Expression Omnibus.  
 
Validation by Real Time qPCR 
Real-time quantitative PCR analysis (RT-qPCR)  to confirm relative changes in mRNA 
levels of selected genes from microarray data sets was performed as described 






cDNA Synthesis kit (Quanta). RT-qPCR analysis was performed in a LightCycler 480 
Multiwell Plate 96 (Roche), using the Light-Cycler 480 SYBR Green I Master Kit 
(Roche). cDNA was diluted 1:100 and each sample was analyzed in triplicate. The list 
of used primers and its sequence is presented in Supplementary Table 1. Cycles 
threshold (Ct’s) and melting curves were determined using LightCycler 480 software, 
version 1.5 (Roche) and results were processed using the 2−ΔΔCt method for relative 
gene expression analysis82, 83. Changes in gene expression were normalized using the 
house-keeping genes HPRT1, GAPDH and B2M as internal controls. 
Functional enrichment and pathway analysis 
Ingenuity® Pathway Analysis (IPA, Ingenuity Systems, Quiagen, USA) was used for 
functional enrichment analysis. To this end, we defined probe sets using remapped chip 
definition file (CDF) based on Entrez gene database. Changes in gene expression were 
assessed between BDP and medium control. The functional interpretation of gene 
signatures was executed using the core analysis function of Ingenuity Pathway Analysis 
(IPA) 3.0. IPA performs functional enrichment analysis based on up- and downregulated 
genes in order to identify the biological processes and functions over-represented in a 
given list of genes. In addition to this, based on information stored in the Ingenuity® 
Knowledge Base, upstream regulator analysis was performed using IPA software, which 
is based on the examination of the known targets of each transcription regulator in the 
list of differentially expressed genes, comparing their direction of change to what is 
expected from the literature. The prediction algorithm calculates a z-score (if ≥2 it is 
predicted to be activated, and if ≤-2 is predicted to be inhibited), and it is designed to 
reduce the chance that random data would generate significant predictions. 
Statistical analysis 
All results are averages of at least three independent experiments and are represented 
as the means ± SD. Differences amongst treatments were detected by analysis of 
variance with the Tukey HSD (honest significant difference) multiple comparison test (a 
= 0.05) using GraphPad Prism 6 software. Microarray raw data were normalized using 
Robust Multi-array average (RMA) and statistical differences evaluated by a two groups 
test (empirical Bayes), for p<0.05.  Genes with significant changes (p<0.05 according 
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to Limma regularized paired t-test) were selected for IPA analysis. Significance of the 
enriched categories (Functional Enrichment Analysis of IPA) was tested by the Fisher 
Exact test p-value. 
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Supplementary Table 1 List of primers used in qRT-PCR validation. 
 
Gene Forward sequence Reverse sequence 
ESRP1 GAATGCTCAGGGTCGAAGGA GGAGAGAAACTGGGCTACCTC 
PPIL6 TTCAGCTGCCCCAACTTTCA TGCCATGCAAATTCTTGAAGAGG 
ALDH1L2 CTCCACTGGCCGGGTTTATT AGCCAGAGGGTCAGCTTTTC 
ASNS ATGTTGGATGGTGTGTTTGC AGTCGCGGAGTGCTTCAAT 
ASS1 CAACACCCCTGACATTCTCG TCTCGTAGATACCTCGGGACT 
ATF5 ACTGGATGACTGAGCGAGTTG GTCTTCCATCTGTTCCAGCTCC 
PAG1 CGCAGTGGATACCATGCTCA AGATTTTGCCTTGCCACTGT 
NQO1 TGACATATAGCATTGGGCACAC TTCTCCTCATCCTGTACCTCTT 
SERPINF1 ATGATGTCGGACCCTAAGGC TGCACGGTCTTCAGTTCTCG 
SNORD56B TCAACAGCGGTTCACCTAGT TCACTCAAACCCAAAGTATCAACA 
   
HPRT1 CCTGGCGTCGTGATTAGTGA CGAGCAAGACGTTCAGTCCT 
GAPDH AGAAGGCTGGGGCTCATTTG AGGGGCCATCCACAGTCTTC 
B2M GGCTATCCAGCGTACTCCAA ACCAGTCCTTGCTGAAAGACAA 
 
 
Supplementary Fig. 1 Representative picture of the isolation of SK-N-MC cells that presented cellular 
membrane integrity (PI negative) and high mitochondrial transmembrane potential (DiOC6(3) positive) using 
FACSAria High Speed Cell Sorter. SSC-A – side scatter, FSC-A – forward scatter. Top panels: control cells; 







Bioavailable polyphenol metabolites are 
transported across the blood-brain barrier and 














This chapter is based on the following manuscript: 
 
Polyphenols journey through blood-brain barrier towards neuronal protection 
Figueira I, Garcia G, Pimpão RC, Terrasso AP, Costa I, Almeida AF, Tavares L, Pais 
TF, Pinto P, Ventura MR, Filipe A, McDougall GJ, Stewart D, Kim KS, Palmela I, Brites 

































This chapter contains data in which the author of this dissertation executed the majority 
of the experiments. Table 2 was performed by A.F. Almeida, Fig 3b was performed by 









Table of contents 
Abstract ................................................................................................................................... 108 
Introduction ............................................................................................................................. 109 
Results .................................................................................................................................... 111 
Bioavailable (poly)phenol metabolites are transported across the BBB endothelium........ 111 
In silico modeling of metabolite properties ......................................................................... 113 
HBMEC contains functionally active efflux transporters .................................................... 115 
Bioavailable (poly)phenol metabolites are not exported to the upper side and their transport 
increases with time ............................................................................................................ 115 
HBMEC metabolize bioavailable (poly)phenol metabolites ............................................... 116 
Bioavailable (poly)phenol metabolites protect brain endothelial cells and neuronal cells.. 117 
Bioavailable (poly)phenol metabolites reduce neuro-inflammation .................................... 120 
Pyr-sulf prevents NF-κB nuclear translocation and alters IκBα levels ............................... 121 
Discussion ............................................................................................................................... 122 
Material and Methods .............................................................................................................. 128 
Reagents............................................................................................................................ 128 
Cell culture conditions ........................................................................................................ 128 
Immunofluorescence .......................................................................................................... 130 
Efflux transporters functional assays ................................................................................. 130 
BBB integrity ...................................................................................................................... 131 
Transport Assays ............................................................................................................... 132 
In silico prediction of pharmacokinetic properties .............................................................. 134 
Protective potential of human bioavailable (poly)phenol metabolites ................................ 134 
Western blot ....................................................................................................................... 136 
Real-time quantitative PCR ................................................................................................ 136 
Statistical analysis .............................................................................................................. 137 
Ethics statement ................................................................................................................ 137 
Acknowledgements ................................................................................................................. 138 
Contributions ........................................................................................................................... 138 
References .............................................................................................................................. 140 






Age-related complications such as neurodegenerative disorders are increasing and 
remain cureless. The possibility of altering the progression or the development of these 
multifactorial diseases through diet is an emerging and attractive approach with 
increasing experimental support. We examined the potential of known bioavailable 
phenolic sulfates, arising from colonic metabolism of berries, to influence hallmarks of 
neurodegenerative processes. In silico predictions and in vitro transport studies across 
blood-brain barrier endothelial cells, at circulating concentrations, provided evidence for 
differential transport, likely related to chemical structure. Moreover, endothelial 
metabolism of these phenolic sulfates produced a plethora of novel chemical entities 
with further potential bioactivities. Pre-conditioning with phenolic sulfates improved 
cellular responses to oxidative, excitotoxicity and inflammatory injuries and this 
attenuation of neuroinflammation was achieved via modulation of NF-κB pathway. Our 
results support the hypothesis that these small molecules, derived from dietary 
(poly)phenols may cross the BBB, reach brain cells, modulate microglia-mediated 









With increased life expectancy1, the world’s population is getting older with concomitant 
incidence of age-related diseases, like Alzheimer’s and Parkinson’s disease, the two 
most common age-related neurodegenerative disorders2. Current therapies only 
alleviate physical complications, being unable to abolish the pathology, comprising a 
huge burden to the society3. The difficulty in finding drugs to treat neurodegenerative 
disorders can be explained by the multitude of factors that lead to disease phenotype 
and effective treatments will need to be multi-faceted4. 
Through the past decades, several epidemiological studies have revealed that 
(poly)phenol-rich diets,  including e.g. fruits and vegetables, can provide beneficial 
effects in humans5, 6, preventing degenerative disorders and cognitive decline7, 8. 
(Poly)phenols are described as pleiotropic and may act against several disease-relevant 
biological pathways9, 10. Nutritional studies have also demonstrated significant cognitive 
benefits and neuroprotective potential of (poly)phenols11-14. Berries are amongst the 
most promising fruits as sources of (poly)phenols with these health benefits11, 15-18. 
Despite the accumulating evidence of beneficial effects, the basic mechanism of action 
of (poly)phenols remain to be elucidated19.Both indirect actions through peripheral 
effects (e.g. enhancement of cerebrovascular blood flow) and direct actions inside the 
brain (e.g. through activation of receptors, neurotrophins and modulation of signaling 
pathways) have been suggested as potential mechanisms. Most in vitro mechanistic 
studies with (poly)phenols have used pure components and do not consider their 
metabolism and bioavailability. Therefore, the effects reported do not necessarily relate 
to what may occur in vivo as (poly)phenol metabolites present in circulation result from 
extensive conjugation due to digestion, hepatic and colonic metabolism, and usually 
differ from their native dietary compounds20. In addition, the concentration ranges used 
are much higher than the levels of circulating “bioavailable” metabolites.  
Recent studies demonstrate that, after intestinal absorption, some (poly)phenol 
metabolites can reach concentrations in the bloodstream that can exert effects in vivo21, 
22. Nevertheless, the effective brain uptake of these (poly)phenols metabolites, with 
possible direct neuroprotective potential, is still regarded with some reservations and 
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the true mechanisms by which they may permeate the blood-brain barrier (BBB) are not 
fully understood. 
The BBB is a dynamic interface that limits and regulates molecular exchanges between 
the blood and the neuronal tissue or its fluid spaces, having a crucial role in providing 
nutrients and non-nutrients (such as (poly)phenols), and controlling the access of 
compounds to the brain23, 24. Assays with mammals revealed that (poly)phenols and 
their metabolites can enter the brain at measurable levels, supporting their direct action  
in a neurological context25-27. Youdim and co-workers have also begun to elucidate the 
mechanisms of permeation of (poly)phenols through the BBB28, 29. Nevertheless, it is not 
yet completely clear whether the primary route by which (poly)phenol metabolites cross 
the BBB is by simple diffusion or by specific carrier-mediated transport. Moreover, there 
is also limited knowledge of how (poly)phenol structure influences their brain 
bioavailability. Additionally, little is known about their further metabolism in the brain.  
In previous work we identified new bioavailable (poly)phenol metabolites in urine and 
human plasma after consumption of a mixed berry puree22, 30 and determined their 
circulating concentrations. These bioavailable metabolites circulate in micromolar 
concentrations whereas their parent compounds are undetected22. Here we report, for 
the first time, that these metabolites are able to cross the BBB endothelium at 
physiologically relevant concentrations. Moreover, endothelial cells metabolize these 
metabolites into novel components, which provides a new array of candidate brain-
available metabolites never previously studied. We also demonstrate that these 
(poly)phenol metabolites exert beneficial effects in different neuronal systems (e.g. cell 
lines, primary cultures and a three-dimensional human cell model), with different 
degrees of complexity and in response to different damages. The (poly)phenol 
metabolites attenuated neuro-inflammatory processes via regulation of nuclear factor 







Bioavailable (poly)phenol metabolites are transported across the BBB 
endothelium 
The transport of bioavailable (poly)phenol metabolites across the BBB was evaluated in 
an immortalized human brain microvascular endothelial cell (HBMEC) line that mimics 
endothelial cells of brain capillaries, considered the anatomical basis of the BBB23, 31.  
(Poly)phenol metabolites known to be bioavailable were synthetized and tested at 5 M 
as they have been quantified at physiological levels ranging from 0.3-12 µM in plasma22 
(Table 1). At this range of concentrations, it was verified that there are no adverse 
effects on cellular viability in HBMEC line up to 24h of incubation for all compounds 
(Supplementary Fig. S1).  
We used the well-validated confluent HBMEC two chamber BBB model32 to investigate 
endothelium transport with metabolite quantification by Orbitrap LC-MS techniques. 
(Poly)phenol metabolites were added in the upper chamber and their putative transport 
through the BBB endothelium assessed after 2h of incubation (Fig. 1a).  
Different concentrations of each compound were detected in the upper and lower 
chambers, suggesting a differential transport of the metabolites (Fig. 1b). For gallic acid 
(GA) derivatives, the combination of both methylation and sulfation, 4-O-methylgallic 
acid-3-O-sulfate (4-MeGA-sulf), increased BBB permeation compared with 4-
methylgallic acid (4-MeGA). Intriguingly, 4-methylcatechol O-sulfate (4-MeCat-sulf) was 
more effectively transported than catechol-O-sulfate (Cat-sulf) (Fig. 1b). Moreover, in 
the case of pyrogallol-O-sulfate (Pyr-sulf), the position of the methylation influenced 
BBB passage; 1-O-methylpyrogallol-O-sulfate (1-MePyr-sulf) was less effectively 
transported whereas 2-O-methylpyrogallol-1-O-sulfate (2-MePyr-sulf) isomer was 
transported as effectively as Pyr-sulf. Additionally, Pyr-sulf consists in a mixture of 
isomers (Pyr-1-sulf and Pyr-2-sulf) (Table 1, see note 2) and we detected only Pyr-2-
sulf in the basolateral compartment of cells.  
No statistically significant difference was observed in the transport percentage when 5 





Table 1. Human bioavailable (poly)phenol metabolites. (Poly)phenol metabolites nomenclature, 
abbreviation, chemical structure and Cmax are presented. 
 
Nomenclature Abbreviation Structure  Cmax (M)1 
Catechol-O-sulfate Cat-sulf 
 
12.2  5.9 
Pyrogallol-O-sulfate2 Pyr-sulf 
       
11.4  6.7 





      
 




















    
0.64 ± 0.5 
4-O-methylgallic acid 4-MeGA 
 
0.30 ± 0.1 
1 Cmax values were determined by evaluation of human plasma samples in a previous work 22.  
2 mixture of two compounds in approximately similar proportion, 53% of Pyrogallol-2-O-sulfate (Pyr-2-sulf) and 47% of 
Pyrogallol-1-O-sulfate (Pyr-1-sulf), and for each of them Cmax was obtained since they are chromatographically 
distinguishable. 
3 mixture of two compounds in approximately similar proportion, 56% of 1-O-methyl pyrogallol-2-O-sulfate (1-MePyr-2-
sulf) and 44% of 1-O-methyl pyrogallol-3-O-sulfate (1-MePyr-3-sulf), chromatographically indistinguishable.  











Fig. 1 Blood-brain barrier transport of human bioavailable (poly)phenol metabolites. (a) Schematic 
experimental design used to assess (poly)phenol metabolites transport across the BBB. (b) Endothelial 
transport of human bioavailable polyphenol metabolites after 2h of incubation. Endothelial transport was 
evaluated by LC-Orbitrap MS and is presented as percentage (%) determined by the ratio of the lower 
compartment concentration and the sum of the upper and lower compartments concentrations. Statistical 
differences for p<0.01 are denoted from a-f. (c-e) Immunofluorescence detection of major efflux 
transporters in HBMEC line: (c) P-gp, in green, (d) MRP1, in red and (e) BCRP, in green. Nuclei stained 
with DAPI (blue). Scale bar: 40 µm. (f-h) HBMEC intracellular accumulation of specific efflux transporters’ 
substrates in the presence of the respective inhibitors: (f) 1µM of verapamil (P-gp inhibitor), (g) 1µM MK-
571 (MRP1 inhibitor) or (h) 1µM of Ko 143 (BCRP inhibitor). Statistical differences are denoted as 
***p<0.001, **p<0.01 and *p<0.05 relatively to control cells. Endothelial transport of (i) Cat-sulf and (j) Pyr-
sulf when co-incubated with efflux transporters inhibitors. Statistical differences in the presence of inhibitors 
are denoted as *p<0.05 relatively to “No inhibitor”. (k) P-gp substrate accumulation for Cat-sulf and Pyr-sulf 
compared with verapamil. Intracellular accumulation of P-gp substrate, Rhodamine 123 was evaluated after 
pre-incubation of cells with the bioavailable (poly)phenol metabolites. Statistical differences are denoted as 
***p<0.001 relatively to control. (l) Endothelial transport of Cat-sulf (solid line) and Pyr-sulf (dashed line) 
along time. Statistical differences along time are denoted as ***p<0.001, relatively to 2h of incubation in 
Cat-sulf, or ### p<0.001, relatively to 2h of incubation in Pyr-sulf. All values are means ± SD, n=3. 
 
 
In silico modeling of metabolite properties 
Accessibility to the brain may be dependent to some extent on the structural properties 
of metabolites. An in silico prediction of blood-brain barrier permeability of the various 
metabolites was carried out using the QikProp software was carried out. QikProp 
predicts the ability of specific molecules to cross the BBB (Table 2). Estimated QikProp 
descriptors were within the range of values for 95% of known drugs (according to 
a
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Schrödinger software, https://www.schrodinger.com/qikprop) and did not vary much 
between the different compounds, which is reasonable considering their structural 
similarity. None of the compounds tested were predicted to have CNS activity only 
assuming passive BBB diffusion (CNS activity: -2).  
For the octanol/water partition coefficient predictor (QPlogPo/w), the (poly)phenol 
metabolites were at the lower range of the recommended values, that indicates poor 
passive diffusion. Interestingly, the metabolites with a methyl group on (4-MeCat-1-sulf, 
4-MeCat-2-sulf, 2-MePyr-sulf, 1-MePyr-2-sulf, 1-MePyr-3-sulf) gave the highest values 
(Table 2). Moreover, 4-MeCat-sulf and Cat-sulf gave the lowest PSA values (Table 2), 
which were below the recommended threshold of 90 Å2, which also suggests that 
passive BBB permeation is more likely33. 
Another important descriptor that predicts the brain/blood partition is the QPlogBB. The 
calculated values for our molecules, although within the recommended values for brain 
drugs, were not high. Additionally, the predicted apparent MDCK cell permeability was 
very low for all compounds. The more charged compounds, such as 4-MeGA-sulf and 
VA-sulf have the lowest values (Table 2).  
 
Table 2. In silico calculations of BBB permeation for human bioavailable (poly)phenol metabolites. QikProp 
descriptors were obtained for each metabolite, namely dipole, volume, donor HB, accptHB, QPlogPo/w, 
QPPCaco, QPlogBB, QPPMDCK, PSA, QPlogKhsa.  
 
 
donorHB – number of donor hydrogen bonds; accptHB – number of acceptor hydrogen bonds; QPlogPo/w – predicted 
octanol/water partition coefficient (for 95% of known drugs values range between -2.0 and 6.5); QPPCaco – predicted 
apparent Caco-2 cell permeability (non-active gut-blood barrier transport; <25 poor, >500 great); QPlogBB – predicted 
brain/blood partition coefficient (for 95% of known drugs values range between -3.0 and 1.2); QPPMDCK – predicted 
apparent MDCK  (Madin-Darby Canine Kidney Epithelial Cells- consider a good model to mimic the BBB) cell permeability 
(non-active blood-brain barrier transport; <25 poor, >500 great); PSA – Van der Waals surface area of polar nitrogen and 
oxygen atoms and carbonyl carbon atoms (for 95% of known drugs values range between 7.0 and 200.0); QPlogKhsa – 








An important feature that could influence compounds ability to be actively transported 
through the BBB is their ability to establish hydrogen bonds with other functional groups. 
The carboxylic acids (VA-sulf, and 4-MeGA-sulf) have relatively high cumulative values 
as hydrogen exchangers (e.g. donorHB + accptHB). Moreover, the other carboxylic 
acid, 4-MeGA had highest value of QPlogKhsa, i.e. it is more likely to bind to human 
serum albumin. Overall, QikProp analysis suggested that none of the metabolites would 
be able to cross the BBB endothelium by passive permeation but some form of active 
transport could be involved.  
 
HBMEC contains functionally active efflux transporters 
Other factors could limit the levels of metabolites inside the brain besides transport 
mechanisms, such as efflux systems. To our knowledge, HBMEC cells have not yet 
been characterized for the expression or activity of major efflux transporters. By 
immunofluorescence, we detected the presence of the three major membrane ATP-
binding cassette protein (ABC)-type efflux transporters in HBMEC cells (Fig. 1c-e), 
previously described to be present in brain endothelial cells and known for their broad 
substrate specificity; P-glycoprotein (P-gp, ABCB1), multidrug resistance-associated 
protein 1 (MRP1, ABCC1) and breast cancer resistance protein (BCRP, ABCG2)34. 
Functional activities of P-gp, MRP1 and BCRP were validated using substrate 
accumulation assays (Fig. 1f-h) and specific inhibitors for each transporter. Verapamil 
was used as a P-gp inhibitor and 1µM was sufficient to reduce its detoxifying capacity 
assessed by the intracellular accumulation of its substrate, Rhodamine 123 (Fig. 1f). 
We also confirmed the functional detoxifying activity of MRP1 (Fig. 1g) and BCRP (Fig. 
1h), by using Calcein-AM and BODIPY-FL, respectively, as specific substrates, and MK-
571 and Ko143 as the respective inhibitors.  
 
Bioavailable (poly)phenol metabolites are not exported to the upper side and 
their transport increases with time  
We also assessed how these efflux transporters could influence the permeation of 
(poly)phenol metabolites, in particular the most plasma-bioavailable metabolites Cat-
sulf and Pyr-sulf22, into the lower compartment of the BBB in vitro model (Fig. 1a). 
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Inhibition of the efflux transporters did not influence the BBB transport of Cat-sulf (Fig. 
1i) and Pyr-sulf (Fig. 1j). However, BCRP may be partly involved in the efflux of Cat-
sulf as there was a significant increase (p<0.05) in its endothelial transport after 
treatment with BCRP specific inhibitor, Ko 143 (Fig. 1i).  
To determine if the metabolites could affect cellular efflux capacity, we evaluated the 
functional activity of the most well-studied efflux transporter in humans, P-gp35. Under 
the same conditions that Verapamil doubled Rhodamine 123 accumulation, no 
statistically- significant alterations in P-gp activity were noted in the presence of Cat-sulf 
and Pyr-sulf at 5 M (Fig. 1k). The same trend was observed for the other bioavailable 
(poly)phenol metabolites (Supplementary Fig. S3). Transport of Cat-sulf and Pyr-sulf 
in the in vitro BBB model increased over 2, 6 and 24h. Although, there was a significant 
increase in transport percentage of both Cat-sulf and Pyr-sulf with time (Fig. 1l), even 
after 24h incubation, no transport of the less physiologically-representative isomer of 
Pyr-sulf (Pyr-1-sulf) was detected. 
 
HBMEC metabolize bioavailable (poly)phenol metabolites 
One phenomenon that may influence endothelium transport percentage for (poly)phenol 
metabolites across BBB is their metabolism within the cells. To identify possible cellular 
metabolites,  the LC-MS data for the upper and lower compartments was searched 
against an in-house database of predicted metabolites22 for compounds  of predicted 
theoretical masses and fragmentation patterns and new putative cellular metabolites 
were detected. These included those arising from cellular conjugation with glucuronic 
acid or glutathione (Supplementary Table S1; results for the remaining metabolites are 
presented in Supplementary Tables S2-4).  
The proposed cellular pathways of Cat-sulf and Pyr-sulf metabolism were designed 
based on canonical enzymatic reactions described in KEGG (Kyoto Encyclopedia of 
Genes and Genomes, Fig. 2a). Moreover, the relative abundance of the novel 
metabolites (Fig. 2b-j) detected in upper or lower compartments, was assessed, which 
indicated that each metabolite had a different pattern with time. Interestingly, we 






glutathionyl-pyrogallol, Fig. 2b) were detected in higher amounts than the ones more 
distant (e.g. acetylcysteine-pyrogallol, Fig. 2c).  
 
 
Fig. 2 Blood-brain barrier endothelial cells metabolization of Pyr-sulf and Cat-sulf. (a) Putative pathways 
and enzymes that could be involved in endothelial metabolization into novel phenolic compounds. Proposed 
metabolization route of the compounds was designed based on canonical enzymatic reactions described 
in KEGG (Kyoto Encyclopedia of Genes and Genomes). ARS -Arylsulfatase; GST - Glutathione S-
transferase; GGT - Gamma glutamyl transferase; AP - Aminopeptidase; Cys-NAT – Cysteine N-acetyl 
transferase; COMT - Catechol O-methyl transferase; UDPG – UDP-Glucuronosyl transferase. Relative 
quantification (peak areas) of the novel phenolic metabolites appearing in upper (grey) and lower (black) 
compartments along time after addition of (b-f) Pyr-sulf or (g-j) Cat-sulf in upper compartment, namely (b) 
Glutathionyl-pyrogallol, (c) Acetylcysteine-pyrogallol, (d) 2-O-methylcatechol-O-sulfate, (e) Glutathionyl-
catechol and (f) Acetylcysteine-2-O-methylcatechol, (g) 2-O-methylcatechol, (h) Catechol-1-O-β-D-
glucoronic acid, (i) Glutathionyl-2-O-methylcatechol, and (j) Acetylcysteine-2-O-methylcatechol.  Note: the 
compound Acetylcysteine-2-O-methylcatechol was detected in both samples (panels’ f and j). 
 
Bioavailable (poly)phenol metabolites protect brain endothelial cells and 
neuronal cells  
Three different cell systems were selected to assess the breadth of neuroprotective 
potential of metabolites on neuronal excitotoxicity and oxidative stress, common 
hallmarks in neurodegenerative disorders36;  a cell line representative/model of the BBB, 
primary cultures of mouse cerebellar granule cells, and human 3D aggregates of both 
neurons and astrocytes. The preventive effects of Cat-sulf and Pyr-sulf were assessed 
after pre-incubation at physiologically-relevant concentrations and prior to administering 
the specific insult. 
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As one of the first lines of defense, endothelial cells of the BBB prevent damage to the 
brain from constant insults37. The HBMEC line treated with 300 µM of hydrogen 
peroxide for 24h was used as a model of brain endothelial injury. Pre-incubation of Cat-
sulf and Pyr-sulf prior to injury improved cell viability, with Pyr-sulf being more effective 
than Cat-sulf (Fig. 3a), maintaining cell viability at untreated cells levels. The other less 
abundant human bioavailable metabolites also caused significant cytoprotective effects 
to different extents (Supplementary Fig. S4).  
Cat-sulf and Pyr-sulf were also assessed in a classic model of excitotoxicity38, in which 
primary cultures of mouse cerebellar granule cells were challenged with glutamate. Both 
Cat-sulf and Pyr-sulf improved cell viability of cerebellar granular cells under glutamate-
induced excitotoxicity (Fig. 3b), again with Pyr-sulf being more effective.  
Pre-incubation of Cat-sulf and Pyr-sulf also caused significant neuroprotection in 3D 
aggregates against tert-butyl hydroperoxide (t-BHP)-induced injury (Fig. 3c). Both 
sulfates were equally protective and gave the same level of protection as conferred by 
idebenone39, a drug used for of Alzheimer’s disease  known  to boost mitochondrial ATP 
production40. Indeed, the other bioavailable metabolites also caused significant 
neuroprotective effects under the same conditions (Supplementary Fig. S4).  
In all 3 cell systems, Pyr-sulf appeared to be more effective than Cat-sulf; therefore we 
decided to explore its mechanisms in greater depth using the 3D aggregates, a more 
physiologically-relevant system, and we compared it against the positive control 
idebenone41. Levels of βIII-tubulin and glial fibrillary acidic protein (GFAP) were studied 
as markers of neurons and astrocytes, respectively (Fig. 3d-f). The 3D aggregates 
challenged with t-BHP showed a significant decrease in βIII-tubulin protein levels but 
not GFAP protein levels, an effect counteracted by idebenone, which increased β-III 
tubulin protein levels. Pyr-sulf pre-incubation was ineffective in altering t-BHP induced 
changes in βIII-tubulin levels (Fig. 3d-f). Therefore, this suggests that t-BHP treatment 
has a greater impact on neuronal cells and this effect could not prevented by Pyr-sulf 
pre-treatment.  Indeed, this cell-specific effect was hidden in the overall neuroprotective 







Fig. 3 Cytoprotective potential of Cat-sulf and Pyr-sulf.  (a) HBMEC line submitted to oxidative stress 
(300µM H2O2); (b) primary mouse cerebellar granule cells exposed to glutamate excitotoxicity (100µM 
glutamate); (c) 3D aggregates containing neurons and astrocytes exposed to oxidative injury (300µM t-
BHP). Cells were pre-incubated with 5µM of each bioavailable polyphenol metabolite for 24h and then 
injured with the respective lesion. Cell viability was assessed and is presented as percentage relatively to 
control. Statistical differences are denoted as ***p<0.001, **p<0.01 and *p<0.05 relatively to control and as 
###p<0.001, ##p<0.01 and #<0.05 relatively to each lesion (H2O2, glutamate or t-BHP). (d-f) Alterations in 
protein markers of the neuronal (β-III tubulin) and astrocytic (GFAP) population of 3D aggregates. (d) 
Representative western blot and (e) β-III tubulin and (f) GFAP fold changes in protein levels normalized to 
GAPDH. Statistical differences are denoted as ***p<0.001, **p<0.01 and *p<0.05 relatively to control and 
as ###p<0.001 relatively to t-BHP. Western blots were analyzed under the same experimental conditions. 
Data are presented as the means ± SD, n=3. 
 
After 24h of pre-incubation with Pyr-sulf before the t-BHP insult, expression of SOD1, 
GPX1 and GSR, important antioxidant enzymes, were not significantly different from 
control, suggesting that the cells may already have returned to basal levels 
(Supplementary Fig. S5). Interestingly, t-BHP treatment alone significantly increased 
SOD1 expression. We also did not see effects on the complex subunits from the 
mitochondrial respiratory chain that could be associated with Pyr-sulf protection 
(Supplementary Fig. S5). Finally we looked for key determinants in apoptosis. Pyr-sulf 
pre-incubation was not able to counteract the increased expression of the apoptosis 
regulator BAX gene. However it slightly increased the levels of the anti-apoptotic BCL-




Bioavailable (poly)phenol metabolites reduce neuro-inflammation 
Neurodegenerative processes are also closely associated with neuro-inflammatory 
responses which are mainly mediated by the resident brain immune cells, microglia. 
Microglia pro-inflammatory activation was achieved by stimulation with 
lipopolysaccharide (LPS)42 and the effect of pre-incubation with metabolites prior to LPS 
insult  was studied (Fig. 4 and Supplementary Fig. S6).  We measured several 
parameters related to inflammatory responses such as reactive oxygen and nitrogen 
species (ROS/RNS), TNF-α inflammatory cytokine and CD40 expression. We found that 
pre-incubation with Pyr-sulf significantly inhibited TNF-α release (~2 fold) upon LPS 
stimulation (Fig. 4a) but no other markers of activation were affected by Pyr-sulf (Fig. 
4b, 4c, and 4d). These results suggest that Pyr-sulf specifically affects TNF production. 
Nevertheless, some of the other less abundant bioavailable (poly)phenol metabolites 
also gave positive effects for the four pro-inflammatory markers, suggesting that each 
compound may have different potential (Supplementary Fig. S6).  
 
Figure 4 Effects on neuroinflammation by Cat-sulf and Pyr-sulf. Pro-inflammatory markers were evaluated, 
namely (a) TNF-α release, (b) nitric oxide, (c) intracellular superoxide production, and (d) CD40 quantified 
in N9 microglial cells. Cells were pre-incubated for 6h with each of the bioavailable (poly)phenol metabolites 
and then challenged with 300ng/mL of LPS. Statistical differences are denoted as ***p<0.001, **p<0.01 and 
*p<0.05 relatively to lesion (LPS). (e) Microglial NF-κB p65 translocation into the nucleus after 60 minutes 






(red); Nuclei (blue) stained with DAPI. Each capture is representative of at least 3 independent biological 
replicates. Scale bar: 10 µm. (f-i) Microglial NF-κB p65 phosphorylation ratio and IκBα fold change in protein 
levels. (f)  IkBα protein levels along time after LPS stimulation. and (g) IkBα fold change in protein levels 
after 60 min of LPS stimulation and representative western blots. (h) NF-κB activation profile along time 
after LPS stimulation looking at NF-κB p65 phosphorylation (ser536) ratio and (i) NF-κB p65 
phosphorylation ratio Cells were pre-treated either with Pyr-sulf or Cat-sulf before LPS stimulation. Control 
cells (white triangles, solid line), LPS-stimulated cells (black triangles, solid line), cells treated with Cat-sulf 
prior to LPS stimulation (black circles, dashed line), cells treated with Pyr-sulf prior to LPS stimulation (black 
squares, dotted line). Statistical differences are denoted as *p<0.05 and **p<0.01 relatively to lesion (LPS). 
Western blots were analyzed under the same experimental conditions. Data are presented as the 
means ± SD, n=3. 
 
Pyr-sulf prevents NF-κB nuclear translocation and alters IκBα levels 
TNF-α levels are mainly  regulated by the NF-κB pathway43. To investigate the 
mechanisms underlying the inhibitory effect of Pyr-sulf on TNF production, we analyzed 
NF-κB activation. We followed NF-κB translocation to the nucleus and its 
phosphorylation levels on ser536. In addition, we analyzed the kinetics of IκBα 
degradation, which inhibits NF-κB translocation to the nucleus43.  
After one hour, LPS induced a clear nuclear translocation of NF-κB to the nucleus of N9 
cells (Fig. 4e). However, pre-incubation with Pyr-sulf but not Cat-sulf prevented LPS-
stimulated NF-κB translocation to the nucleus in microglia. Similar results were obtained 
with primary cultures of rat microglia (Supplementary Fig. S7). N9 cells treated with 
LPS showed, as expected, a significant decrease in IκBα levels after 15 min when 
compared to non-treated cells (Fig. 4f). Pre-incubation with Pyr-sulf did not prevent IκBα 
reduction at 15 min, but it boosted the recovery of IκBα levels after 30-60 min of LPS 
treatment (Fig. 4f and 4g). Interestingly, Pyr-sulf alone enhanced IκBα basal levels, 
even without an inflammatory stimulus (Fig. 4g and Supplementary Fig. S8). The NF-
κB phosphorylated-p65/total p65 ratio peaked at 15 min (Fig. 4h) and then decreased 
to basal cellular levels at 60 min (Fig. 4h and 4i). This kinetics was unchanged by pre-
treating either with Pyr-sulf or Cat-sulf (Supplementary Fig. S8). Overall, our data 






Dietary (poly)phenols present neuroprotective potential but their selective permeability 
across BBB, poor absorption, rapid metabolism and systemic elimination limit their 
bioavailability and could limit their protective efficacy21, 27.  
Taking advantage of a robust, though simplified, in vitro model of the human BBB which 
has been validated for CNS drugs32, 44, 45, we confirmed that plasma-bioavailable 
(poly)phenol metabolites could be transported across the BBB endothelium. The 
differences in endothelial transport for the metabolites could be related with their degree 
of chemical modification: methylation combined with sulfation enhanced the transport of 
gallic acid and catechol derivatives, but the same was not true for pyrogallol derivatives. 
In fact, Youdim and colleagues noted that transmembrane diffusion of some 
(poly)phenol metabolites in vitro was related to their lipophilicity, where less polar (e.g. 
methylated) derivatives achieved greater uptake than more polar derivatives (e.g. 
sulfates and glucuronides)28, 29. Nevertheless, it is not clear whether the primary route 
by which (poly)phenols metabolites cross the BBB is by simple diffusion or by carrier-
mediated transport.   
Our data for BBB endothelial transport can be partially explained by the in silico 
predictions. For instance, 4-MeCat-sulf, the metabolite with the higher endothelial 
transport percentage, also presented the higher QPlogPo/w. Moreover, for this 
metabolite and for Cat-sulf, the lowest PSA values were reported, below the 
recommended threshold of 90 Å2 to be considered suitable for passive BBB 
permeation33. It is important to highlight that the descriptors calculated by the in silico 
analysis have to be regarded as whole and are integrated only assuming passive BBB 
diffusion. However, the contribution of active transport and metabolic transformation 
should not be discounted. In fact, the chemical ability of some metabolites to establish 
hydrogen bonds (indicated by some descriptors) with other functional groups of 
biomolecules (e.g. amine and hydroxyl groups of proteins like albumin) could suggest a 
propensity for an active transport mechanism in BBB. Nevertheless, such descriptors 
do not necessarily imply that the studied molecules are inactive in the brain, as there 
are other ways to transport molecules across the BBB, as it is seen for very polar 






medicines and other drugs. Overall our experimental results, together with the in silico 
predictions, suggest that transport across BBB could not be simply justified by passive 
permeation and some form of active transport must also be involved.  
Interestingly, HBMEC cells seemed to favor the transport of one isomer of Pyr-sulf, Pyr-
2-Sulf, which was also the main form found in human plasma22, 30. Even after an 
extended incubation period (24 h), no transport of the other isomer, Pyr-1-sulf was 
detected, suggesting selective transport. This may be due to the enhanced hydrogen 
bonding ability of the vicinal diol structure in Pyr-2-sulf compared to Pyr-1-sulf which 
could influence protein binding46. Existence of an isomer-selective transport in 
endothelial cells of BBB has already been reported for (+)-catechin and (-)-epicatechin47, 
although this is a stereoisomer rather than a positional isomer. Our results suggest that 
HBMEC may favor the uptake of the more bioavailable metabolite of a mixture in equal 
proportions. 
The presence of efflux transporters was confirmed for the first time in HBMEC cells and 
these ABC-type transporters may contribute to overall BBB transport of the (poly)phenol 
metabolites. There was a slight but significant increase in Cat-sulf transport in the 
presence of a BCRP inhibitor, which suggests that this efflux transporter can limit Cat-
sulf transport. In fact, other studies have also highlighted the involvement of BCRP in 
limiting (poly)phenol access to the brain. For instance, quercetin, when co-administrated 
with a P-gp or BCRP inhibitor, entered BBB epithelia but was then specifically exported 
by the BCRP28. Such phenomenon may partly explain why quercetin presents very 
limited bioavailability, despite its plasma bioavailability.  
As well as acting as substrates for these efflux pumps, (poly)phenol metabolites can 
modulate the activity of ABC transporters, putatively influencing brain bioavailability of 
other compounds (reviewed in 48). However, our results for P-gp activity suggest that 
none of the metabolites activated or inhibited this efflux pump. Therefore we propose 
that differential transport observed across the BBB endothelium cannot be a 
consequence of a differential efflux of the (poly)phenol metabolites. It should be noted 
that the BBB is a complex interface composed not only by endothelial cells but also by 
astrocytes and perycites23, 31, and these cell types may also influence BBB transport of 
(poly)phenol metabolites in vivo.  
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Taking advantage of the power of the MS analysis, we observed that HBMEC 
metabolized the phenolic sulfates into novel metabolites, mainly glutathione and 
glucuronic acid derivatives. Indeed, capillary endothelial cells are known to possess the 
enzymes required for these conversions, such as glutathione S-transferase, UDP-
glucuronosyltransferase49, gamma glutamyl transpeptidase and catechol-O-
methyltransferase49. Enzymes known primarily for hepatic drug metabolism have also 
been shown to exist in the brain, albeit at relatively low specific activities50 in particular 
at the blood-brain interfaces where they influence cerebral availability of toxic 
compounds49, 51. An in vitro study to assess (+)-catechin and (-)-epicatechin permeability 
across the BBB detected new glucuronide derivatives using the human brain capillary 
endothelial cell line hCMEC/D347. Similarly, Liang and co-workers52 performed a 
comprehensive LC-MS study on (+)-catechin metabolism product distribution in rat 
tissues and reported 3-O-Me-catechin-5-O-glucoronide was present in the brain tissue. 
Our studies also provided evidence for the interconversion of some metabolites into new 
metabolites. For example, acetylcysteine-2-O-methylcatechol, was detected in both 
Cat-sulf and Pyr-sulf samples, although in different relative amounts. Also, novel 
metabolites were detected in samples from gallic acid derivatives and from VA-sulf. The 
extensive metabolism of these simple phenolic sulfates by HBMEC reinforces the 
importance of studying the metabolites of (poly)phenols and not their parent 
compounds. We speculate that further interconversions may occur to, for example, 
valeric acid and hydroxyphenyl-propanol derivatives 52 and the physiological relevance 
of these new metabolites is unknown. Moreover, other cell types resident in the BBB 
besides endothelial cells, may also contribute to the generation of different new 
(poly)phenol variants. Further studies with more complex BBB in vitro models (e.g. co-
cultures of brain endothelial cells with astrocytes) will better elucidate potentially novel 
brain-targeted (poly)phenol metabolites. On the other hand, by contributing also for the 
synaptic function, astrocytes role in (poly)phenol metabolites supply to neurons in a 
neuronal in vivo context must be further contemplated.  
The (poly)phenol metabolites caused a cytoprotective effect in the BBB cells challenged 
with hydrogen peroxide. Pyr-sulf, the most abundant metabolite detected in circulation22, 






hydrogen peroxide. BBB endothelial protection by resveratrol has been described37 but, 
to our knowledge, this is the first time that protection has been demonstrated using 
physiological concentrations of bioavailable (poly)phenol metabolites.  
Neuroprotective effects of dietary (poly)phenols in primary neuronal cultures and in a 
3D model containing neurons and astrocytes was also observed. In glutamate 
excitotoxicity conditions, pathologically relevant for neurodegenerative disorders, 
neurons are damaged by the excessive stimulation of nerve receptors through this 
neurotransmitter accumulation in the synaptic cleft53. Pyr-sulf caused significant 
neuroprotection in primary mouse cerebellar granule cells exposed to toxic glutamate 
concentrations. A similar protection was recently noted for pterostilbene, a resveratrol 
analog, described to be brain bioavailable, which attenuated glutamate-induced 
oxidative stress injury in murine hippocampal neuronal HT22 cells at physiological 
circulating levels54. 
The 3D aggregates are a very robust system, with different functional cell types 
(neurons and astrocytes), interlinked and communicating, in a three-dimensional 
architecture, which is more directly related with in vivo environment of brain cells41, 55. 
The neuroprotection by human bioavailable (poly)phenol metabolites in these neuron-
astrocyte models reinforces the pharmacological importance of these metabolites. 
Exposure to t-BHP induced greater damage to neurons than astrocytes within the 3D 
aggregates but Pyr-sulf did not recover the levels of the neuronal marker, βIII-tubulin 
and also did not affect GFAP protein levels (the astrocyte marker).  Neurons have been 
described to have a greater susceptibility to oxidative injury as compared to astrocytes56. 
In fact, our 3D aggregates are mainly composed of astrocytes (~77% of the cells)41. 
Glial cells (astrocytes and microglia) are responsible for the repair process of the brain 
after injury57, being stronger and less susceptible to damage than neurons. Protection 
by Pyr-sulf in this system could then be related with the improving functionality of 
astrocytic population inside aggregates and not directly reducing the deleterious effects 
of the oxidative injury. However, there is still a lack of studies demonstrating the effect 
of phenolic metabolites on these cells. It have already been described that resveratrol 
can ameliorate glutamatergic metabolism and transmission and thus synaptic plasticity 
and neuroprotection58-60. The missing link between (poly)phenol metabolites effects and 
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neuroglial communication/signaling is therefore of upmost importance to be addressed 
for an effective translation of how diet can alter age-related neurological diseases, like 
Alzheimer’s disease. 
Inflammation and neurodegeneration are normally associated in neurological 
conditions. Here, we found that, Pyr-sulf, besides its neuroprotective effect, also 
attenuated TNF-α release in microglia challenged with LPS. TNF-α, a classic and 
reliable marker of microglia activation, is known to be regulated by NF-κB. Dietary 
phenolics, such as quercetin, curcumin and resveratrol, have been shown to inhibit 
signaling pathways involved in microglia cells activation61, namely NF- B. However, the 
effect of their metabolites has not yet been assessed probably due to their poor 
bioavailability. To our knowledge, this is the first study where dietary (poly)phenol 
metabolites have been shown to modulate NF-κB-mediated microglia activation. Our 
results show that Pyr-sulf, at physiological concentrations, is able to modulate IκBα 
protein levels, either by promoting its synthesis or by decreasing its degradation, which 
retains NF-κB in the cytoplasm and prevents NF-κB-dependent gene transcription. 
Indeed, this could explain the reduction in TNF-α levels in LPS-stimulated microglia pre-
incubated with Pyr-sulf. 
 
Taken together, these data provide new insights for the (poly)phenol metabolites to be 
further explored in biochemical pathways and validated in vivo using appropriate animal 
models. Although (poly)phenol metabolites could impact on brain health and cognition 
indirectly through peripheral and cerebrovascular blood flow improvement, this work 
highlights their potential to have direct effects towards neuronal cells. The phenolic 
sulfate metabolites studied are transported across endothelial cells of the BBB and 
metabolized to form new chemical entities with their own potential biological effects. 
While we cannot predict the biological role/relevance of these biotransformations, the 
fact that BBB cells modify (poly)phenols metabolites is of vital importance for further 
studies. These biotransformation processes by HBMEC may facilitate metabolite 
elimination from brain or, on the other hand, such modifications may enhance retention 
or assist further uptake and delivery to other neuronal cell types, therefore spreading 






and is a crucial preventive factor of neurological diseases, ensuring BBB endothelium 
protection through diet could have wide-spread consequences in the body. The 
neuroprotective potential of these phenolic sulfates, used at physiologically relevant 
concentrations, comparable to those detected in human plasma22, reflects their 
importance as modulators of cell metabolism and the ultimate importance of dietary 
habits to health and disease progression. Moreover, our studies on the abundant serum-
bioavailable metabolite, Pyr-sulf, emphasized the potential pleiotropic neuroprotective 
effects of these phenolic metabolites. The marked reduction in TNF-α release may be 
associated with the neuroprotective power of Pyr-sulf: the capacity of Pyr-sulf to pre-
condition cells, preventing NF-κB nuclear translocation and being able to better respond 
to oxidative stimuli, an excitotoxicity burst or an inflammatory situation, confirms the 
potential of these human bioavailable (poly)phenol metabolites to mitigate in the intricate 
complexity of a neurodegenerative disorder.  
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Material and Methods 
 
Reagents 
All the used chemicals were purchased from Sigma-Aldrich, unless stated otherwise. 
Acetonitrile (ACN, LC-MS grade) was purchased from Fisher Scientific Ltd. 
(Leicestershire, UK). LC-MS grade water was produced by an Elix/MilliQ purification 
system (Millipore, Waterford, UK). 4-Methylgallic acid and 2-methylpyrogallol were 
obtained from Apin chemicals and taxifolin was obtained from Extrasynthese. The 
synthesized compounds were: 4-methylgallic acid-3-O-sulfate (4-MeGA-sulf, 57% yield, 
79% purity, containing 6% of 4-methylgallic acid and 13% of 4-methylgallic acid-3,5-O-
disulfate), 4-methylcatechol-O-sulfate (4-MeCat-sulf, 66% yield, mixture of two 
compounds indistinguishable, pure), vanillic acid-4-O-sulfate (VA-sulf, quantitative yield, 
pure), catechol-O-sulfate (Cat-sulf, 66% yield, pure), pyrogallol-O-sulfate (Pyr-sulf, 75% 
yield, mixture of two compounds in equal proportions), 1-methylpyrogallol-O-sulfate (1-
MePyr-sulf, mixture of two compounds in equal proportions, 58% yield) and 2-
methylpyrogallol-O-sulfate (2-MePyr-sulf, 44% yield, 89% purity, containing 11% of 2-
methylpyrogallol-O-disulfate). Synthesized compounds were obtained as sodium salts 
and were firstly dissolved in DMSO (Fluka) before dilution to final concentration in 
specific cell media (see Table 1). 
 
Cell culture conditions 
 HBMEC line 
Human brain microvascular endothelial cell (HBMEC) line was used as a simplified and 
validated in vitro model of the BBB32, 44, 45, 62. This cell line was derived from primary 
cultures of HBMEC transfected with SV40 large T antigen63. HBMEC line was cultured 
in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS 
- Biochrom AG), 10% NuSerum IV (BD Biosciences), 1% non-essential amino acids 
(NEAA - Biochrom AG), 1% minimal essential medium (MEM) vitamins (Biochrom AG), 
1mM sodium pyruvate (Biochrom AG), 2mM L-glutamine (Biochrom AG), and 1% 






studies, cells were seeded at a density of 8×104 cell/mL in 24-well and 96-well plates, 
respectively, and treated after 48h in culture. For integrity and transport studies, cells 
were seeded on polyester transwell inserts (0.4 μm, Corning Costar Corp., USA) at a 
density of 8×104 cell/insert and treated after 8 days in culture. Inserts and plates were 
coated with rat-tail collagen-I (BD Biosciences, Erembodegem, Belgium) before 
seeding. All experiments were performed after monolayer formation.  
 
 Mouse cerebellar granular cells 
Primary cultures of cerebellar granule cells were prepared according to the already 
described method38. Cells were isolated from cerebella of 7d-old BALB-C mice and 0.5 
x 106 cell/mL were cultured in Neurobasal Medium (Gibco) supplemented with 2% B-27 
without antioxidants (Gibco) and 2% KCl (20mM, Sigma-Aldrich), containing 0.25% L-
glutamine (200 mM, Sigma-Aldrich) and 0.48% penicillin-streptomycin (P/S, 5000 U mL-
1, Gibco). Experiments were performed on 24-well plates with coverslips coated with 50 
µg/mL poly-D-lysine (Sigma-Aldrich). 20 µM of cytosine arabinoside (Sigma-Aldrich) 
was added 48 h after inoculation to prevent glia cell proliferation. All the experiments 
were performed between days 7-11 in culture.  
 
 N9 murine microglial cell line 
The N9 murine microglial cell line was kindly provided by Dr. Teresa Faria Pais. Cells 
were cultured in EMEM (Eagle Minimum Essential Media, Sigma-Aldrich) supplemented 
with 10% FBS (Gibco), 200 mM L-glutamine (Sigma-Aldrich), 1% NEAA (Sigma-Aldrich) 
and maintained at 37°C, 5% CO2. Cells were detached by agitation before suspension 
of the culture media with a pipette (no cellular detaching agent was used).  
 
 NT2 cell line 
NTera-2/cl.D1 (NT2) cells, obtained from American Type Cell Culture Collection 
(ATCC), were differentiated in stirred suspension culture systems, as 3D aggregates, 
as previously described41. A single cell suspension of undifferentiated NT2 cells was 
seeded in DMEM (Dulbeco Minimum Essential Media), 10% FBS, 1% P/S (all from 
Invitrogen), in a 125 mL spinner vessel equipped with ball impeller (Wheaton). After 
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three days of aggregation, differentiation was induced by addition of 10 µM retinoic acid 
(Sigma-Aldrich), for three weeks, with a 50% medium exchange performed every 2-3 
days. Following this period (from day 24 onwards), the medium was composed by 
DMEM, 5% FBS, 1% P/S. Stable 3D co-cultures of neurons and astrocytes were 
maintained up to day 50 of culture and applied in neuroprotection assays (from day 38 
to day 50). 
 
Immunofluorescence 
Both HBMEC and N9 cells were grown in 24-well plates with coated coverslips and 
immunostaining performed as already described62, 64. Briefly, HBMEC coverslips were 
incubated overnight at 4°C with primary antibodies anti-P-gp (1:50, Calbiochem), anti-
MRP1 (1:100, Millipore) and anti-BCRP (1:100, Millipore) and N9 cells coverslips were 
incubated overnight at 4°C with rabbit polyclonal anti-NF-κB p65 (C-20) (1:200, Santa 
Cruz Biotechnology). Incubation with secondary antibodies Alexa 594 anti-rabbit IgG 
(1:500) and Alexa 488 anti-mouse IgG (1:500) (Invitrogen) lasted for 2h at room 
temperature. Nuclei were counterstained with DAPI. Between incubations cells were 
washed three times with PBS. HBMEC staining was examined using a Leica DFC 490 
camera (Leica, Germany) adapted to an AxioScope.A1 microscope (Zeiss, Germany), 
ZEN 2012 blue edition software by Carl Zeiss Microscopy GmbH, 2011. Confocal 
fluorescent Z-series N9 cells were acquired using on a Leica SP5 live upright confocal 
(Leica, Wetzlar), using a 63x 1.3NA oil immersion objective, the UV lamp and DPSS 
561nm yellow-green laser. Post-acquiring treatment was performed using ImageJ 
software (NIH, USA). 
 
Efflux transporters functional assays 
Activity of each efflux transporter was determined by measuring cellular accumulation 
of respective substrate65, 66, and results were expressed as fold-change as compared to 
the respective control. Activity of P-gp, MRP1 and BCRP were determined by measuring 
the cellular accumulation of the substrates Rhodamine 123 (Sigma-Aldrich), Calcein-
AM (Santa Cruz Biotechnology), and BODIPY-FL Prazosin (Life Technologies), 






Ringer–Hepes solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 5.5 
mM D-glucose, 20 mM Hepes, pH 7.4) containing 10 mM of each substrate, separately. 
The solution was quickly removed, HBMEC were washed three times with PBS and 
solubilized in 0.1 M NaOH. Substrate content was determined using a FLUOstar Omega 
fluorescent plate reader (BMG Labtechnologies, Ortenberg, Germany; for P-gp, 
excitation at 505 nm, emission at 534 nm; for MRP1, excitation at 495 nm, emission at 
516 nm; for BCRP excitation at 503 nm, emission at 512 nm). A reference efflux 
transporter inhibitor was used as positive control: P-gp inhibitor, Verapamil (1µM, 
Sigma-Aldrich); MRP1 inhibitor, MK-571 (1 µM, Santa Cruz Biotechnology); and BCRP 
inhibitor, Ko 143 (1 µM, Santa Cruz Biotechnology). Protein content was evaluated by 
the Bradford method 67 using Bio-Rad’s Protein Assay reagent (Bio-Rad).  
 
BBB integrity  
Trans-endothelial electrical resistance (TEER) 
TEER was evaluated as reported previously62. Briefly, TEER readings were performed 
using an End Ohm™ chamber coupled to an EVOMX resistance meter (World Precision 
Instruments, Inc., USA). Readings were collected before the addition of bioavailable 
(poly)phenol metabolites and at the end of the incubation time. TEER was calculated as 




To evaluate selective paracellular permeability of the HBMEC monolayer after exposure 
to the bioavailable (poly)phenol metabolites, a permeability assay was conducted with 
sodium fluorescein (molecular weight: 376 Da). The permeability was determined as 
described before62. The endothelial permeability coefficient Pe was calculated as 
described68 as a percentage of variation from control. In all the assays, monolayer 
integrity was monitored by TEER and sodium-fluorescein paracellular permeability, 
which confirmed that the passage of metabolites across BBB cells was not due to a 





HBMEC were plated in semi-permeable membranes (inserts) placed in cell culture 
wells. This two-chamber system, where the upper and lower chambers mimic the blood 
and brain compartments, respectively, and the confluent HBMEC monolayer represents 
the BBB. Transport assays were conducted in HBSS (Hank's Balanced Salt Solution) 
with calcium and magnesium (Gibco), supplemented with 0.1% FBS. Confluent 
monolayers of the HBMEC were incubated with 5 μM of each compound for 2h, time 
described for compounds to interact and/or being transported across cells26, 69. In order 
to evaluate a time-dependent transport, 5 μM of Cat-sulf and Pyr-sulf were added to the 
upper site and samples from upper and lower site were collected after 2, 6 and 24h. To 
evaluate efflux transporters influence in the BBB transport of the bioavailable 
(poly)phenol metabolites, co-incubation of 5 μM of Cat-sulf and Pyr-sulf with inhibitors 
of P-gp, (1 μM Verapamil), of MRP1 (1 μM MK-147) and of BCRP (1 μM Ko 143) was 
also performed. Monolayer integrity was ensured in all experiments as described. In the 
end, cell medium from upper and lower compartments were collected and frozen at -80 
°C until analysis. Transport analysis were performed after sample deproteinization by 
LC-Orbitrap MS as described below. 
 
 Sample deproteinization 
To 1 mL of upper or lower compartment cell medium it was added: 139 µL of 50% formic 
acid, ascorbic acid (final concentration of 1 mM) and taxifolin as internal standard (final 
concentration of 9 µM). To precipitate proteins, 2.5 mL of ACN was added dropwise and 
samples were vortexed before centrifugation at 3200 g for 15 min. The supernatant was 
removed and dried under centrifugal evaporation (CentriVap Vaccum Concentrator, 
Labconco). Samples were dissolved in 5% ACN in 0.1% formic acid and immediately 
analyzed by LC-Orbitrap MS. 
 
 LC-Orbitrap MS 
Samples were separated on an HPLC Accela 600 HPLC system (Thermo Scientific, 
Bremen, Germany) using a C18 Synergi Hydro RP18 column (Phenomenex, 






fitted with a Security GuardTM guard system containing an Aqua 10 μm C18 Guard 
Cartridge (2mm ID×4 mm; Phenomenex) and eluted over a gradient of 98% solvent A 
(0.1% formic acid in ultra-pure water) to reach 5% B (0.1% formic acid in ACN) at 5 min, 
35% B at 25min, increase to 100% B at 26 min, 100% B at 29 min, and back to 2% B at 
30 min at a flow rate of 0.2 mL/min. Analysis was done on an LTQ OrbitrapTM XL hybrid 
mass spectrometer (Thermo Scientific, Bremen, Germany). 
 
MS analysis was performed using data-dependent Nth order double play analysis 
comprising full scan mass range 80–2000 amu, 30 000 resolution, data-type centroid 
and data dependent MS/MS (60 s of exclusion duration) on the top three most intense 
ions detected above threshold automatically in the independent scan event. ESI settings 
were as follows: source voltage, 3.4 kV; capillary temperature was 275°C with a sheath 
gas at 40 psi and auxiliary gas at 5 psi. MS data handling software (Xcalibur 
QualBrowser software, Thermo Electron Corp.) was used to search for predicted 
metabolites by their appropriate m/z value. All peaks were checked for m/z value and 
fragmentation products. Calibration curves, ranging from 0.3125 to 10µM, were 
constructed from all the metabolites, and each concentration point was injected in 
triplicate. Standard curves were all linear within the concentration range and linearity 
was ensured as R2 0·997–1·000. Limit of quantification was determined by analysis in 
triplicate of standards at low concentrations, and was defined as signal: noise ratios of 
1:10. Endothelial transport was calculated as percentage determined by the ratio of 
lower compartment concentration and the sum of upper and lower compartments 
concentrations.  
 
Search for novel compounds resulting from HBMEC metabolization was performed in 
the same samples using Xcalibur QualBrowser software using an in-house database of 
putative bioavailable (poly)phenol metabolites30. Putative ID of predicted metabolites 




In silico prediction of pharmacokinetic properties 
Maestro software (Schrödinger, Release 2015-4, LLC, New York, 2014) was used to 
create a three-dimensional computer models of studied compounds. The global 
minimum geometry was used as an input for the QikProp application (Schrödinger 
Release 2015-4, LLC, New York, 2014) to estimate various theoretical descriptors 
relevant for compound permeability through the BBB70. From QikProp pharmaceutically-
relevant properties, the following parameters were retained for evaluation: octanol/water 
partition coefficient; predicted brain/blood partition coefficient; apparent Caco-2 or 
MDCK cell permeability; predicted CNS activity; Van der Waals surface area of polar 
nitrogen and oxygen atoms and carbonyl carbon atoms (PSA); prediction of binding to 
human serum albumin.  
 
Protective potential of human bioavailable (poly)phenol metabolites 
 Cytoprotection in HBMEC 
HBMEC were incubated in the presence of H2O2 (Sigma-Aldrich). Briefly, 24 h after 
seeding, cells growth medium was removed and cells were pre-incubated for 24h with 
5 µM of each compound. After pre-incubation, media was replaced by new media 
containing 300 µM H2O2, for 24 h71, 72. In the end, medium was removed and cell viability 
was assessed using the CellTiter-Blue® Cell Viability Assay (Promega), according to the 
manufacturer’s instructions. 
 
Neuroprotection in cerebellar granule cells 
Physiological concentrations (5 µM) of the two most abundant metabolites were added 
to the cells at 7d in culture. Cells were then incubated for 24 h and morphology was 
evaluated. At day 8 in culture, 100 µM of glutamate (Sigma-Aldrich) was added to the 
respective wells. Cells were incubated for another 24 h, morphology was evaluated and 
viability determined by fluorescence microscopy through Propidium Iodide (PI) and 
Hoechst 33342 staining, as previously described38. 
 






Aggregates were collected between days 38 and 50, distributed in 12- or 96-well plates 
and cultured in DMEM, 5% FBS, 1% P/S. Human bioavailable (poly)phenol metabolites 
(5 µM) were added to the cultures and 24 h after tert-buthyl hydroperoxide (t-BHP; 
Sigma-Aldrich) oxidative lesion was induced, for a cell viability reduction of 
approximately 50%, in 48 h41. Cell viability was accessed before exposure to test 
compounds, before t-BHP lesion induction and 48 h after lesion induction by 
PrestoBlue® Cell Viability Reagent (Thermo Fisher Scientific), accordingly to 
manufacturer’s instructions. Idebenone (provided by Grupo Tecnimede) was used as 
positive control. Final cell viability was calculated as a percentage of cell viability before 
lesion induction. 
 
Attenuation of neuroinflammation 
N9 microglial cells were plated into 6-well plates (5 x 105 cells mL-1) and then pre-
incubated with 5 µM of each (poly)phenol metabolite. After 6 h, medium was discarded 
and cells were washed once with phosphate buffer saline (PBS) prior to addition of fresh 
medium with 300 ng/mL lipopolysaccharide from Escherichia coli 055:B5 (LPS, Sigma–
Aldrich). Pro-inflammatory mediators release to medium were quantified as described: 
 NO release 
The NO release to media was quantified according to73 by Griess Reagent 
(Sigma–Aldrich) according to manufacturer’s instructions.  
 TNF-α quantification by ELISA 
Cell supernatants were harvested after 24 h and stored at -80 °C until analysis. 
Murine TNF-α release was assayed by sandwich ELISA according to the manufacturer’s 
instructions (PeproTech®; Princeton Business Park, Rocky Hill NJ, United States)74. All 
the reagents and plates used were provided in the kit. The plate was incubated at room 
temperature in a Synergy HT microplate reader (Biotek®, Winooski, USA) for 35 min, 
with 5-min intervals Abs405 readings.  
  CD40 and superoxide (O2•-) quantification by flow cytometry 
Culture media was discarded and PBS was added to detach N9 adherent cells, 
which were then incubated with mouse anti-FcγR (same as CD-16/32, from E-
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Biosciences) in FACS buffer (PBS containing 2% FBS and 0.01% NaN3) for 30 minutes 
at 4 °C before staining. Cells were spun down at 1000 g, washed once with FACS buffer 
and stained with 5 µg/mL mouse anti-CD40 - FITC (clone 3/23, from BD Biosciences®); 
and with 5 µg/mL DHE probe (Dihydroethidium, Invitrogen™, Carlsbad, CA, USA) as 
superoxide indicator75. Events were acquired using CUBE 6 cytometer, from Partec®. 




NT2 aggregates and N9 protein samples western blot analysis was performed41. 
Aggregates were lysed with TX-100 lysis buffer (50 mM Tris, 5 mM EDTA, 150 mM 
NaCl, 1% Triton X-100, pH 7.4) and N9 protein extraction was performed with RIPA 
buffer. Primary antibodies were incubated overnight at RT, followed by secondary 
antibodies (horseradish peroxidase-conjugated, ECL anti-mouse IgG, anti-rat IgG or 
anti-rabbit IgG; Pierce, Millipore and GE Healthcare), incubated for 2h at room 
temperature. Anti-GAPDH antibody (Thermo Scientific) was used as loading control. 
Primary antibodies used for protein detection were: anti-βIII-Tubulin (Millipore), anti-
GFAP (DAKO), and MitoProfile Total OXPHOS WB primary antibody cocktail (Abcam), 
anti-phospho-NF-κB p65 (ser536) antibody (Cell Signalling), anti-NF-κB p65 (C-20) 
(Santa Cruz Biotechnology), and anti-IκB-α (C-21) antibody (Santa Cruz 
Biotechnology). Membranes were developed using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare) and visualized using a ChemiDocTM XRS+ 
System (BioRad). 
 
Real-time quantitative PCR 
Real-time quantitative PCR analysis (qRT-PCR) was performed as described in76. 
Briefly, total RNA was extracted with High Pure RNA Isolation kit (Roche) and reverse 
transcription performed with Transcriptor High Fidelity cDNA Synthesis kit (Roche). 
qRT-PCR analysis was performed in a LightCycler 480 Multiwell Plate 96 (Roche), using 
the Light-Cycler 480 SYBR Green I Master Kit (Roche). cDNA was diluted 1:2 and each 






presented in Supplementary Table S5. Cycles threshold (Ct’s) and melting curves 
were determined using LightCycler 480 software, version 1.5 (Roche) and results were 
processed using the 2−ΔΔCt method for relative gene expression analysis76, 77. Changes 
in gene expression were normalized using the house-keeping gene RPL22 (coding for 
ribosomal protein L22) as internal control. 
 
Statistical analysis 
The results reported in this work are the averages of at least three independent 
experiments and are represented as the means ± SD. Differences amongst treatments 
were detected by analysis of variance with the Tukey HSD (honest significant difference) 
multiple comparison test (a = 0.05) using SigmaStat 3.10 (Systat) software. 
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Supplementary Figure S1. Toxicity of human bioavailable (poly)phenol metabolites in HBMEC line. Cells 
were pre-incubated with 5µM of each bioavailable polyphenol metabolite for 24h. Cell viability was 






Supplementary Figure S2. Blood-brain barrier transport of human bioavailable (poly)phenol metabolites. 
2h of incubation. Endothelial transport was evaluated by LC-Orbitrap MS and is presented as percentage 





















































Supplementary Figure S3. P-glycoprotein substrate accumulation for (poly)phenol metabolites tested. 
Intracellular accumulation of P-gp substrate, Rhodamine 123 was evaluated by fluorescence after pre-
incubation of cells with each of the bioavailable (poly)phenol metabolites compared with P-gp inhibitor, 
verapamil. Results are presented normalized for protein content. All values are means ± SD, n=3. 
 
 
Supplementary Figure S4. Cytoprotective potential of human bioavailable (poly)phenol metabolites in 
different cell systems: (a) HBMEC line submitted to oxidative stress (300µM H2O2); (b) 3D aggregates 
exposed to oxidative injury (300µM t-BHP). Cells were pre-incubated with 5µM of each bioavailable 
polyphenol metabolite for 24h and then injured with the respective insult. Cell viability was assessed and is 


























































































































and * p<0.05 relatively to control and as ###p<0.001, ##p<0.01 and #<0.05 relatively to each insult (H2O2 










Supplementary Figure S5. Alterations in oxidative stress, mitochondrial complexes and apoptosis in 3D 
aggregates. (a) Levels of gene expression of SOD1, GPX1 and GSR, or (c) BAX and BCL-2 in control 3D 
aggregates (white), 3D aggregates injured with t-BHP (black), 3D aggregates pre-incubated with 200nM 
Idebenone (Ide) and injured with t-BHP (light grey) and 3D aggregates pre-incubated with 5µM Pyr-sulf and 
injured with t-BHP (dark grey). Changes in gene expression were normalized using the housekeeping gene 
RPL22 (coding for ribosomal protein L22) as internal control. (b) Protein levels of mitochondrial subunits of 
the respiratory chain in 3D aggregates: representative western blot and corresponding fold changes in 
protein levels normalized to GAPDH. Statistical differences are denoted as **p<0.01 and *p<0.05 relatively 
to control and as #p<0.05 relatively to t-BHP. All values are mean (fold change relative to control) ± SD of 
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Supplementary Figure S6. Human bioavailable polyphenol metabolites effects on neuroinflammation. Pro-
inflammatory markers were evaluated, namely (a) nitric oxide, detected by Griess reaction, (b) TNF-α 
release, detected by quantitative ELISA, intracellular superoxide production (c) and CD40 (d) quantified by 
flow cytometry in N9 murine microglial cells. Cells were pre-incubated for 6h with each of the bioavailable 
(poly)phenol metabolites and then challenged with 300ng/mL of LPS. Statistical differences are denoted as 













































































































































































Supplementary Figure S7. Microglial NF-κB p65 translocation into the nucleus after 60 minutes of LPS 
stimulation. Immunofluorescence microscopy images of primary cultures of rat microglia*: (a) control cells, 
(b) microglia stimulated with LPS only, and (c) microglia pre-treated with Cat-sulf or (d) Pyr-sulf for 6 h 
before LPS-stimulation. NF-κB (red); Nuclei (cyan) stained with DAPI. Scale bar: 30 µm.  
 
* Establishment of rat primary cell cultures of microglia 
Briefly, new born Wistar rats were dissected and the heads removed. Cortices were placed into petri dishes and 
meninges removed. Brains were mechanically disrupted and the suspension centrifuged. Cells were cultured in high-
glucose DMEM with Glutamax and supplemented with 10% FBS, 5 μg/mL insulin, 2.0 mg/mL L-glucose and 1% 
Pen/Strep for 14–21 days. Granulocyte-macrophage colony-stimulating factor was added at the beginning of the culture 
and subsequently every 3 days at a final concentration of 0.25 ng/mL. At day 14, confluent mixed glial cell cultures were 
shaken for 2 h at 200 rpm. Microglial cells were obtained from the supernatant after filtering through 100-μm cell strainers. 
Cells were re-suspended in DMEM M2279 with Glutamax supplemented with 10% FBS, 50 μM β-mercaptoethanol and 
1% Pen/Strep. Cells were plated in 24 well plates for 1 h. Adherent cells were washed twice with PBS to remove cell 
































Supplementary Figure S8. Microglial NF-κB p65 phosphorylation ratio and IκBα protein levels for cells 
treated only with Cat-sulf and Pyr-sulf. (a) IkBα protein levels along time.  (b) NF-κB activation profile along 
time looking at NF-κB p65 phosphorylation (ser536) ratio. Cells were pre-treated either with Pyr-sulf (white 
squares, dotted line) or Cat-sulf (white circles, dashed line). All values are means ± SD, n=3. (c) 







































































Supplementary Table S1. Putative new cellular metabolites arising from human bioavailable (poly)phenol 
metabolites in HBMEC, namely from Pyr-sulf and Cat-sulf. Using in-house database of predicted human 
bioavailable (poly)phenol metabolites and taking advantage of Orbitrap-MS data collected, search for novel 
metabolites was performed using Xcalibur QualBrowser software. Putative ID of predicted metabolites was 
determined by exact mass, according to their appropriate m/z value in both upper and lower compartment 










































































































Supplementary Table S2. Putative new cellular metabolites arising from human bioavailable (poly)phenol 
metabolites in HBMEC, namely from VA-sulf. Using in-house database of predicted human bioavailable 
(poly)phenol metabolites and taking advantage of Orbitrap-MS data collected, search for novel metabolites 
was performed using Xcalibur QualBrowser software. Putative ID of predicted metabolites was determined 
by exact mass, according to their appropriate m/z value in both upper and lower compartments samples for 









m/z Apical Basolateral 
VA-sulf Vanillic acid 
 










473,1104 472,4 + + 
 
 
Supplementary Table S3. Putative new cellular metabolites arising from human bioavailable (poly)phenol 
metabolites in HBMEC, namely from 4-MeGA and 4-MeGA-sulf. Using in-house database of predicted 
human bioavailable (poly)phenol metabolites and taking advantage of Orbitrap-MS data collected, search 
for novel metabolites was performed using Xcalibur QualBrowser software. Putative ID of predicted 
metabolites was determined by exact mass, according to their appropriate m/z value in both upper and 



























278,0096 277,2 + + 
4-MeGA-sulf Galloylglycine 
 






















Supplementary Table S4. Putative new cellular metabolites arising from human bioavailable (poly)phenol 
metabolites in HBMEC, namely from 4-MeCat-sulf, 1-MePyr-sulf and 2-MePyr-sulf. Using in-house 
database of predicted human bioavailable (poly)phenol metabolites and taking advantage of Orbitrap-MS 
data collected, search for novel metabolites was performed using Xcalibur QualBrowser software. Putative 
ID of predicted metabolites was determined by exact mass, according to their appropriate m/z value in both 






























Supplementary Table S5. List of primers used in qRT-PCR analysis. 
 
Gene Cell type/Function 
Primers forward (top) 
and reverse (bottom) 
RPL22 




SOD1 Superoxide dismutase 1 
AGGCCCCTTAACTCATCT 
CTACAGGTACTTTAAAGCAACTCT 
GPX1 Glutathione peroxidase 1 
TTTGGGCATCAGGAGAACGC 
AGCATGAAGTTGGGCTCGAA 
GSR Glutathione reductase 
CGTGGAGGTGCTGAAGTTCTC 
TCATGGTCATGACTGGTAGCC 
BCL-2 B-cell lymphoma 2 
ATCGCCCTGTGGATGACTGAG 
CAGCCAGGAGAAATCAAACAGAGG 
BAX BCL-2 associated X protein 
TGGAGCTGCAGAGGATGATTG 
GAAGTTGCCGTCAGAAAACATG  









Bioavailable polyphenol metabolites are 










This chapter is based on the following manuscript: 
Circulating (poly)phenol metabolites: neuroprotection in a 3D cell model of 
Parkinson’s disease 






















This chapter contains data in which the author of this dissertation executed the majority 
of the experiments. Supplementary Fig S1b and supplementary Fig S2a and S2c were 
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Parkinson’s disease (PD) is one of most common age-related neurodegenerative 
disorders, still without cure. The prevention and treatment of neurodegeneration, 
characterized by a multifactorial phenotype, require novel therapeutic strategies. 
Epidemiological and clinical studies have proven that diets rich in (poly)phenols are able 
to reduce the incidence and prevalence of such disorders, exhibiting remarkable 
multipotent ability to modulate several pathways. Thus, (poly)phenols, proven to act as 
pleiotropic agents, can constitute a promising alternative to prevent PD onset and 
progression. Our goal was to investigate the potential protective effects against PD of 
bioavailable metabolites derived from dietary (poly)phenols, identified in an human 
intervention study.  A 3D human brain cell model was generated by differentiation of 
Lund human mesencephalic neural progenitor cells (LUHMES) in an agitation-based 
culture system. Differentiated neurospheroids, enriched in dopaminergic neurons and 
presenting synaptic activity were obtained. (Poly)phenol metabolites differentially 
modulated central signaling pathways, such as Nrf2 and p53, in LUHMES 
neurospheroids. The neuroprotective effect of these bioavailable (poly)phenol 
metabolites was confirmed in a PD cell model, based in 1-methyl-4-phenylpyridinium 
(MPP+) lesion over LUHMES neurospheroids. These (poly)phenol metabolites were 
proven to act through hormesis mechanism and to modulate key genes involved in 
apoptosis and Nrf2 signaling, emerging as potential new candidates to prevent PD 






The increase in life expectancy of the developed countries has led to a higher incidence 
of chronic disorders like neurodegenerative disorders. Parkinson’s disease (PD) is the 
second most common neurodegenerative disorder and the first motor debilitating 
degenerative disease1, 2. PD is a chronic, incurable disorder, which affects 1–3% of the 
elderly population worldwide and the great majority of PD cases are sporadic with no 
apparent genetic association 3. Changes found in the brain of PD patients comprise the 
loss of dopaminergic neurons in the substantia nigra pars compacta and the presence 
of protein aggregates containing α-synuclein4. PD symptoms result from a decrease in 
dopamine levels which might be caused by a disturbance of dopamine exchange system 
functioning (synthesis, transport, synaptic release, and reception). Proteins associated 
with dopamine synthesis and retention include tyrosine hydroxylase (TH), dopamine 
transporter (DAT), monoamine vesicular transporter (VMAT2), and aromatic amino acid 
decarboxylase (AADC)5. Among several factors, the regulation of TH activity and  gene 
transcription play a large role in PD pathogenesis5.  
Dopaminergic neurons in PD display defects in mitochondrial function, increased 
oxidative stress and neuroinflammation6. Through the past years, it has been shown 
that oxidative stress is central to the pathology of this disease7. Moreover, the substantia 
nigra of PD patients shows increased levels of oxidized lipids, proteins and DNA, 
together with a decrease in reduced glutathione (GSH) levels8. In PD, a main source of 
free radicals stems from alterations in complex I of the mitochondrial respiratory chain, 
which compromises proper mitochondrial functioning and ATP production9. Increased 
neuroinflammation in PD is also a consequence of increased reactive oxygen species 
(ROS) and leads to microglia secretion of cytokines, causing the activation of the 
transcription factor NF-B10. Such activation enhances the sensitivity of dopaminergic 
neurons to oxidative stress and ultimate cell death.  
Development of PD may also be linked with the toxic action of environmental factors. 
As such, enzymes involved in detoxification systems, both from phase I (i.e. proteins of 
the cytochrome P450 superfamily), or phase II [i.e. glutathione-S-transferases (GSTT1, 
GSTM1, GSTP1) and N-acetyl transferase (NAT2)] metabolism, can play an important 
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role in the pathogenesis of the disease5.  As such, the multi-factorial nature of PD 
contributes to the process of nigral cell death, of which mitochondrial dysfunction and 
increased production of ROS are the most important mechanisms. The multiple primary 
causes of PD may be ultimately linked to a final common signal-transduction pathway 
leading to programmed cell death of the dopaminergic neurons11. 
The prevention and treatment of PD, characterized by a mechanistic complexity, need 
novel therapeutic strategies targeted to multiple genes and proteins. In fact, PD usually 
starts long before its manifestations appear. By taking advantage of diets that may be 
able to prevent disease onset and/or progression is important 12. Nowadays, attention 
is being given to (poly)phenols as strong attenuators of oxidative stress and 
inflammation, key processes in PD progression, presenting fewer side effects than most 
drugs available. (Poly)phenols exhibit a remarkable multipotent ability to modulate, for 
instance, oxidative stress, metal toxicity, inflammation and immune response, 
apoptosis, signal transduction, ion channels, among others (reviewed in 13). Studies 
have showed that dietary (poly)phenols are able to reduce the incidence and prevalence 
of neurodegenerative disorders, with significant benefits for brain health14-16. Moreover, 
there is growing evidence of the potential against different cellular and molecular 
mechanisms of PD of (poly)phenols. For instance, (poly)phenols like resveratrol17, 18, 
epigallocatechin gallate19, 20, quercetin 21 and apigenin22 have shown to be able to 
modulate PD associated progressive dopaminergic degeneration, mitochondrial 
dysfunction, apoptosis, protein aggregation and neuroinflammation. However, the 
mechanism of action of (poly)phenol metabolites, simpler compounds which result from 
human metabolism over dietary (poly)phenols, in PD is still only marginally addressed23, 
24. Such circulating metabolites can present a promising strategy for disease prevention 
with potential to be explored. Simple phenolic sulfates, colonic-derived metabolites of 
dietary (poly)phenols were identified in biological samples of human volunteers which 
took a berries mixture25, 26, cranberries27, mango28 or black tea29 . Such sulfates, when 
tested in circulating concentrations, were shown to be significantly transported across a 
simplified in vitro model of the blood-brain barrier (BBB)30, holding great promise as 





neuroprotective and anti-neuroinflammatory potential against common 
neurodegeneration hallmarks in vitro30. 
The purpose of this study was to investigate potential protective effects of selected 
human bioavailable metabolites derived from the degradation of dietary 
(poly)phenols26.A 3D human brain cell model generated from LUHMES human neuronal 
precursor cells was used. LUHMES were differentiated into neurospheroids containing 
post-mitotic neurons with enrichment in dopaminergic neurons31-33 in agitation-based 
culture system. For induction of a PD-like phenotype, LUHMES neurospheroids were 
treated with the dopaminergic neurotoxicant 1-methyl-4-phenylpyridinium (MPP+), an 
inhibitor of complex I of the mitochondrial respiratory chain with high affinity to the 
dopamine transporter of dopaminergic neurons, leading to incomplete oxygen reduction 
and generation of ROS, with depletion of overall ATP levels32. The 3D cell model of PD 
was employed to assess the effects of physiological concentrations (poly)phenol 
metabolites. (Poly)phenol metabolites were not toxic to neurospheroids and were 
neuroprotective towards the dopaminergic lesion applied. Moreover, these metabolites 
were able to modulate genes related with central canonical pathways involved in stress 
response. Major modulated genes, such as ATF4 and BCL2, seem to be involved in the 
neuroprotection observed, with relevance towards the molecular hallmarks of PD. To 
our knowledge, this is the first study assessing the potential of circulating (poly)phenol 





Circulating (poly)phenol metabolites are neuroprotective towards MPP+ 
Simple phenolic sulfates, colonic-derived metabolites of dietary (poly)phenols which 
were identified in blood and urine samples of a human intervention study25, 26, were 
shown to be significantly transported across a simplified in vitro model of the BBB, being 
neuroprotective against different neurodegeneration hallmarks30. As such, these 
phenolic sulfates may comprise a great promise as possible brain-targeted compounds 
but never assessed in a specific brain pathology. To evaluate their potential, we 
employed a PD cell model of MPP+-induced lesion in a 3D human cell system. 
Differentiated LUHMES neurospheroids were obtain and presented to be enriched in 
post-mitotic neurons (Supplementary Fig. S1), as indicated by the increased mRNA 
and protein levels of major neuronal (e.g. III-tubulin, synaptophysin) and dopaminergic 
(e.g. TH, DAT) markers, with concomitant decrease in early neuroepithelial progenitors 
markers (e.g. Nestin). These neurospheroids were also enriched dopaminergic neurons, 
as confirmed by the presence of TH-positive neurons (Supplementary Fig. S2). MPP+ 
lesion reduced cell viability in a dose-dependent manner, with an IC50 of 5M. A 
downregulation in the dopaminergic TH gene expression was observed along lesion 
time, with no significant alterations in III-tubulin and DAT gene expression 
(Supplementary Fig. S3). Interestingly, protein levels of both III-tubulin and TH did 
not significantly decrease with MPP+ lesion (Supplementary Fig. S3).  
 
LUHMES neurospheroids were incubated for 24h with physiologic-circulating 
concentrations (5M) of two human phenolic sulfates: catechol-sulfate (Cat-sulf) and 
pyrogallol-sulfate (Pyr-sulf)25, 26, 30 (Fig. 1a) and assessed in parallel with Idebenone 
(Ide), a known antioxidant drug which is a short-chain analogue of coenzyme Q1034, 35. 
Ide treatment lead to a reduction in oxidative stress markers and was shown to protect 
against ROS-induced damage in several in vitro cultures, as primary cortical neurons 





of impaired mitochondrial complex I35, such as the conditions caused by MPP+ lesion  in 
our system. 
 
Fig. 1. Toxicity and neuroprotective potential of (poly)phenol metabolites against MPP+ lesion in LUHMES 
neurospheroids. (a) Chemical structure representation of catechol-O-sulfate (Cat-sulf) and pyrogallol-O-
sulfate (Pyr-sulf, a mixture of two isomers). Toxicity of dietary (poly)phenol metabolites (Cat-sulf, Pyr-sulf) 
and Idebenone (Ide) in LUHMES neurospheroids after 24h of incubation in terms of (b) cell viability and (c) 
ATP levels. Neuroprotection evidenced in terms of (d) cell viability or (e) ATP fold change. LUHMES 
neurospheroids were pre-incubated with different dietary (poly)phenol metabolites (5M Cat-sulf, 5M Pyr-
sulf) or with 200nM Ide for 24h and then treated or not with 5μM of MPP+. Cell viability was assessed by 
Presto blue assay after 24h of injury. ATP fold change was assessed by CellTiter Glo Assay after 48h of 
injury and is expressed relatively to control condition (without MPP+). Statistical differences are denoted as 
**p<0.01 and *p<0.05 relative to control and denoted as ###p<0.001 and ##p<0.01 relative to MPP+ insult 
obtained by one-way ANOVA analysis with Tukey’s post multiple comparison test. Data are mean ± SEM 
of three independent cultures. 
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By opposition to Ide, both Cat-sulf and Pyr-sulf presented a slight toxicity in LUHMES 
neurospheroids in terms of cell viability, reducing it to just about 85% (Fig. 1b). 
Moreover, Cat-sulf also induced a small but significant decrease in ATP production (Fig. 
1c). Despite these effects, Cat-sulf and Pyr-sulf were shown to be protective over an 
MPP+ lesion, although in different extents.  Only the pre-incubation with Ide or Cat-sulf 
was able to maintain cell viability higher than in MPP+ lesion and at the same extent 
(Fig. 1d). Moreover, both metabolites pre-incubation, Cat-sulf and Pyr-sulf, and Ide pre-
incubation as well were capable to increase ATP intracellular levels (Fig. 1e).  
 
Circulating (poly)phenol metabolites modulate central signaling pathways  
The effects of both Cat-sulf and Pyr-sulf at the circulating concentrations in LUHMES 
neurospheroids (Fig. 1b and 1c) suggest that they can be promoting a pre-conditioning 
hormetic effect: low doses of these phenolic sulfates can be triggering a cellular 
response that help them to cope later with the MPP+ lesion (as observed, Fig. 1d and 
1e). To evaluate the mechanism and signaling pathways underlying this protective 
response, a custom PCR array was performed to evaluate key players in the top signal 
transduction pathways. Of the total 93 target genes assessed (Table S2), 66 were 
amplified. Both Cat-sulf and Pyr-sulf treatment induced changes in gene transcription, 
with fold changes ranging from -4.63 to 13.7, for Cat-sulf, and ranging from -3.12 to 
7.08, for Pyr-sulf comparatively to untreated (control) neurospheroids.  
Taking advantage of functional enrichment analysis of Ingenuity Pathway Analysis (IPA) 
software, major Canonical Pathways and Upstream Regulators were identified as 
significantly modulated by Cat-sulf and Pyr-sulf in LUHMES neurospheroids (Fig. 2-4). 
Enrichment analysis delivered the significant over-represented pathways across the list 
of differentially expressed genes (Fig. 2a). In this analysis, nuclear factor erythroid 2-
related factor 2 (Nrf2)-mediated Oxidative Stress Response was identified as the top 
canonical pathway, with the highest -log(p-value) and high z-score, and comprising 
mainly upregulated target genes under Nrf2 regulation: the Antioxidant Responsive 
Elements (ARE). Nrf-2 signaling pathway was predicted to be more activated (higher 
activation z-score) by Pyr-sulf than by Cat-sulf (Fig. 2a and 2b). Genes such as RAF1 





disassembly, as well as genes under ARE promoter such as chaperones and stress 
response proteins (HERPUD1, HSP90AA, HSP90B1), phase I and II metabolizing 
enzymes (NQO1, GCLC, GCLM), and antioxidant proteins (SQSTM1, ATF4, SOD, 
HMOX1, GSR, TXNRD1, FTH1) were significantly modulated in the presence of Cat-
sulf and Pyr-sulf (Fig. 2b). 
 
Peroxisome Proliferator-Activated Receptors (PPAR) signaling was the canonical 
pathway predicted to be more inhibited (lowest activation z-score) by both Cat-sulf and 
Pyr-sulf (Fig. 2a). PPAR act as ligand-activated transcription factors leading to the 
transcription of target genes involved in the catabolism of fatty acids 36. 
A stronger effect of Pyr-sulf towards NF-B signaling canonical pathway was also 
observed in LUHMES neurospheroids (Fig. 2a), as well as in JAK/STAT signaling (Fig. 
2a and 2c). In fact, Cat-sulf and Pyr-sulf presented opposite effects in this canonical 
pathway: Cat-sulf seems to lead to the inhibition of JAK/STAT cascade, while Pyr-sulf 
leads to a slight activation of this pathway (Fig. 2a and 2c). For instance, Cat-sulf leads 
to a strong down-regulation of AKT1 and BCL2L1 genes, with the up-regulation of 
SOCS3 gene (a JAK2 kinase inhibitor), while Pyr-sulf leads to an up-regulation of genes 
coding for STAT complex, leading to an overall predicted activation of the pathway (Fig. 
2c).  
By opposition, Cat-sulf lead to a higher activation of p53 signaling canonical pathway 
than Pyr-sulf (Fig. 2a). In fact, TP53 emerged as a strong upstream regulator predicted 
to be activated by Cat-sulf (Fig. 3a) and also, in a lesser extent, by Pyr-sulf (Fig. 3b). 
Downstream of TP53 genes like ATF4, BAX, BCL2L1 or GSR presented to be 





Fig. 2. Circulating (poly)phenol metabolites effects in canonical pathways in LUHMES neurospheroids. (a) 
Heat map of the canonical pathways significantly modulated by (poly)phenol metabolites in neurospheroids 
obtained with Ingenuity® Pathway Analysis (IPA). Pathways are ordered by activation z-score (predicted 
activation, higher z-score – orange; predicted inhibition, lower z-score – blue). (b)Nrf2-mediated oxidative 
stress response pathway obtained with IPA from the analysis of dataset modulated by Cat-sulf and by Pyr-
sulf. (c) JAK/STAT signalling pathway obtained with IPA from the analysis of dataset modulated by Cat-sulf 
and by Pyr-sulf. Genes whose expression was significantly modulated by Cat-sulf are surrounded in black 
and modulated by Pyr-sulf are surrounded in grey, together with other genes involved in the cascade (but 
not significantly modulated, not colored). Up-regulated genes are presented in red, down-regulated genes 







Fig. 3. Circulating (poly)phenol metabolites effects in upstream regulators in LUHMES neurospheroids. 
Identification of TP53 as an upstream regulator of transcriptional regulation by (a) Cat-sulf and by (b) Pyr-
sulf. Identification of ATF4 as an upstream regulator of transcriptional regulation by (c) Cat-sulf and by (d) 
Pyr-sulf. Bioinformatic analysis with IPA software predicted the activation of both TP53 and ATF4 (orange) 
as a regulators of genes that are upregulated (depicted in red) and downregulated (depicted in green). 
Regulator effects of ATF4 towards cellular functions for (e) Cat-sulf and (f) Pyr-sulf. Bioinformatic analysis 
with IPA software predicted the activation of ATF4 (orange) as a regulator of genes that are upregulated 
(depicted in red) and downregulated (depicted in green). Arrows represent predicted relationships: orange 
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– leads to activation; blue – leads to inhibition; yellow – findings inconsistent with state of downstream 
molecule; grey – effect not predicted. 
 
Another upstream regulator identified in both datasets was the transcription factor ATF4 
(Fig. 3c and 3d). Regulator Effects tool of IPA software integrated results from Upstream 
Regulator and Downstream Effects tools, creating hypotheses to explain the 
mechanisms triggered both by Cat-sulf (Fig. 3e) and Pyr-sulf (Fig. 3f). For Cat-sulf, the 
predicted activation of ATF4 lead to the upregulation of genes involved in heat shock 
response (HERPUD1, HSPA5), in endoplasmic reticulum stress and unfolded protein 
response (CALR, DDIT3, HSP90B1) and in cell cycle control (CDKN1A, CDKN1B, 
GADD45A), leading to an overall increase in cell viability (Fig. 3e).  
Similarly, Pyr-sulf induces the upregulation of the same genes but with the upregulation 
of more heat shock response genes (HSPA5, HSPA4, HSP90AA1) and also SQSTM1 
(Sequestosome 1, a gene that encodes for a multifunctional protein that binds ubiquitin 
and regulates activation of NF-B signalling pathway), genes predicted to be directly 
activated by ATF4 and indirectly activated by albumin (ALB), acyl-CoA oxidase 1 
(ACOX1) and angiopoietin 2 (ANGPT2) (Fig. 3f). Overall, Pyr-sulf seems to be 
contributing to LUHMES neurospheroids cellular homeostasis (Fig. 3f).  
 
 
Circulating (poly)phenol metabolites neuroprotection acts by transcriptional 
modulation of apoptosis and Nrf2 target genes 
Due to the neuroprotective potential of both Cat-sulf and Pyr-sulf towards MPP+ lesion 
(Fig. 1d and 1e), and their differential role in modulating several genes involved in 
central canonical pathways in LUHMES cells (Fig. 2 and 3), changes in gene expression 
of specific genes involved in apoptosis regulation and in Nrf2-mediated response were  
evaluated in the PD 3D cell model.  
The mRNA levels of major apoptosis players, the anti-apoptotic BCL2 and the pro-
apoptotic BAX, were significantly modulated in neuroprotection conditions. After 6h of 
MPP+ lesion, the pre-incubation with Ide, Cat-sulf and Pyr-sulf leads to an increase in 
BCL2 mRNA levels (Fig. 4a). However, after 24h of lesion, metabolites pre-incubation 
is no longer able to modulate BCL2 levels but leads to a significant decrease in BAX 





Pyr-sulf towards MPP+ lesion, being significantly increased for all conditions at 6h of 
lesion, and lasting in time (24h of lesion) for Ide and Pyr-sulf (Fig. 4a). 
 
 
Fig. 4. Circulating (poly)phenol metabolites neuroprotective potential through genes modulation in 
LUHMES neurospheroids treated with MPP+. (a) RT-qPCR analysis of apoptosis-related genes: BCL2, BAX 
and the ratio BLC2/BAX for neurospheroids pre-incubated with Ide, Cat-sulf or Pyr-sulf and then challenged 
for 2, 6 or 24h with MPP+. (b) RT-qPCR analysis of Nrf2 target genes: ATF4, GSR, NQO1 and HSP40 for 
2, 6 or 24h with MPP+. Statistical differences are denoted as *p<0.05, **p<0.01, and  ***p<0.001 relative to 
each time point of MPP+ insult. Data are mean ± SEM of three independent cultures. 
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Nrf2 target genes ATF4, GSR, NQO1 and HSP40 were also significantly upregulated in 
the presence of the metabolites (Fig. 4b). After 2h of lesion with MPP+, no significant 
alterations were denoted for mRNA levels of ATF4, NQO1 and GSR. However, Ide and 
Cat-sulf lead to an increase in heat-shock protein 40 (HSP40) mRNA levels, which is 
sustained until 6h of lesion in Cat-sulf conditions (Fig. 4b). ATF4 levels decreased with 
lesion time, being this trend only counteracted by Ide, at 6h, and by Pyr-sulf later in time 
(Fig. 4b). Moreover, at 6h of lesion, there is a significant increase in glutathione 
reductase (GSR) induced by Cat-sulf, and in NAD(P)H quinone oxidoreductase (NQO1) 
induced by Cat-sulf and Pyr-sulf (Fig. 4b). After 24h of MPP+ lesion, Pyr-sulf seems to 
be coping with cells to deal with the insult, responding to the effects caused by the 
toxicant, helping to restore the mRNA levels of chaperones, phase I and II enzymes and 







The complexity of age-related disorders, like PD, makes the identification of novel 
interventions particularly challenging. Current therapies only alleviate physical 
complications of advanced stages of the disease, without being able to treat it. The 
possibility to prevent or slow the progression of neurodegenerative diseases through 
diet would have huge social and economic repercussions. 
(Poly)phenol-rich foods, like fruits and vegetables, have been described in last years to 
present brain health benefits with impacts in neurodegeneration14, 15, 37, which has 
gathered researchers attention. In fact, different food and beverages seem to originate 
some common breakdown products which can be found in circulation and excreted in 
urine in human volunteers25-29. For instance, berries, which are rich in anthocyanins, 
hydroxybenzoic acids and hydroxycinnamic acids, when digested, originate some 
(poly)phenol metabolites in circulation that are common with the ones found in 
circulation after the consumption of other completely different food matrixes, like black 
tea, which is rich in flavonols like catechin and epicatechin26, 29. In fact, structurally 
diverse substrates yield essentially the same set of microbiota-derived (poly)phenol 
metabolites. These circulating (poly)phenol metabolites are mainly simple phenolic 
sulfates26, where two of the most abundant detected after the consumption of a berry 
mixture puree were catechol-O-sulfate (Cat-sulf), and pyrogallol-1-O-sulfate and 
pyrogallol-2-O-sulfate (Pyr-sulf), in which some volunteers reach concentrations as high 
as 20M26. As such, these bioavailable (poly)phenol metabolites can constitute true 
effectors in cellular and molecular mechanisms of the disease never explored before for 
a neurodegenerative disorder like PD. 
Previous work from our lab have demonstrated that both Cat-sulf and Pyr-sulf can be 
transported across BBB endothelia at physiological concentrations30, holding great 
promise as selective targets with protective potential for brain cells, with ultimate impact 
in the prevention of neurodegeneration. In fact, these metabolites proven to be 
protective in different cell models with increasing complexity, recapitulating common 
hallmarks of major neurodegenerative diseases, namely, oxidative stress at BBB level, 
neuronal glutamatergic excitotoxicity, oxidative stress in a three-dimensional cell model 
170 
of neurons and astrocytes, and neuroinflammation in microglial cells30. Their potential 
towards PD, however, was never reported before.  
Differentiated LUHMES neurospheroids comprise a valuable tool for the assessment of 
(poly)phenol metabolites potential. In this work in particular, it was assessed 
(poly)phenol metabolites potential against one of the most important hallmarks of PD 
which is the death of dopaminergic neurons, in here recapitulated by a dopaminergic 
lesion caused by MPP+38. The three-dimensional architecture of cells offer physiological 
advantages compared with two-dimensional cultures, mimicking better the brain 
environment complexity, presenting cell-cell interactions. Moreover, LUHMES 
differentiated neurospheroids were enriched in dopaminergic neurons, which expressed 
DAT, TH and III-tubulin. Some GFAP-positive cells were also observed at 7d of 
differentiation, which can suggest that, in a 3D microenvironment, LUHMES cells may 
be able to be differentiated into glial lineages. A consistent differentiated phenotype was 
obtained after 7d of differentiation of 3D culture, resulting in the irreversible conversion 
of LUHMES neuronal precursors into a dopaminergic-enriched neuronal population. 
Differentiated neurospheroids showed a higher number of mature neurons with 
functional synaptic terminals able to respond to depolarizing stimuli (data not shown), 
highlighting the fact that LUHMES neurospheroids synaptic terminals are able to fuse 
the synaptic vesicles with the plasma membrane and perform exocytosis and 
neurotransmitters release. A variety of spontaneous firing patterns was also identified 
in individual cells of LUHMES neurospheroids (data not shown), suggesting the 
presence of both neurons and astrocytes, since the latter can also present spontaneous 
Ca2+ transients, although with significant lower frequencies compared to neurons39, 40. 
This observation reinforces our results showing presence of GFAP-positive cells 
homogenously distributed across the neurospheroids, as well as the increased protein 
and mRNA levels of astrocytic markers along differentiation.  
 
LUHMES differentiated neurospheroids responded to MPP+ lesion, as already reported 
before32, 38, comprising a disease-relevant cell model to study the potential of 
(poly)phenol metabolites towards a dopaminergic lesion with relevance to PD. Although, 





circulating concentrations to LUHMES neurospheroids. Such observation, may  
comprise a hormetic phenomenon: exposures to low doses of certain phytochemicals 
(which can be slightly toxic) pre-condition the cells to greater and later insults41. 
Moreover, we confirmed the neuroprotective effect of these (poly)phenol metabolites in  
LUHMES neurospheroids challenged with MPP+. In hormesis situations, the cells’ 
machinery is triggered through the activation of different alert mechanisms such as the 
modulation of pathways involved in stress response, which will help the cells to cope 
with further damages42. To test our hypothesis, a PCR array targeting major signal 
transduction pathways was designed and Cat-sulf and Pyr-sulf effects assessed in 
terms of gene expression.  
 
Cellular signaling pathways and molecular mechanisms that mediate hormetic 
responses typically involve enzymes such as kinases and deacetylases, and 
transcription factors such as Nrf2 and NF-κB. In such conditions, cells increase their 
production of several proteins including growth factors, phase 2 and antioxidant 
enzymes, and protein chaperones42. In fact, Nrf2 signaling pathway emerged as the top 
canonical pathway modulated by these circulating (poly)phenol metabolites, being more 
activated by Pyr-sulf. The Nrf2 transcription factor, by binding to antioxidant response 
elements (AREs), leads to the expression of antioxidant and detoxifying enzymes, which 
will protect the cells against oxidative damage and will provide protection against 
exogenous agents through phase II enzymes activity43, 44. Recent reports start 
evidencing the potential of dietary (poly)phenols, not its circulating metabolites,  towards 
Nrf245-48, even though the detailed mechanism of action is not yet fully elucidated. There 
are some evidences of two mechanisms of Nrf2 activation by (poly)phenols: (i) direct, 
through the formation of a semiquinone radical which will activate Nrf2 by modifying Nrf2 
inhibitor (Keap1) thiols; and (ii) indirect, through the activation of several kinase 
pathways resulting in the phosphorylation of Nrf2 and subsequent induction Nrf2-
dependet genes. Quinones derived from catechol, resorcinol and hydroquinone have 
been reported to dissociate Nrf2 from Keap1 through a direct mechanism45. Moreover, 
some catechol-derived quinones like levodopa, carnosol49, epigallocatechin 3-gallate50 
or quercetin51 can provide protective potential through the selective alteration of Keap1 
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and subsequent activation of Nrf2 pathway, without presenting extensive quinoprotein 
formation, which can be deleterious. We may suggest that a stronger effect of Pyr-sulf 
in the Nrf2 canonical pathway, comparatively to Cat-sulf, could reflect a greater capacity 
of this catechol-derived metabolite in stabilization of Nrf2 and consequent disruption of 
Nrf2/Keap1 interaction, leading to a more pronounced transcriptional activity of AREs45.  
 
A stronger effect of Pyr-sulf, comparatively to Cat-sulf, towards NF-κB signaling pathway 
was observed in LUHMES neurospheroids, which is in accordance with our previous 
results30. In LPS-stimulated microglia, Pyr-sulf was able to dramatically reduce TNF- 
levels caused by LPS and also modulated NF-κB nuclear translocation; by opposition, 
Cat-sulf was unable to exert such protective potential towards inflammation30. Although 
we are aware of differential NF-κB regulation in microglia and neuronal cells, these 
observations can give us clues about a putative common mechanism of action with 
beneficial effects in two different brain cell settings. The impact of catechol-type 
(poly)phenols in NF-κB signaling pathway is starting to be elucidated. For instance, 
piceatannol (3,3',4'5-tetrahydroxystilbene) derived from grapes, rhubarb and 
sugarcane, suppressed NF-κB pathway in MCF-10A cells 52. The authors speculate that 
an electrophilic quinone is formed as a consequence of oxidation of catechol moiety of 
piceatannol through direct interaction with critical cysteine thiols of IKKβ [the activating 
kinase of NF-κB inhibitor (IκB)] thereby inhibiting its catalytic activity52. Moreover, 
chlorogenic acid and caffeic acid, phenolic compounds found in coffee, also with a 
catechol moiety, significantly suppressed NF-κB transcriptional activity, nuclear 
translocation of the p65 subunit, and phosphorylation of IκB kinase (IKK) in Caco-2 
cells53. The authors argue that the functional moiety responsible for the anti-
inflammatory effects in both phenolic compounds was the catechol group, which allows 
scavenging of intracellular ROS, thereby inhibiting H2O2-induced IL-8 production via 
suppression of pyruvate dehydrogenase kinase (PKD)-NF-κB signaling in human 
intestinal epithelial cells53. However, such approaches did not took advantage of 
circulating metabolites derived from dietary (poly)phenols, like Cat-sulf and Pyr-sulf, in 






The tumor suppressor protein p53 and the p53 signaling pathway were predicted to be 
activated in LUHMES neurospheroids in the presence of both (poly)phenol metabolites. 
p53 plays a major role in inhibition of angiogenesis and, upon damage, it can activate 
DNA repair proteins, induce growth arrest by holding the cell cycle, or initiate apoptosis 
through BAX, BCL2 and caspase 3 induction, for instance54. These results could 
comprise an adaptive reaction of the cells, as a reflex of a neurohormetic effect: by 
inducing an adaptive response at sub-toxic doses, such compounds may protect against 
stronger insults41. Our previous data already reported a neurohormetic potential of 
(poly)phenol components resulting from in vitro digestion of blackberries through the 
activation of p53 signaling55. Such (poly)phenol digested components, despite of being 
immersed in a complex mixture, represent a more physiological in vitro approach to 
study nutritionally-relevant effects than the usage of parent dietary (poly)phenols which 
are not bioavailable nor bioaccessible55. The work presented here represents a step 
forward once bioavailable (poly)phenol metabolites, at circulating concentrations, 
significantly modulated p53 signaling pathway in LUHMES neurospheroids, validating 
the neurohormetic potential that (poly)phenols resulting from berries consumption could 
bear. 
 
The significant effects of (poly)phenol metabolites in ATF4, both an inducer and a target 
of Nrf2, were here evidenced, emerging as an upstream regulator with ultimate 
beneficial effects in terms of cell homeostasis and viability. Our previous work have 
already highlighted the pivotal role of this transcription factor in response to (poly)phenol 
components resulting from in vitro digestion of blackberries55 and its potential towards 
neuroprotection. In fact, ATF4 upregulation has already been described to protect 
against neuronal death in cellular models of PD56 and can comprise a mechanism by 
which Cat-sulf and Pyr-sulf can be neuroprotective. 
 
Genes involved in apoptosis response, like BCL2 and BAX, and targets genes of Nrf2 
pathway, like ATF4, NQO1, GSR and HSP40, emerged as significantly upregulated by 
Cat-sulf and Pyr-sulf. Their key role in major canonical pathways and upstream 
regulators identified in our datasets made them suitable candidates to evaluate in 
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dopaminergic lesion conditions as putative intervenient with neuroprotective potential. 
Both Cat-sulf and Pyr-sulf incubation lead to a significant increase in mRNA levels of 
the anti-apoptotic BCL2 and a decrease in BAX, the pro-apoptotic agent, counteracting 
the trend caused by the toxicant MPP+. Modulation of apoptosis could be certainly one 
mechanism of action by which these circulating (poly)phenol metabolites can be 
neuroprotective in a PD-like scenario. Evidences also suggest that oxidative stress is a 
major factor contributing to the vulnerability of dopaminergic cells and beneficial effects 
of the induction of AREs (Nrf2-target genes) towards PD is already described57. For 
instance, the induction of gene expression of NQO1 was shown to confer protection to 
dopaminergic neurons in both cell culture and animal models of PD 58. The upregulation 
of NQO1 observed here, caused by the pre-incubation with Cat-sulf or with Pyr-sulf, and 
after 6h of MPP+ lesion, corroborates such observations. Additionally, a decrease in 
glutathione (GSH) levels is one of the earliest biochemical alterations detected in 
association with PD and GSH itself regulates dopaminergic cell death through a wide 
variety of homeostatic processes 59. In fact, in the substantia nigra of PD patients, there 
is a depletion of GSH with no change in oxidized glutathione (GSSG) levels60. By 
promoting the upregulation of the transcripts of glutathione reductase (GSR), enzyme 
which converts GSSG into GSH, (poly)phenol metabolites can be counteracting another 
important PD hallmark. Many neurodegenerative diseases, like PD, are 
‘proteinopathies’ where toxic proteins aggregate and fibers that accumulate in an age-
dependent process. The accumulation of insoluble protein aggregates with age implies 
a failure of the cellular protein quality control system, which consists of molecular 
chaperones, the ubiquitin-proteasome system and the autophagy-lysosome system 61. 
In that sense, overexpression of Hsp70 chaperone is almost universally protective in 
models of PD62-64; however, the ATPase activity of Hsp70 (DnaK) is stimulated by its co-
chaperone, Hsp40 (DnaJ), and these proteins often work in concert 65. The upregulation 
of Hsp40 transcripts can be suggestive of an Hsp40-mediated activation of the 
regulatory mechanism of Hsp70 activity, with ultimate neuroprotective effects55. 
 
A better understanding of hormesis at the cellular and molecular levels is leading to 





observed that circulating (poly)phenol metabolites trigger several mechanisms which 
help the cells to cope with a later insult. Despite its multitude and complexity, it is 
believed that it may be possible to palliate some molecular symptoms of PD pathology 
with one single hit at the transcription factor Nrf266. Circulating (poly)phenols 
metabolites, derived from human metabolism of different (poly)phenol-rich foods and 
which are BBB permeable, could fulfil this role. These circulating (poly)phenol 
metabolites modulate neuronal cells gene expression in order to tackle key points 
involved in PD never reported before for such metabolites. Moreover, as different 
sources of (poly)phenols give rise to the same circulating metabolites, it may be 
suggestive that such metabolites can be pivotal to keep our body health. In fact, such 
metabolites ability to tackle different cellular mechanisms, much likely to be involved in 
several chronic pathologies like neurodegenerative diseases, reinforce their potential as 
putative nutritional pleiotropic actors. Nevertheless, it may be only the first glimpse 
towards the understanding of the molecular effects on the benefits of the food we eat 
concerning age-related diseases like PD but, it can open doors for more mechanistic 
studies taking advantage of these circulating metabolites, physiological concentrations 
and disease-relevant cell models. 
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Material and Methods 
 
Cell culture and 2D differentiation 
Undifferentiated LUHMES cells (kindly provided by Dr. M. Leist) were routinely 
cultivated in proliferation medium, comprising Advanced DMEM/F12 (Gibco, Life 
Technologies) supplemented with 2mM L-Glutamine (Sigma-Aldrich), 1x N2 
Supplement (Gibco) and 0.04 
R&D Systems). For propagation in monolayer, flasks (Nunc) were pre-coated with 
-L-ornithine (PLO, Sigma-Aldrich) and 1g/mL fibronectin (Sigma-Aldrich).  
 
3D stirred suspension culture  
LUHMES cells were cultured in stirred suspension culture systems in a humidified 
atmosphere of 5% CO2, at 37◦C. Undifferentiated LUHMES cells were inoculated as 
single cell suspension in a silanized 125mL spinner vessel (Corning) equipped with a 
magnetic paddle impeller, at a density of 1.2 x 105 cell/mL in 125mL of proliferation 
medium. After 48h of aggregation, 70% of medium was changed to differentiation 
medium to induce neurospheroid cell differentiation in 3D. Differentiation medium 
comprised Advanced DMEM/F12 supplemented with 2mM L-Glutamine, 1x N2 
Supplement, 1mM dibutyryl cAMP (Sigma-Aldrich), 2g/mL tetracycline (Sigma-
Aldrich), and 2ng/mL recombinant human glial cell line-derived neurotrophic factor 
(GDNF, R&D Systems). Replacement of 50% of culture medium by fresh differentiation 
medium was performed every 2-3 days. Cultures were maintained up to 14 days of 
differentiation. The agitation rate was increased along culture to avoid aggregate 
clumping and to control aggregate size (from initial 60rpm, to 70rpm at differentiation 
step initiation, and up to 80rpm by the end of the culture).  
 
Neurospheroid monitoring along time 
At different time points along culture progression, viability of differentiated 
neurospheroids was assessed using a fluorescence microscopy based method, the 
fluoresceine diacetate (FDA)/propidium iodide (PI) assay67. Moreover, cell proliferation 





488 Assay kit (Life Technologies). Neurospheroids sampling was performed along 
differentiation and neurospheroids disrupted in 0.1 M citric acid with 1% Triton X-100, 
at 37 °C, overnight, and nuclei stained with 0.1% crystal violet68 and counted in a Fuchs–
Rosenthal haemocytometer chamber. A sample size of at least 1 mL of culture was used 
to reliably determine cell concentration, neurospheroids counting and perform 
aggregate size measurements using ImageJ software. 
 
Standard experimental setup 
Differentiated neurospheroids (at 7 days of stirred differentiation) were collected and 
seeded in PLO-fibronectin coated 96, 24 or 12-well plates (Falcon) accordingly to 
following assays. After 24h, 200nM of Idebenone (positive control, provided by Grupo 
Tecnimede) or 5 µM of each (poly)phenol metabolite (catechol-sulfate, Cat-sulf or 
pyrogallol-sulfate, Py-sulf) was added and, after 24h of incubation, differentiation 
medium was carefully removed and new differentiation medium containing 5µM of MPP+ 
(Sigma-Aldrich) was added to neurospheroids for different timepoints. Cell viability and 
ATP levels were assessed after 24h of injury, and mRNA levels of different targets at 0, 
2h, 6h and 24h of injury with MPP+. 
 
Neurospheroids synaptic activity 
Evoked synaptic activity of neurospheroids was assessed by the method of Gaffield 
2006 69 and already reported by us70. LUHMES neurospheroids were collected at 0 and 
7 days of differentiation and seeded in PLO-fibronectin pre-coated glass coverslips, and 
incubated with 100mM KCl buffer (5mM HEPES-NaOH, pH 7.4; 10mM glucose; 2.5mM 
calcium chloride; 1mM magnesium chloride; 100mM potassium chloride; 37mM sodium 
chloride) for 5min. Afterwards, 100mM KCl buffer was removed and neurospheroids 
incubated with 10µM FM-1-43 dye (Invitrogen) in 5mM KCl buffer (5mM HEPES-NaOH, 
pH 7.4; 10mM glucose; 2.5mM calcium chloride; 1mM magnesium chloride; 5mM 
potassium chloride; 37mM sodium chloride) for 15min. Neurospheroids were washed 
for 1min with 5mM KCl buffer with ADAVASEP-7 (Sigma), followed by three washes 
with 5mM KCl buffer. Exocytosis was stimulated with 100mM KCl buffer and samples 
were visualized live using a fluorescence microscope (Leica DMI6000) in order to 
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monitor the decrease in fluorescence intensity over time. Fluorescence intensity was 
measured using ImageJ software. 
Spontaneous synaptic activity of LUHMES neurospheroids was assessed by their 
response in calcium assay71. Neurospheroids with 7 days of differentiation were 
incubated with 1x Fluo-4 Direct calcium reagent (Invitrogen) for 30 min at 37˚C, 5% CO2 
and for 15 min at RT. Samples were then imaged live using spinning disk microscopy 
(Nikon Eclipse Ti-E, confocal scanner: Yokogawa CSU-x1). Fluorescence change over 
time is defined as ΔF/F0 = (F-F0)/F0, where F is the fluorescence at any time point, and 
F0 the baseline fluorescence determined by baseline fitting across the whole movie for 
each cell using SparkMaster plugin of ImageJ software. 
 
Immunofluorescence microscopy 
Neurospheroids were collected at 7 days of differentiation and processed for 
immunofluorescence staining70. Briefly, neurospheroids were fixed in 4% (w/v) 
paraformaldehyde (Sigma-Aldrich) solution in PBS with 4% (w/v) sucrose and 
processed directly for immunostaining. The primary antibodies used for cell 
characterization were anti- -tubulin (III-tub, Millipore), anti-glial fibrillary acidic protein 
(GFAP, DAKO) and anti-tyrosine hydroxylase (TH, Santa Cruz Biotechnology). The 
secondary antibodies used were goat anti-mouse IgG-AlexaFluor 488 and goat anti-
rabbit IgG AlexaFluor 594 (Life Technologies). Cell nuclei were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI, Life Technologies). Preparations were visualized using 
a point-scan confocal (Leica SP5) microscope. Merge between channels, maximum z-
projections, and orthogonal projections, as well as linear brightness and contrast 
adjustment of the images were created using ImageJ software. 
 
Western blot 
Neurospheroids were lysed in TX-100 lysis buffer (50mM Tris, 5mM EDTA, 150mM 
NaCl, 1% Triton X-100 and 1x complete protease inhibitors cocktail (Roche)) and protein 
quantification was carried out using the Micro BCATM Protein Assay kit (Thermo Fisher). 
Protein samples were subjected to a gel electrophoresis using a NuPAGE 4-12% Bis-





polyvinylidene difluoride (PVDF) membrane. Membranes were blocked with 5% non-fat 
dried milk powder in 0.1% Tween-20 in PBS (blocking solution) for 1h, followed by 
incubation with primary antibodies overnight at 4◦C, diluted in blocking solution and then 
with secondary antibodies (horseradish peroxidase-conjugated, ECL anti-mouse IgG or 
anti-rabbit IgG; GE Healthcare) diluted 1:5000 in blocking solution, for 2h at RT. Anti-α-
tubulin or anti-GAPDH antibodies were used as control to confirm equal loading of total 
protein. Membranes were developed using Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare) and visualized using a ChemiDocTM XRS+ System 
(BioRad). Primary antibodies used for protein detection were anti-βIII-tubulin (Millipore), 
anti-synaptophysisn (Syn, Millipore), anti-GFAP (DAKO), anti-TH (Santa Cruz), anti-
Nestin (Millipore), anti-GLT1 (Millipore) and anti-Pitx3 (Abcam). 
 
Gene expression 
Neurospheroids total RNA was extracted with High Pure RNA Isolation kit (Roche) and 
quantified using NanoRop 2000c (ThermoScientific). Reverse transcription was 
performed with Transcriptor High Fidelity cDNA Synthesis kit (Roche), using Anchored-
oligo(dT)18 Primer. Real-time quantitative PCR analysis (RT-qPCR) was performed as 
described72. RT-qPCR analysis was performed in a LightCycler 480 Multiwell Plate 96 
(Roche), according to LightCycler 480 SYBR Green I Master kit (Roche). cDNA was 
in triplicate. The list of used primers and sequence is presented in Supplementary 
Table S1. RealTime ready assays from Universal Probe Library (Roche) were used with 
forward and reverse primers (400 nM) and fluorescently labeled hydrolysis probes (200 
nM) lyophilized in a Custom Panel 384 (configuration no. 100127094, Roche, 
Supplementary Table S2) and were performed according to manufacturer’s 
instructions. Real-time polymerase chain reaction analysis were performed in a final 
volume of 10 the LightCycler® 480 Probes Master (Roche). Cycles threshold 
(Ct’s) and melting curves were determined using LightCycler 480 software, version 1.5 
(Roche) and results were processed using the 2-Ct method for relative gene 
expression analysis72, 73. Changes in gene expression were normalized using the 
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housekeeping genes RPL22, in the case of RT-qPCR, and GAPDH, B2M and ACTB, in 
the case of RealTime Ready assay. 
 
Functional enrichment and pathway analysis 
Ingenuity® Pathway Analysis (IPA, Ingenuity Systems, USA) was used for functional 
enrichment analysis. The Core Analysis function included in IPA was applied to analyze 
the lists of differentially expressed genes identified in of RealTime Ready PCR data. 
Based on the list of up and downregulated genes, IPA performs functional enrichment 
analysis in order to identify the biological processes and functions over-represented in 
a given list of genes. In addition to this, based on information stored in the Ingenuity® 
Knowledge Base, upstream regulator analysis was performed using IPA software. The 
upstream regulator analysis tool of IPA is based on the examination of the known targets 
of each transcription regulator in the list of differentially expressed genes, and it 
compares their direction of change to what is expected from the literature. 
 
Cell viability assays 
Neurospheroids were collected from spinner vessels at day 7 of differentiation and were 
distributed in pre-coated 96-well plates, with 15 neurospheres/well in differentiation 
medium. Six wells were used per test condition. As endpoints, metabolic activity was 
assessed by Presto Blue assay (Invitrogen), as a measure of resazurin conversion, and 
intracellular ATP levels by CellTiter Glo (Promega), by luminescence, according to 
manufacturer’s instructions. Final cell viability (metabolic capacity) and intracellular ATP 




Statistical analysis was performed using GraphPad Prism 6 software. RT-qPCR, ATP 
fold change, neurotoxicity and neuroprotection data are mean ± SEM from at least three 
independent experiments (independent spinner vessels) performed with technical 
replicates. One-way ANOVA analysis with Tukey’s post multiple comparison test was 





Significance of the top enriched categories in IPA was tested by the Fisher Exact test 
p-value. The prediction algorithm of IPA calculates a z-score, and it is designed to 
reduce the chance that random data would generate significant predictions. 
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Supplementary Fig. S1 LUHMES neurospheroids cell culture characterization along time. Cells were 
inoculated in stirred suspension culture systems and aggregated (Agg) for 2 days. Dopaminergic 
differentiation was induced by removing FGF from medium and by introduction of GDNF, cAMP and 
tetracycline during 14 days (Differentiation Medium). (a) Representative images of the culture status at the 
indicated differentiation (Diff) days: fluorescent live/dead assay using fluorescein diacetate (FDA) for 
identification of live cells (green) and propidium iodide (PI) for identification of dead cells (red). (b) 
Representative images of neurosphere proliferation status at the indicated differentiation (Diff) days and 
percentage of proliferative cells (EdU positive cells): EdU labeling of proliferative cells (green) and nuclei 






Supplementary Fig. S2 LUHMES neurospheroids culture neural population characterization. (a) RT-qPCR 
analysis of Nestin, III-tubulin, synaptophysin, TH and DAT gene expression;  fold increase in gene 
expression of neurospheroids along culture time normalized for 0d of differentiation. Statistical differences 
are donated as ***p<0.001, **p<0.01 and *p<0.05 relative to 0d differentiation. (b) Detection of βIII-tubulin, 
synaptophysin, TH, Pitx3, GFAP, GLT-1 and Nestin by Western blot analysis and corresponding fold 
change in protein levels obtained by densitometry normalized for 0d of differentiation; α-tubulin was used 
as loading control. Statistical differences are donated as *p<0.05, **p<0.01, ***p<0.001 and relative to 0d 
differentiation. (c) Immunofluorescence microscopy of neurospheroids (7d Diff); scale bar: 20μm; βIII-





Supplementary Fig. S3 Parkinson’s disease 3D cell model. Differentiated LUHMES neurospheroids (7d 
Diff) were submitted to a dopaminergic neurotoxicant, 1-methyl-4-phenylpyridinium (MPP+). (a) Dose-
response curve of 0.5-100µM MPP+ induced lesion for 24 hours with respective IC50, determined by Presto 
blue assay. (b) RT-qPCR analysis of III-tubulin, TH and DAT gene expression;  fold change in gene 
expression of neurospheroids treated with 5M MPP+ after 6, 24 and 48h. Statistical differences are 
denoted as * p<0.05 or ***p<0.0001 as indicated. (c) Detection of βIII-tubulin and TH by western blot 
analysis and corresponding fold change in protein levels obtained by densitometry and normalized for 
control condition (no MPP+). GAPDH was used as loading control. Data are mean ± SD of three 







Supplementary Table S1 List of primers used for RT-qPCR analysis. 
Gene Cell type/Function 
Primers forward (top) 
and reverse (bottom) 
RPL22 




TUJ1 III-tubulin  
GGGCCTTTGGACATCTCTTC 
CCTCCGTGTAGTGACCCTTG 
TH Tyrosine hydroxylase 
AGCCCTACCAAGACCAGACG 
GCGTGTACGGGTCGAACTT 









GFAP Glial fibrillary acid protein 
AGAGAGGTCAAGCCCAGGAG 
GGTCACCCACAACCCCTACT 
ATF4 Activating transcription factor 4 
GGCTGGCTGTGGATGGGTTG 
CTCCTGGACTAGGGGGGCAA 
GSR Glutathione reductase 
CGTGGAGGTGCTGAAGTTCTC 
TCATGGTCATGACTGGTAGCC 
NQO1 NAD(P)H quinone dehydrogenase 1 
TGACATATAGCATTGGGCACAC 
TTCTCCTCATCCTGTACCTCTT 
HSP40 DnaJ (heat shock protein 40 kD) 
AGGAAGGCCTAAAGGGGAGT 
AGGGATTTCTGCCACCGAAG 
BCL-2 B-cell lymphoma 2 
ATCGCCCTGTGGATGACTGAG 
CAGCCAGGAGAAATCAAACAGAGG 
BAX BCL-2 associated X protein 
TGGAGCTGCAGAGGATGATTG 
GAAGTTGCCGTCAGAAAACATG  
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138446  ACSL3  ACS3; FACL3; PRO2194  acyl-CoA synthetase long-chain family 
member 3 [Source:HGNC 
Symbol;Acc:3570]  
127578  ACSL4  ACS4; FACL4; LACS4; MRX63; 
MRX68  
acyl-CoA synthetase long-chain family 
member 4 [Source:HGNC 
Symbol;Acc:3571]  
119501  ACSL5  ACS2; ACS5; FACL5  acyl-CoA synthetase long-chain family 
member 5 [Source:HGNC 
Symbol;Acc:16526]  
100816  AKT1  AKT; MGC99656; PKB; PKB-ALPHA; 
PRKBA; RAC; RAC-ALPHA  
v-akt murine thymoma viral oncogene 
homolog 1 [Source:HGNC 
Symbol;Acc:391]  
114661  ATF4  CREB-2; CREB2; TAXREB67; 
TXREB  
activating transcription factor 4 (tax-
responsive enhancer element B67) 
[Source:HGNC Symbol;Acc:786] 
115129  ATF6  ATF6A  activating transcription factor 6  
[Source:HGNC Symbol;Acc:791]  
118103  ATG12  APG12; APG12L; FBR93; HAPG12  ATG12 autophagy related 12 homolog (S. 
cerevisiae) [Source:HGNC 
Symbol;Acc:588]  
125999  ATG5  APG5; APG5-LIKE; APG5L; ASP; 
hAPG5  
ATG5 autophagy related 5 homolog (S. 
cerevisiae) [Source:HGNC 
Symbol;Acc:589]  
120541  ATG7  APG7-LIKE; APG7L; 
DKFZp434N0735; GSA7  
ATG7 autophagy related 7 homolog (S. 
cerevisiae) [Source:HGNC 
Symbol;Acc:16935]  
102998  AXIN2  AXIL; DKFZp781B0869; MGC10366; 
MGC126582  
axin 2  
[Source:HGNC Symbol;Acc:904]  
142318  BAX  BCL2L4  BCL2-associated X protein 
[Source:HGNC Symbol;Acc:959]  
142759  BBC3  FLJ42994; JFY1; PUMA  BCL2 binding component 3  
[Source:HGNC Symbol;Acc:17868]  
100083  BCL2  Bcl-2  B-cell CLL/lymphoma 2 [Source:HGNC 
Symbol;Acc:990]  
100085  BCL2A1  ACC-1; ACC-2; BCL2L5; BFL1; GRS; 
HBPA1  
BCL2-related protein A1  
[Source:HGNC Symbol;Acc:991]  
100088  BCL2L1  Bcl-X; bcl-xL; BCL-XL/S; bcl-xS; 
BCL2L; BCLX; BCLXL; BCLXS; 
DKFZp781P2092  
BCL2-like 1 [Source:HGNC 
Symbol;Acc:992]  
100115  BECN1  ATG6; beclin1; VPS30  beclin 1, autophagy related  
[Source:HGNC Symbol;Acc:1034]  
100122  BID  FP497; MGC15319; MGC42355  BH3 interacting domain death agonist  
[Source:HGNC Symbol;Acc:1050]  
100135  BIRC3  AIP1; API2; c-IAP2; cIAP2; HAIP1; 
hiap-1; HIAP1; MALT2; MIHC; 
RNF49  
baculoviral IAP repeat-containing 3  
[Source:HGNC Symbol;Acc:591]  
146274  BMP2  BMP2A  bone morphogenetic protein 2  
[Source:HGNC Symbol;Acc:1069]  
146294  BMP4  BMP2B; BMP2B1; MCOPS6; OFC11; 
ZYME  
bone morphogenetic protein 4  
[Source:HGNC Symbol;Acc:1071]  
110980  BTG2  MGC126063; MGC126064; PC3; 
TIS21  
BTG family, member 2  
[Source:HGNC Symbol;Acc:1131]  
- CALR  cC1qR; CRT; FLJ26680; RO; SSA  calreticulin [Source:HGNC 
Symbol;Acc:1455]  
113395  CCL5  D17S136E; MGC17164; RANTES; 
SCYA5; SISd; TCP228  
chemokine (C-C motif) ligand 5 





142502  CCND1  BCL1; D11S287E; PRAD1; U21B31  cyclin D1 [Source:HGNC 
Symbol;Acc:1582]  
101384  CCND2  KIAK0002; MGC102758  cyclin D2 [Source:HGNC 
Symbol;Acc:1583]  
144097  CDKN1A  CAP20; CDKN1; CIP1; MDA-6; P21; 
p21CIP1; p21Cip1/Waf1; SDI1; 
WAF1  
cyclin-dependent kinase inhibitor 1A (p21, 
Cip1) [Source:HGNC Symbol;Acc:1784]  
100855  CDKN1B  CDKN4; KIP1; MEN1B; MEN4; 
P27KIP1  
cyclin-dependent kinase inhibitor 1B (p27, 
Kip1) [Source:HGNC Symbol;Acc:1785]  
- CEBPD  C/EBP-delta; CELF; CRP3; NF-IL6-
beta  
CCAAT/enhancer binding protein (C/EBP), 
delta [Source:HGNC Symbol;Acc:1835]  
113740  CPT2  CPT1; CPTASE  carnitine palmitoyltransferase 2  
[Source:HGNC Symbol;Acc:2330]  
141077  CSF1  M-CSF; MCSF; MGC31930  colony stimulating factor 1 (macrophage)  
[Source:HGNC Symbol;Acc:2432]  
116795  DAB2  DOC-2; DOC2; FLJ26626  disabled homolog 2, mitogen-responsive 
phosphoprotein (Drosophila) [Source:HGNC 
Symbol;Acc:2662]  
100355  DDIT3  CEBPZ; CHOP; CHOP-10; CHOP10; 
GADD153; MGC4154  
DNA-damage-inducible transcript 3  
[Source:HGNC Symbol;Acc:2726]  
115809  DNAJC3  FLJ21288; HP58; P58; P58IPK; 
PRKRI  
DnaJ (Hsp40) homolog, subfamily C, 
member 3 [Source:HGNC 
Symbol;Acc:9439]  
143550  EGFR  ERBB; ERBB1; HER1; mENA; 
PIG61  
epidermal growth factor receptor  
[Source:HGNC Symbol;Acc:3236]  
148159  EMP1  CL-20; EMP-1; TMP  epithelial membrane protein 1 
[Source:HGNC Symbol;Acc:3333]  
103087  FABP1  FABPL; L-FABP  fatty acid binding protein 1, liver  
[Source:HGNC Symbol;Acc:3555]  
145362  FAS  ALPS1A; APO-1; APT1; CD95; 
FAS1; FASTM; TNFRSF6  
Fas (TNF receptor superfamily, member 6) 
[Source:HGNC Symbol;Acc:11920]  
- FCER2  CD23; CD23A; CLEC4J; FCE2; 
IGEBF  
Fc fragment of IgE, low affinity II, receptor 
for (CD23) [Source:HGNC 
Symbol;Acc:3612]  
104340  FOSL1  FRA; fra-1; FRA1  FOS-like antigen 1 [Source:HGNC 
Symbol;Acc:13718]  
117090  FTH1  FHC; FTH; FTHL6; MGC104426; 
PIG15; PLIF  
ferritin, heavy polypeptide 1  
[Source:HGNC Symbol;Acc:3976]  
101471  GADD45A  DDIT1; GADD45  growth arrest and DNA-damage-inducible, 
alpha [Source:HGNC Symbol;Acc:4095]  
115714  GADD45B  DKFZP566B133; GADD45BETA; 
MYD118  
growth arrest and DNA-damage-inducible, 
beta [Source:HGNC Symbol;Acc:4096] 
110864  GATA3  HDR; MGC2346; MGC5199; 
MGC5445  
GATA binding protein 3  
[Source:HGNC Symbol;Acc:4172]  
147654  GCLC  GCL; GCS; GLCL; GLCLC  glutamate-cysteine ligase, catalytic subunit 
[Source:HGNC Symbol;Acc:4311]  
114136  GCLM  GLCLR  glutamate-cysteine ligase, modifier subunit 
[Source:HGNC Symbol;Acc:4312]  
111427  GSR  MGC78522  glutathione reductase  
[Source:HGNC Symbol;Acc:4623]  
102005  HERPUD1  HERP; KIAA0025; Mif1; SUP  homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like 
domain member 1  
[Source:HGNC Symbol;Acc:13744]  
142326  HES1  bHLHb39; FLJ20408; HES-1; HHL; 
HRY  
hairy and enhancer of split 1, (Drosophila) 
[Source:HGNC Symbol;Acc:5192]  
- HES5  bHLHb38  hairy and enhancer of split 5 (Drosophila)  
[Source:HGNC Symbol;Acc:19764]  
142325  HEY1  BHLHb31; CHF-2; CHF2; HERP2; 
HESR-1; HESR1; HRT-1; MGC1274; 
OAF1  
hairy/enhancer-of-split related with YRPW 
motif 1 [Source:HGNC Symbol;Acc:4880]  
192 
112778  HEY2  bHLHb32; CHF1; GRIDLOCK; GRL; 
HERP1; HESR2; HRT2; MGC10720  
hairy/enhancer-of-split related with YRPW 
motif 2 [Source:HGNC Symbol;Acc:4881]  
137073  HEYL  bHLHb33; HEY3; HRT3; MGC12623  hairy/enhancer-of-split related with YRPW 
motif-like [Source:HGNC Symbol;Acc:4882]  
110977  HMOX1  bK286B10; HO-1; HSP32  heme oxygenase (decycling) 1  
[Source:HGNC Symbol;Acc:5013]  
110865  HSP90AA1  FLJ31884; HSP86; Hsp89; HSP89A; 
Hsp90; HSP90A; HSP90AA2; 
HSP90N; HSPC1; HSPCA; 
HSPCAL1; HSPCAL4; HSPN; LAP2  
heat shock protein 90kDa alpha (cytosolic), 
class A member 2 [Source:HGNC 
Symbol;Acc:5256]  
100489  HSP90B1  ECGP; GP96; GRP94; TRA1  heat shock protein 90kDa beta (Grp94), 
member 1 [Source:HGNC 
Symbol;Acc:12028]  
110730  HSPA4  APG-2; HS24/P52; hsp70; hsp70RY; 
MGC131852; RY  
heat shock 70kDa protein 4 
[Source:HGNC Symbol;Acc:5237]  
110805  HSPA5  BiP; FLJ26106; GRP78; MIF2  heat shock 70kDa protein 5 (glucose-
regulated protein, 78kDa) [Source:HGNC 
Symbol;Acc:5238]  
100945  ICAM1  BB2; CD54; P3.58  intercellular adhesion molecule 1  
[Source:HGNC Symbol;Acc:5344] 
104631  ID1  bHLHb24; dJ857M17.1; ID  inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein 
[Source:HGNC Symbol;Acc:5360]  
110609  IFNG  IFG; IFI  interferon, gamma [Source:HGNC 
Symbol;Acc:5438]  
117683  IFRD1  PC4; TIS7  interferon-related developmental regulator 1 
[Source:HGNC Symbol;Acc:5456]  
144798  IRF1  IRF-1; MAR  interferon regulatory factor 1  
[Source:HGNC Symbol;Acc:6116]  
108043  JAG1  AGS; AHD; AWS; CD339; HJ1; 
JAGL1; MGC104644  
jagged 1 
[Source:HGNC Symbol;Acc:6188]  
112383  LFNG  SCDO3  LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
[Source:HGNC Symbol;Acc:6560]  
146268  LRG1  HMFT1766; LRG  leucine-rich alpha-2-glycoprotein 1  
[Source:HGNC Symbol;Acc:29480]  
106176  MAP3K1  MAPKKK1; MEKK; MEKK1  mitogen-activated protein kinase kinase 
kinase 1 [Source:HGNC Symbol;Acc:6848]  
102930  MCL1  bcl2-L-3; BCL2L3; EAT; Mcl-1; 
MCL1-ES; mcl1/EAT; MCL1L; 
MCL1S; MGC104264; MGC1839; 
TM  
myeloid cell leukemia sequence 1 (BCL2-
related) [Source:HGNC Symbol;Acc:6943]  
104396  MMP7  MMP-7; MPSL1; PUMP-1  matrix metallopeptidase 7 (matrilysin, 
uterine) [Source:HGNC Symbol;Acc:7174]  
100977  MYC  bHLHe39; c-Myc; MRTL  v-myc myelocytomatosis viral oncogene 
homolog (avian) [Source:HGNC 
Symbol;Acc:7553]  
142322  NOTCH1  hN1; TAN1  notch 1 [Source:HGNC Symbol;Acc:7881]  
147227  NQO1 DHQU; DIA4; DTD; NMOR1; NMORI; 
QR1  
NAD(P)H dehydrogenase, quinone 1 
[Source:HGNC Symbol;Acc:2874] 
113212  OLR1  CLEC8A; LOX-1; LOX1; LOXIN; 
SCARE1; SLOX1  
oxidized low density lipoprotein (lectin-like) 
receptor 1 [Source:HGNC 
Symbol;Acc:8133] 
101524  PCNA  MGC8367; PCNAAS  PCNA antisense RNA (non-protein coding) 
[Source:HGNC Symbol;Acc:37184]  
104411  PPARD  FAAR; MGC3931; NR1C2; NUC1; 
NUCI; NUCII; PPARB  
peroxisome proliferator-activated receptor 
delta [Source:HGNC Symbol;Acc:9235]  
111252  PTCH1  BCNS; FLJ26746; FLJ42602; HPE7; 
NBCCS; PTC; PTC1; PTCH; 
PTCH11  
patched 1  





105606  RAF1  c-Raf; CRAF; NS5; Raf-1  v-raf-1 murine leukemia viral oncogene 
homolog 1 [Source:HGNC 
Symbol;Acc:9829]  
101596  RB1  OSRC; p105-Rb; pp110; pRb; RB  retinoblastoma 1 [Source:HGNC 
Symbol;Acc:9884]  
117069  SLC27A4  ACSVL4; FATP4; IPS  solute carrier family 27 (fatty acid 
transporter), member 4 [Source:HGNC 
Symbol;Acc:10998]  
101122  SOCS3  ATOD4; CIS3; Cish3; MGC71791; 
SOCS-3; SSI-3; SSI3  
suppressor of cytokine signaling 3  
[Source:HGNC Symbol;Acc:19391]  
119555  SORBS1  CAP; DKFZp451C066; 
DKFZp586P1422; FLAF2; FLJ12406; 
KIAA1296; ponsin; R85FL; SH3D5; 
sh3p12; SORB1  
sorbin and SH3 domain containing 1  
[Source:HGNC Symbol;Acc:14565]  
113560  SQSTM1 A170; OSIL; p60; p62; p62B; PDB3; 
ZIP3  
sequestosome 1 [Source:HGNC 
Symbol;Acc:11280]  
101180  STAT1  DKFZp686B04100; ISGF-3; STAT91  signal transducer and activator of 
transcription 1, 91kDa [Source:HGNC 
Symbol;Acc:11362]  
147880  TNF  DIF; TNF-alpha; TNFA; TNFSF2  Tumor necrosis factor Precursor (TNF-
alpha)(Tumor necrosis factor ligand 
superfamily member 2)(TNF-a)(Cachectin) 
[Contains Tumor necrosis factor, membrane 
form;Tumor necrosis factor, soluble form] 
[Source:UniProtKB/Swiss-
Prot;Acc:P01375]  
101266  TNFSF10  Apo-2L; APO2L; CD253; TL2; TRAIL  tumor necrosis factor (ligand) superfamily, 
member 10 [Source:HGNC 
Symbol;Acc:11925]  
116591  TXNL4B  Dim2; DLP; FLJ20511  thioredoxin-like 4B 
[Source:HGNC Symbol;Acc:26041]  
114835  TXNRD1  GRIM-12; MGC9145; TR; TR1; Trxr1; 
TXNR  
thioredoxin reductase 1  
[Source:HGNC Symbol;Acc:12437]  
109914  ULK1  ATG1; ATG1A; FLJ38455; FLJ46475; 
Unc51  
unc-51-like kinase 1 (C. elegans)  
[Source:HGNC Symbol;Acc:12558]  
146965  WISP1  CCN4; WISP1c; WISP1i; WISP1tc  WNT1 inducible signaling pathway protein 1 
[Source:HGNC Symbol;Acc:12769]  
104468  WNT1  INT1  wingless-type MMTV integration site family, 
member 1 [Source:HGNC 
Symbol;Acc:12774]  
104488  WNT2B  WNT13; XWNT2  wingless-type MMTV integration site family, 
member 2B [Source:HGNC 
Symbol;Acc:12781]  
104494  WNT3A  MGC119418; MGC119419; 
MGC119420  
wingless-type MMTV integration site family, 
member 3A [Source:HGNC 
Symbol;Acc:15983]  
146266  WNT5A  hWNT5A  wingless-type MMTV integration site family, 
member 5A [Source:HGNC 
Symbol;Acc:12784]  
47821  WNT6    wingless-type MMTV integration site family, 
member 6 [Source:HGNC 
Symbol;Acc:12785]  
   
 
 
102065  B2M    beta-2-microglobulin [Source:HGNC 
Symbol;Acc:914]  
143636  ACTB  PS1TP5BP1  actin, beta [Source:HGNC 
Symbol;Acc:132]  




























Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are a global 
challenge and most of these diseases remain incurable and are strongly linked with 
aging populations. Dementias alone affect more than 7 million people in Europe and 
their care is estimated to cost EUR 130 billion a year (neurodegenerationresearch.eu/). 
The increasing burden of neurodegenerative diseases in the developed countries has 
fostered research in the fields of brain disease understanding and drugs development. 
However, the challenge facing the world of diagnosing, treating and caring for people 
affected by neurodegenerative diseases is extremely intimidating and no single country 
alone has the expertise or resources necessary to tackle all of the big questions in this 
area.  
Potential alternatives to the current available drugs, that only alleviate major physical 
debilitating complications of disease progression, have emerged in the latest years. 
Nutrition can be one modifiable factor that could help to prevent, or at least retard, 
neurodegenerative diseases progression; it can be related with the adherence to more 
healthy dietary habits, valuing the intake of foods rich in (poly)phenols, like fruit and 
vegetables1. In fact, diets rich in fruits and vegetables have been recommended to 
reduce the risk of development of several chronic diseases2. Epidemiological and clinical 
studies have showed that dietary (poly)phenols are able to reduce the incidence and 
prevalence of such disorders, exhibiting remarkable multipotent ability to modulate 
several pathways3-6. The prevention and treatment of neurodegenerative disorders, 
characterized by mechanistic complexity, will require novel therapeutic strategies 
directed to multiple targets, such as (poly)phenols can do. 
Berries are amongst the most promising sources of (poly)phenols, consistently 
associated with health benefits, containing a great diversity of compounds7. However, 
the precise contribution of dietary (poly)phenols and circulating (poly)phenol metabolites 
to human health is still not fully elucidated. Absorption and blood concentrations of some 
(poly)phenols is quite low, which can hamper the research in terms of understanding 
their effects in specific biomarkers of disease. The difficulty in demonstrating 
(poly)phenol true effects can also be justified by the uncertain metabolic fate that dietary 
(poly)phenols can have. In fact, it is necessary to identify the bioavailable metabolites 
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resulting from (poly)phenol ingestion through the diet, as well as their ability to overcome 
and/or interact with cellular barriers and reach target tissues. The work presented in this 
thesis is just the tip of the iceberg, concerning the point of view in how a nutritional 
approach, namely in exploring berries’ potential towards brain health in 
neurodegeneration contexts, and how it can promote health benefits. And, of course, as 
any work in research, it raises more questions than answers that should be pursued. 
Previous work from our lab has highlighted the importance of biochemical modifications 
that occur throughout berries’ digestion and the ultimate impact that those comprise in 
terms of cellular bioactivities8, 9. However, the molecular mechanism behind berries 
neuroprotection effects remained to be elucidated. In my thesis work, we went deeper 
in understanding regarding the effects of bioaccessible components from berries 
resulting from in vitro digestion in terms of blood-brain barrier (BBB) endothelial 
permeability and the major cellular pathways modulated by them with potential 
neuroprotective effects (Chapter 2). Bioaccessible components resulting from in vitro 
digestion of berries have proven to be transported across the BBB, presenting 
cytoprotective effects at endothelial level. Moreover, they also showed to be 
neuroprotective in primary cultures of mouse cerebellar granule cells and in NT2-derived 
neurospheres, comprising a mixed population of neurons and astrocytes (Chapter 2). 
These bioaccessible components have, proven to be able to modulate central pathways 
involved in cell response, like mTOR, unfolded protein response and p53 signaling, with 
the rise of novel gene targets never reported before to be modulated by these 
components, like ATF5. Our work, together with others10-13, represents a shift in 
mentality in the study of (poly)phenols’ health benefits that has emerged in the last 
decade: by contemplating the digestion process, though in a simplistic way, we were 
able to overcome limitations of studying the compounds present in the raw food that we 
eat (dietary (poly)phenols), being in a better position to disclose the nutrition impact. 
Accumulating research over the years has thoroughly explored pure dietary 
(poly)phenols mode of action in age-related pathologies14-16. Such approach is of 
extreme importance but, unfortunately, is not always directly translatable to human’s 






Within the active field of in vitro digestion in food research, the COST Action INFOGEST 
aimed to harmonize in vitro protocols simulating human digestion on the basis of 
physiologically inferred conditions. A harmonized static in vitro digestion method was 
implemented and validated across laboratories of the network17, 18. This harmonized 
model, despite of being more complex and more physiologically-relevant than the one 
used in my thesis, still presents some limitations, such as the lack of intestinal cells and 
microbiota contribution to the digestive process. Recent studies have already evidenced 
the impact of both to overall bioaccessibility and bioavailability of the compounds 
resulting from digestion19-22. Nevertheless, this COST Action effort represents a step 
forward with the aim to seek for a research in the field of nutrition every time more close 
to human physiology and metabolism. In my opinion, the paramount contribution of 
microbial metabolism should be comprehensively addressed in further studies regarding 
the attainment of bioaccessible components from food matrixes and their ultimate 
impact for human health. 
In our lab we also have demonstrated that major bioavailable (poly)phenol metabolites 
resultant from berries consumption in humans are, in fact, derived from colonic 
microflora metabolism23, 24. From the human intervention study conducted where the 
volunteers took a berries-mix puree, biological samples (urine and blood) were 
analyzed. The analysis took into account a library of theoretically predicted metabolites 
which was rationally designed and the hits validated with chemically synthesized 
(poly)phenol metabolites23, 24. Some of the most abundant (poly)phenol metabolites 
detected in biological samples were simple phenolic sulfates, which in some volunteers 
reached concentrations as high as 20µM24. This human intervention study previously 
conducted in our lab was the first to identify and quantify these particular phenolic 
sulfates in human samples24.Other researchers have identified the same phenolic 
sulfates in biological samples of volunteers that ingested other (poly)phenol-rich 
sources, such as cranberries, mango and tea25-27. It seems that different food matrixes, 
rich in different dietary (poly)phenols, once metabolized, give rise to the same 
breakdown products. Such bioavailable (poly)phenol metabolites offer than an 
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unexplored potential as true circulating molecules with putative effector potential in 
target tissues. 
As such, in my thesis, we unveiled the power of circulating (poly)phenol metabolites in 
terms of BBB permeability and protective effects towards neurodegeneration and 
neuroinflammation (Chapter 3). We observed that all the phenolic sulfates studied were 
able to be transported across a simplified model of the BBB at circulating 
concentrations, although in different extent. Such differences in endothelial transport 
were speculated to be related with differences in chemical structure of these metabolites 
and/or putative interactions with efflux transporters. Moreover, these phenolic sulfates 
were not only able to be uptaken by endothelial cells, but also to be biotransformed into 
new (poly)phenol metabolites with unexplored potential. What are the bioactivities of 
these new cellular metabolites we do not know but certainly it would be of extreme 
importance to study them thoroughly once those are the ones that ultimately could reach 
brain cells. Chemical synthesis of these cellular (poly)phenol metabolites, mainly 
glutathione and acetylcysteine derivatives, should be pursued and neuroprotective 
potential assessed in relevant cell models of neurodegenerative diseases. 
As a key tool used along this thesis, we took advantage of a validated, though simplified, 
in vitro model of the BBB (Chapters 2 and 3). In vivo, the BBB is much more than an 
endothelial monolayer, comprising a complex interface composed by several cell types, 
working in concert. As such, it would be very interesting to compare our results with the 
ones using more relevant BBB model systems, such as recently established quadrupole 
co-cultures with iPSC (BBB endothelial cells, perycites, astrocytes and neurons), more 
close to in vivo characteristics of a fully functional BBB, mimicking the neurovascular 
unit28. Increasing the complexity of the cell model would support our observations: if the 
same new cellular metabolites arose in more complex systems, that would justify that 
we would be one step closer to the real agents acting in the prevention of chronic 
diseases. As a final validation, of course, the logic step would be to evaluate in vivo BBB 
transport and metabolism with labelled compounds in animal models29, 30. Such 
knowledge would impact our understanding about (poly)phenols mode of action, with 






The two most abundant (poly)phenol metabolites and BBB endothelium permeable, 
catechol-sulfate (Cat-sulf) and pyrogallol-sulfate (Pyr-sulf), proven to be strong 
candidates to be further explored in a neuronal context. We observed that both were 
cytoprotective, at endothelial level, and neuroprotective towards oxidative insults in 
different cell models with increasing complexity (Chapter 3). Pyr-sulf also proven to be 
a strong attenuator of LPS-induced neuroinflammation in microglial cells, with the 
involvement of NF-κB pathway modulation. (Poly)phenols potential towards 
neuroinflammation and NF-κB pathway is already described for several dietary 
(poly)phenols, like resveratrol31 and curcumin32. Our work, by taking advantage of 
(poly)phenol metabolites at circulating concentrations, highlighted a putative 
mechanism of action of bioavailable metabolites in neuroinflammation: Pyr-sulf, despite 
of not being able to prevent IκBα degradation and NF-κB phosphorylation, with 
consequent NF-κB nuclear translocation after 15 min of LPS exposure, helps to maintain 
NF-κB back to the cytoplasm by increasing the IkBα protein levels at 60 min (Chapter 
3). The orchestrated and precise mechanism by which Pyr-sulf promotes such 
alterations in microglia along inflammation should be explored in deeper extent with, for 
instance, the evaluation of NF-kB target genes levels and also with the assessment of 
NF-kB nuclear translocation along time. By taking advantage of specific inhibitors of the 
NF-kB pathway or specific antisense oligonucleotides it would also allow a profounder 
understanding of the molecular mechanisms of these phenolic sulfates, to our 
knowledge never reported before. Due to the opposite effects of Cat-sulf and Pyr-sulf in 
neuroinflammation, metabolites which only differ by one hydroxyl group, it would be very 
interesting to study their role in other pathways involved in inflammatory responses like 
PKC (NFAT), MAPK/ERK, MAPK/JNK or JAK/STAT; in fact, we may guess that the 
most potent metabolite in NF-κB pathway may not be the most potent towards other 
pathways and such knowledge would help to better direct a future nutraceutical and/or 
pharmacological approach of these metabolites. 
To close a circle of understanding of dietary (poly)phenols metabolites’ neuronal 
benefits, the usage of a human cell model of a specific neurodegenerative disorder was 
attained. A three-dimensional cellular model enriched in dopaminergic neurons was 
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used, taking advantage of differentiable human neuronal precursor cells (Chapter 4). 
This model allowed us to propose potential pathways modulated by bioavailable 
(poly)phenol metabolites in a dopaminergic neuronal population, with potential impact 
to Parkinson’s disease (PD). In fact, Pyr-sulf and Cat-sulf seem to act by a pre-
conditioning effect: though being slightly toxic to cells, they are able to modulate central 
canonical pathways like Nrf2, p53 and NF-κB signaling in a three-dimensional 
environment, with relevance to neuroprotection). The up-regulation of Nrf2-target genes 
like NQO1, GSR, ATF4 and HSP40 and consequent modulation of such genes in the 
presence of a dopaminergic neurotoxicant, MPP+, by Cat-sulf and Pyr-sulf, with ultimate 
protective effects to cells, evidenced one of the possible mechanisms by which the food 
that we eat can prevent and/or retard age-related neurodegenerative diseases – 
hormesis. The biochemical mechanisms of hormesis is not yet well understood but it is 
accepted that it can be triggered by low doses of toxins or other stressors which might 
activate the repair mechanisms of the cells or organism as a pre-conditioning effect. 
This repair process primes the cells to cope better with the insult and other damages 
that can arise33. 
The usage of MPP+ in the 3D cell model highlights the dopaminergic-protective potential 
of bioavailable (poly)phenol metabolites with impact to PD pathology, in which the most 
affected brain cells are the dopaminergic neurons from substantia nigra34. Both Cat-sulf 
and Pyr-sulf proven to be neuroprotective against MPP+ in different extent (Chapter 4). 
Of course, several other factors lead to PD complexity and are possibly more important 
than mitochondrial dysfunction and ROS production caused by MPP+ to disease 
progression, such as α-synuclein aggregation and Lewy body formation34. As such, we 
should build up our data by the usage of other cellular models that can recapitulate 
better the disease phenotype, such as PD-patient derived iPSC dopaminergic cells or 
animal models with α-synuclein aggregates or even presenting α-synuclein familiar 
mutations. It would be very interesting to study if the pathways modulated by these 
metabolites in such scenarios and if they would be different and worth to explore. 






resulting from (poly)phenol-rich sources’ digestive process and microbiota metabolism 
to our brain health. 
Most of our current knowledge on (poly)phenol research was obtained taking advantage 
of particular characteristics of cellular model systems with different degrees of 
complexity and their contribution in unveiling novel potential lead molecules is 
unquestionable. But, all models present limitations that should be considered. 
Pharmaceutical research drove the development of superior models from which the 
research in the field of human bioavailable (poly)phenol metabolites could benefit. The 
possibility to test their bioactivities in “mini-brains” settings, such as complex three-
dimensional cultures of neurons, astrocytes, oligodendrocytes, pericytes, microglia and 
brain microvascular endothelial cells, would be of upmost importance. Systems like 
those would be much superior than, for instance, the most used cancer cell lines in 2D 
for (poly)phenol research, being closer to the modelling of the human brain as we may 
get. Several authors have attempted to obtain valuable 3D screening tools for drug 
testing to better understand how the function of a simple network of individual neurons 
adds up to the complexity of brain function, and how this knowledge can be applied to 
medicine35-37. Current state of art neural systems still present some challenges to 
overcome in order to give the right answers to the most complex diseases and 
(poly)phenols field of research can certainly benefit from that38. 
The work presented in this thesis focus on the nutritional impact of the food we eat to 
our brain health and the experimental approaches taken always considered conditions 
as close to physiological as possible. In all cell models used, circulating concentrations 
were applied, with all the benefits and limitations that such choice may encompass: by 
using physiological concentrations, the effects seen are more translatable to nutritional 
impact to our health, but it is always a more challenging approach once the low 
concentrations used can be masked by the overall setting. On the other hand, the 
(poly)phenol metabolites studied can also be regarded as putative novel therapeutics 
which can be encapsulated and provided as a drug. The bioavailability is an important 
issue and therefore the discussion about putative formulation of (poly)phenols and 
(poly)phenol metabolites is needed to overcome this problem,. As for any other drug, it 
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is important to address several questions about (poly)phenol metabolites behavior in 
human body like absorption, distribution, metabolism and excretion (ADME),; to 
overcome some bioavailability problems, it is necessary to investigate limitations in the 
absorption and metabolism of these compounds and their presence in the target tissues. 
In the case of neurodegenerative diseases, as already mentioned, it is of extreme 
importance the understanding of the ability of (poly)phenols to interact and/or cross the 
BBB and if they keep their bioactivity39. Several animal studies have attempted to 
disclose some of these questions but the answers gathered so far can also present 
problems due to huge differences in biology and metabolism of (poly)phenols comparing 
to humans.  
Finally, the most reliable information on (poly)phenol bioactivity is indeed provided by 
clinical trials; however, their design should be further improved specially regarding the 
application of strict guidelines and high number of individuals. Thus, the standardization 
of clinical trials using natural compounds is of extreme importance for the rationale 
application of (poly)phenols in a nutraceutical and pharmacological context. Moreover, 
the absorption and metabolism of (poly)phenols involves multiple pathways which are 
subject to substantial inter-individual variation40. Some dietary (poly)phenols can be 
absorbed at intestinal level but most are hydrolyzed and metabolized by the colonic 
microbiota41. Phenolic sulfates studied in this thesis, as already mentioned, are colonic-
derived metabolites, already reported by other authors to be present in human fluids25, 
26. But in humans, different metabolizing phenotypes, or “metabotypes”, have been 
reported, as for instance for ellagitannins42, and such “metabotypes”, which can be 
determined by the concentration and activity of intestinal carriers and post-absorptive 
metabolizing enzymes, and by the composition and activity of the colonic microbiota, 
will be strongly influenced by the genotype of the subject43. Thus, for the same dietary 
intake, exposure to bioactive metabolites can be markedly different between individuals. 
A personalized optimal nutrition can be based in the knowledge of human “metabotypes” 
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